A fusion protein comprising a complement pathway inhibitor and angiogenesis inhibitor and its uses

By designing a fusion protein containing the CRIg extracellular domain and specifically binding to VEGF, the complement and angiogenesis pathways are blocked, solving the problem of the difficulty in effectively treating macular degeneration in existing technologies, and achieving effective treatment for both dry and wet AMD.

CN116234822BActive Publication Date: 2026-11-17ZHINAFU PHARM TECH CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202180053141.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-07-07
Filing Date
2021-07-07
Publication Date
2026-11-17
Estimated Expiration
2041-07-07

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively treat and prevent eye diseases, especially macular degeneration, particularly dry and wet AMD, mainly because retinal damage and neovascularization caused by activation of the complement system and angiogenesis pathways have not been effectively inhibited.

Method used

A fusion protein comprising an extracellular domain of CRIg or a fragment thereof and a protein that specifically binds to VEGF has been designed to inhibit complement-related mechanisms and angiogenesis by blocking complement-related pathways and angiogenesis pathways. This provides a fusion protein dimer and a polynucleotide encoding the fusion protein for use in preparing pharmaceutical compositions to treat or prevent eye diseases.

Benefits of technology

This fusion protein can effectively inhibit complement-related mechanisms and angiogenesis, significantly reduce retinal damage and new blood vessel formation, and provide an effective treatment for macular degeneration, especially for dry and wet AMD.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116234822B_ABST
    Figure CN116234822B_ABST
Patent Text Reader

Abstract

This invention provides a fusion protein dimer comprising the extracellular domain of CRIg or a fragment thereof and a protein that specifically binds to VEGF. This protein not only inhibits complement-related pathways but also effectively regulates angiogenesis. Therefore, the fusion protein dimer can be effectively used to treat and prevent complement-related diseases, particularly ocular diseases such as macular degeneration, and thus has high industrial applicability.
Need to check novelty before this filing date? Find Prior Art

Description

Background Technology

[0001] This invention relates to a fusion protein containing a complement pathway inhibitor protein and an angiogenesis inhibitor protein; and compositions for treating eye diseases, particularly macular degeneration, using the same.

[0002] Age-related macular degeneration (AMD) is a disease characterized by central vision loss associated with abnormalities in the Bruch's membrane, choroid, neuroretina, and / or retinal pigment epithelium. The macula, approximately 1 / 3 to 1 / 2 cm in diameter, exists in the center of the retina. Below the retina, the choroid is a collection of blood vessels embedded in fibrous tissue, and the pigment epithelium (PE) lies above the choroidal layer. In this configuration, the choroidal vessels supply nutrients to the retina. The choroid and PE are located in the anterior part of the eye.

[0003] Age-related macular degeneration (AMD) is a type of macular degeneration characterized by progressive vision loss in the central visual field, altered color perception, and impaired dark adaptation and sensitivity. AMD is broadly classified into dry AMD and wet AMD. Dry AMD is associated with the atrophy and death of cells in the central retina or macula, which are essential for good vision in activities such as reading, driving, or facial recognition. Approximately 10% to 20% of patients with dry AMD progress to type 2 AMD, also known as wet AMD.

[0004] The most significant risk factors for both types of AMD are age and the deposition of choroidal drusen (abnormal extracellular deposits located behind the retinal pigment epithelium). Choroidal drusen is a characteristic deposit associated with AMD. Known choroidal drusen include complement activators, inhibitors, activation-specific complement fragments, and terminal pathway factors, such as the cell membrane attack complex (MAC or C5b-9). Furthermore, wet AMD is associated with choroidal neovascularization (CNV). The pathogenic mechanisms of CNV are poorly understood, but factors such as inflammation, local ischemia, and local production of angiogenic factors are considered important.

[0005] Meanwhile, the complement system is a key component of innate immunity to microbial infection and includes a group of proteins that are normally present in an inactive state in serum. These proteins are activated via classical, lectin, and alternative pathways. Molecules on the surface of microorganisms activate these pathways, leading to the formation of a protease complex called C3 convertase.

[0006] Activation of the complement pathway produces bioactive fragments, including complement proteins such as the anaphylatoxins of C3a and C5a and the C5b-9 cell membrane attack complex (MAC), which mediate inflammatory responses in leukocyte chemotaxis, activate macrophages, neutrophils, platelets, mast cells, and endothelial cells, and increase vascular permeability, cell lysis, and tissue damage. Furthermore, some ocular diseases have been reported to be related to complement (Japanese Patent Application No. 2007-536964). However, the demand for effective treatments for ocular diseases, particularly macular degeneration, has been increasing, and research into macular degeneration therapeutics is ongoing. Invention Overview

[0008] Therefore, as a result of research on the effective treatment and prevention of eye diseases, especially macular degeneration, the inventors of this application have demonstrated that a fusion protein that blocks complement-related pathways and angiogenesis pathways can be used as a therapeutic agent for macular degeneration, thus completing this invention.

[0009] In one aspect, the present invention provides a fusion protein comprising an extracellular domain or a fragment thereof of an immunoglobulin superfamily (CRIg) and a protein that specifically binds to vascular endothelial growth factor (VEGF).

[0010] In another aspect, the present invention provides a fusion protein dimer in which two fusion proteins are linked together.

[0011] In another aspect, the present invention provides a polynucleotide encoding the fusion protein.

[0012] In another aspect, the present invention provides a carrier comprising the polynucleotide.

[0013] In another aspect, the present invention provides a transformed cell introduced into the vector.

[0014] In another aspect, the present invention provides a pharmaceutical composition for treating or preventing eye diseases, comprising the fusion protein or the fusion protein dimer as an active ingredient.

[0015] In another aspect, the present invention provides the use of a fusion protein or a dimer thereof in the treatment of eye diseases, wherein the fusion protein or the dimer thereof comprises an extracellular domain of CRIg or a fragment thereof and a protein that specifically binds to VEGF.

[0016] In another aspect, the present invention provides the use of a fusion protein or a dimer thereof in the preparation of a medicament for treating or preventing eye diseases, wherein the fusion protein comprises an extracellular domain of CRIg or a fragment thereof and a protein that specifically binds to VEGF.

[0017] In another aspect of the present invention, a method for treating and / or preventing eye diseases is provided, the method comprising administering to a subject a fusion protein or a dimer thereof, said fusion protein comprising an extracellular domain of CRIg or a fragment thereof and a protein that specifically binds to VEGF.

[0018] The fusion protein is a protein used to inhibit complement-related pathways and contains an extracellular domain of CRIg or a fragment thereof and a protein that specifically binds to VEGF. It can effectively inhibit not only complement-related mechanisms but also angiogenesis. Therefore, ocular diseases caused by the complement system and ocular diseases caused by angiogenesis can be effectively treated or prevented. As a result, the fusion protein can be usefully used for the effective treatment of macular degeneration, particularly dry and wet macular degeneration. Attached Figure Description

[0019] The exemplary embodiments can be understood in more detail from the following description taken in conjunction with the accompanying drawings, wherein:

[0020] Figure 1 Images of the SDS-PAGE results for C1.01, C1.02, C1.03, C1.04, C1.05, and C1.06.

[0021] Figure 2 Images of SDS-PAGE results for C1.03m, C1.04m, and aflibercept.

[0022] Figure 3 Images of SDS-PAGE results for C1.01m, C1.02m, C1.06m, and C1.07m.

[0023] Figure 4 Images of SDS-PAGE results for rabbit C3, rabbit C3b, rat C3, and rat C3b.

[0024] Figure 5 This is a schematic diagram of the fusion protein, which is shown in sequence as CRIg-Fc (C1.01, left), CRIg-Fc-VEGF binder (C1.02, middle) and VEGF binder-Fc-CRIg (C1.04, right).

[0025] Figure 6a and 6b A graph showing the binding affinity of C1.01 and C1.02 to human C3b and human VEGF165 by concentration, analyzed by Biacore.

[0026] Figure 7a and 7bA graph showing the binding affinity of C1.01m and C1.02m to mouse C3b and human VEGF165 by concentration, analyzed by Biacore.

[0027] Figure 8a A graph showing the binding affinity of C1.01, C1.02, C1.03, and C1.04 to human C3b using ELISA.

[0028] Figure 8b A graph showing the binding affinity of aflibercept, C1.02, C1.04, and C1.05 to human VEGF165 via ELISA.

[0029] Figure 8c A graph showing the binding affinity of C1.01, C1.02, and C1.03 to mouse C3b by ELISA.

[0030] Figure 8d A graph showing the binding affinity of C1.02 to human C3b, human C2, and human C4 using ELISA.

[0031] Figure 9a The hydrodynamic radius diagram of C1.01 is represented by dynamic light scattering analysis.

[0032] Figure 9b The hydrodynamic radius diagram of C1.02 is represented by dynamic light scattering analysis.

[0033] Figure 10 This is a graph showing viscosity based on C1.02 concentration.

[0034] Figure 11a A graph showing the inhibitory effects of C1.01, C1.02, and C1.06 on the alternative complement pathway using hemolysis analysis (AH50).

[0035] Figure 11b This is a graph showing the inhibitory effects of C1.02, C1.04, C1.04m, and C1.05 on the alternative complement pathway using hemolysis analysis (AH50).

[0036] Figure 11c This is a graph showing the inhibitory effects of C1.01m, C1.02m, C1.06m, and C1.07m on the alternative complement pathway using hemolysis analysis (AH50).

[0037] Figure 12a This is a graph showing the inhibitory effects of C1.01, C1.02, and C1.06 on the alternative complement pathway using hemolysis analysis (CH50).

[0038] Figure 12bThis is a graph showing the inhibitory effects of C1.02, C1.04, C1.04m, and C1.05 on the classical complement pathway using hemolysis analysis (CH50).

[0039] Figure 12c This is a graph showing the inhibitory effects of C1.01m, C1.02m, C1.06m, and C1.07m on the classical complement pathway using hemolysis analysis (CH50).

[0040] Figure 13 This is a graph showing the inhibitory effects of aflibercept, C1.01, C1.02, C1.05, and C1.06 on VEGF signaling using reporter cells.

[0041] Figure 14 This is a graph showing the inhibitory effects of C1.01, C1.02, and C1.05 on the VEGF signaling pathway using a wound healing assay.

[0042] Figure 15a This is a graph showing the binding affinity of C3b to C1.02 and C3b to C1.06 in humans and cynomolgus monkeys, as demonstrated by ELISA.

[0043] Figure 15b This is a graph showing the binding capacity of C3b to C1.02 and the binding capacity of C3b to C1.06 in humans, rats, and rabbits using ELISA.

[0044] Figure 15c This is a graph showing the binding capacity of VEGF to C1.02 and the binding capacity of VEGF to C1.01 in humans, cynomolgus monkeys, rats, and rabbits using ELISA.

[0045] Figure 16a These are images obtained by fluorescein angiography to confirm choroidal neovascularization in a mouse model at induction (day 0) and 7 days after induction (day 7) for each experimental group.

[0046] Figure 16b The figures show the body weight of each experimental group in the mouse model used for choroidal neovascularization at induction (day 0), 3 days after induction (day 3), and 7 days after induction (day 7).

[0047] Figure 16c This is a quantitative graph showing the degree of choroidal neovascularization in each experimental group from the time of induction (day 0) to day 7 (day 7) after induction.

[0048] Figure 17This is a quantitative graph showing the intensity of choroidal neovascularization at 7 and 14 days after induction in the rabbit model of choroidal neovascularization in each experimental group.

[0049] Figure 18a To quantify whether choroidal neovascularization existed in the rat model of choroidal neovascularization during induction and 10 days after induction in each experimental group.

[0050] Figure 18b To quantify the vascular leakage area during and 10 days after induction of the rat model of choroidal neovascularization in each experimental group.

[0051] Figure 19 To display a view of the image, which shows a dry macular degeneration model for each experimental group ( Figure 19 The outer nuclear layer (ONL) from a to 19c, and the cell count in the outer nuclear layer ( Figure 19 d) Area of ​​the outer core layer ( Figure 19 e) and C3 expression levels in the retina ( Figure 19 The diagram in f).

[0052] Figure 20a The graph shows the concentration of C1.02 in the vitreous fluid after intravitreal injection of 2,500 μg C1.02 into rabbits; and

[0053] Figure 20b This is a graph showing the concentration of C1.02 in the aqueous humor of a rabbit after injecting 2,500 μg of C1.02 into the rabbit's vitreous body. Invention Details

[0055] The fusion protein contains a CRIg extracellular domain.

[0056] In one aspect, the present invention provides a fusion protein containing an extracellular domain or a fragment thereof of an immunoglobulin superfamily (CRIg) and a protein that specifically binds to vascular endothelial growth factor (VEGF).

[0057] As used herein, the term "CRIg" refers to the complement receptor immunoglobulin encoded by the VSIG4 gene, also known as the Z39Ig protein. CRIg belongs to the type 4 complement receptor group of the four types of complement receptors and is expressed on the surface of macrophages (such as Kupffer cells, which perform phagocytosis in the liver). CRIg is a membrane protein (membrane-integrated protein) that binds to extracellular regions including immunoglobulin domains. CRIg binds to complement fragments C3b and iC3b and has the function of recognizing and eliminating bacteria entering the body or infectious bacteria in the bloodstream via phagocytes.

[0058] The CRIg includes a subtype or a slicing form of CRIg. Subtypes include CRIg subtype 1, 2, or 3. Slicing forms include CRIg(L) or CRIg(S). CRIg(L) may include V-type and C2-type terminal Ig domains, and CRIg(S) may include only the V-type domain. Specifically, CRIg(S) may contain a sequence as shown in SEQ ID NO:20.

[0059] The extracellular domain of the CRIg may be part of a receptor that excludes the transmembrane domain and the cytoplasmic domain.

[0060] The CRIg may include fragments of the extracellular domain of CRIg. A fragment of the extracellular domain of CRIg refers to a cleavage form having the same or similar activity as the extracellular domain of CRIg. Specifically, the fragment refers to a fragment of CRIg that has the activity of promoting complement or phagocytosis by binding to C3b or iC3b.

[0061] In one embodiment, the CRIg may comprise an amino acid sequence as shown in SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:74, or SEQ ID NO:151. Specifically, the human CRIg may comprise an amino acid sequence as shown in SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:151, while the mouse CRIg may comprise the amino acid sequence of SEQ ID NO:21. Furthermore, the extracellular domain of the mouse CRIg may comprise an amino acid sequence as shown in SEQ ID NO:75, and the extracellular domain of the human CRIg may comprise an amino acid sequence as shown in SEQ ID NO:22 or SEQ ID NO:74.

[0062] As used herein, the term "vascular endothelial growth factor (VEGF)" refers to the vascular endothelial growth factor produced by cells that stimulate angiogenesis. VEGF is an important signaling protein that participates in angiogenesis by dividing and proliferating vascular endothelial cells and increasing vascular permeability. VEGF is known to stimulate abnormal angiogenesis in wet AMD retina.

[0063] Furthermore, as used herein, VEGF or VEGF-based proteins may be collectively referred to as the term "VEGF". VEGF-based proteins may have the same or similar activities as VEGF. Here, "activity" may refer, for example, to the specific binding of VEGF receptors, and such specific binding can be measured by methods known to those skilled in the art.

[0064] In one embodiment, the VEGF-based protein may be one or more selected from the group consisting of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, placental growth factor (PlGF), and recombinant VEGF. Preferably, the VEGF may be VEGF-A, B, or PlGF.

[0065] As used herein, the term "placental growth factor (PlGF)" refers to a transmembrane protein encoded by chromosomes 2p21-p16. PlGF acts as a selective ligand for VEGFR-1 and promotes angiogenesis. PlGF shares 40% or more amino acid identity with VEGF. In one embodiment, PlGF may be PlGF-1 or PlGF-2.

[0066] As used herein, the term "recombinant VEGF" refers to a VEGF recombined by splicing and replacing exons. Depending on the number of amino acids, the recombinant VEGF can be VEGF111, VEGF121, VEGF145, VEGF148, VEGF165, VEGF183, VEGF189, or VEGF206. In one embodiment, the recombinant VEGF can be VEGF165.

[0067] As used in this article, the term "protein that specifically binds to VEGF" refers to an antibody that specifically binds to VEGF or the extracellular domain of the VEGF receptor.

[0068] As used herein, the term "VEGF receptor" refers to a receptor that binds to VEGF. In this context, the VEGF receptor can be any one selected from the group consisting of VEGF receptor 1 (VEGFR-1), VEGF receptor 2 (VEGFR-2), and VEGF receptor 3 (VEGFR-3). The VEGF receptor includes an immunoglobulin (Ig)-like domain, an extracellular domain, and an intracellularly isolated kinase domain. The VEGF receptor is activated by binding to a VEGF ligand, which may lead to dimerization or phosphorylation. In one embodiment, the VEGF receptor can be VEGF receptor 1 or 2.

[0069] As used herein, the term "extracellular domain of the VEGF receptor" refers to the domain of the VEGF receptor that binds to VEGF. Specifically, the extracellular domain of the VEGF receptor refers to the portion of the extracellular domain of the VEGF ligand that includes the transmembrane and cytoplasmic regions of the VEGF receptor.

[0070] Furthermore, the extracellular domain of the VEGF receptor can be a fragment of the VEGF receptor that binds to VEGF. In one embodiment, the fragment of the VEGF receptor includes domains D1, D2, or D3 of the VEGF receptor, which are VEGF-binding regions or combinations thereof. Preferably, the fragment of the VEGF receptor may include D2 and D3.

[0071] In one embodiment, the extracellular domain of the VEGF receptor includes the D2 and D3 domains of VEGF receptor 1 or 2. Furthermore, the extracellular domain of the VEGF receptor may bind to VEGF-A, VEGF-B, or PlGF to inhibit angiogenesis. In this case, in one embodiment, the extracellular domain of the VEGF receptor may contain the amino acid sequence shown in SEQ ID NO:14. Additionally, the extracellular domain of the VEGF receptor may be in a form containing a portion of the extracellular domain of the VEGF receptor shown in SEQ ID NO:14 that has been cleaved or replaced.

[0072] As used in this article, "antibody that specifically binds to VEGF" refers to an antibody that induces an antigen-antibody reaction by specifically binding to VEGF or its fragments, also known as an anti-VEGF antibody.

[0073] Antibody is a general term for a molecule that can bind to VEGF to form a specific antigen-antibody relationship. Furthermore, antibodies can be used in any form as long as they contain an antigen-binding domain capable of specifically binding to VEGF. Antibodies or fragments thereof can be antigen-binding fragments (Fab), F(ab)2, single-chain variable fragments (scFv), di-scFv, single-domain antibodies (sdAb), chimeric antibodies, humanized antibodies, human antibodies, or variants thereof.

[0074] The anti-VEGF antibody can be a nanobody. In this case, the antibody may contain CDR1 as shown in SEQ ID NO:49, CDR2 as shown in SEQ ID NO:50, and CDR3 as shown in SEQ ID NO:51. Specifically, the antibody may be BI-836880.

[0075] Anti-VEGF antibodies may include any one selected from the group consisting of aflibercept, bevacizumab, ranibizumab, ramucirumab, brolucizumab, faricimab, KSI-301, vanucizumab, BI-836880, HuMab G6-31, B20-4.1, BAT-5906, navicixizumab, dilpacimab, hPV-19, and AT-001. Preferably, the anti-VEGF antibody may include a variable region of aflibercept, bevacizumab, ranibizumab, brolucizumab, KSI-301, vanucizumab, BI-836880, or BAT-5906.

[0076] In this context, aflibercept refers to a recombinant human fusion protein that inhibits VEGF-A and PlGF in blood vessels. Aflibercept can be injected directly into the eye. Bevacizumab is an antibody, an angiogenesis inhibitor, that inhibits VEGF-A in blood vessels to suppress blood vessel growth. In the treatment of macular degeneration, bevacizumab can be injected directly into the eye. Ranibizumab is a Fab that treats wet macular degeneration by inhibiting angiogenesis. Ramucirumab is an angiogenesis-mediated substance, or an antibody that inhibits VEGF receptor 2. Broxetine is an scFv that binds to VEGF-A, inhibits angiogenesis, and treats wet macular degeneration. Farecizumab is a bispecific antibody that inhibits VEGF-A and angiopoietin-2.

[0077] The KSI-301 antibody has therapeutic effects on wet macular degeneration. Varnucilizumab is a bispecific humanized monoclonal antibody that inhibits VEGF-A and angiopoietin-2. BI-836880 is a humanized bispecific nanobody that inhibits VEGF and angiopoietin-2. G6-31 is a Fab fragment that inhibits human VEGF. B20-4.1 is an scFv fragment that inhibits human VEGF.

[0078] The BAT-5906 antibody has therapeutic effects on wet macular degeneration. Nacerciizumab is an anti-DLL4 / VEGF bispecific antibody. Depacizumab is an anti-DLL4 / VEGF bispecific antibody, also known as ABT-165. hPV-19 is an anti-VEGF antibody with anti-angiogenic and anti-tumor activity. AT-001 is an antibody that inhibits human VEGF receptor 3 to suppress angiogenesis.

[0079] In one embodiment, the anti-VEGF antibody may include the variable region of BI-836880. Specifically, the antibody may include a heavy chain variable region comprising CDR1 as shown in SEQ ID NO:49, CDR2 as shown in SEQ ID NO:50, and CDR3 as shown in SEQ ID NO:51.

[0080] In one embodiment, the anti-VEGF antibody may include a variable region of bevacizumab. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO:77, HCDR2 as shown in SEQ ID NO:78, and HCDR3 as shown in SEQ ID NO:79, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO:80, LCDR2 as shown in SEQ ID NO:81, and LCDR3 as shown in SEQ ID NO:82.

[0081] In one embodiment, the anti-VEGF antibody may include a variable region of ranibizumab. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO:83, HCDR2 as shown in SEQ ID NO:84, and HCDR3 as shown in SEQ ID NO:85, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO:86, LCDR2 as shown in SEQ ID NO:87, and LCDR3 as shown in SEQ ID NO:88.

[0082] In one embodiment, the anti-VEGF antibody may include a variable region of ramoximab. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO:89, HCDR2 as shown in SEQ ID NO:90, and HCDR3 as shown in SEQ ID NO:91, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO:92, LCDR2 as shown in SEQ ID NO:93, and LCDR3 as shown in SEQ ID NO:94.

[0083] In one embodiment, the anti-VEGF antibody may include a variable region of fareximab. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO:101, HCDR2 as shown in SEQ ID NO:102, and HCDR3 as shown in SEQ ID NO:103, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO:104, LCDR2 as shown in SEQ ID NO:105, and LCDR3 as shown in SEQ ID NO:106.

[0084] In one embodiment, the anti-VEGF antibody may include a variable region of KSI-301. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO:107, HCDR2 as shown in SEQ ID NO:108, and HCDR3 as shown in SEQ ID NO:109, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO:110, LCDR2 as shown in SEQ ID NO:111, and LCDR3 as shown in SEQ ID NO:112.

[0085] In one embodiment, the anti-VEGF antibody may include a variable region of varuscitizumab. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO:113, HCDR2 as shown in SEQ ID NO:114, and HCDR3 as shown in SEQ ID NO:115, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO:116, LCDR2 as shown in SEQ ID NO:117, and LCDR3 as shown in SEQ ID NO:118.

[0086] In one embodiment, the anti-VEGF antibody may include the variable region of BAT-5906. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO:119, HCDR2 as shown in SEQ ID NO:120, and HCDR3 as shown in SEQ ID NO:121, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO:122, LCDR2 as shown in SEQ ID NO:123, and LCDR3 as shown in SEQ ID NO:124.

[0087] In one embodiment, the anti-VEGF antibody may include a variable region of nascixizumab. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO:125, HCDR2 as shown in SEQ ID NO:126, and HCDR3 as shown in SEQ ID NO:127, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO:128, LCDR2 as shown in SEQ ID NO:129, and LCDR3 as shown in SEQ ID NO:130.

[0088] In one embodiment, the anti-VEGF antibody may include a variable region of depacimab. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO:131, HCDR2 as shown in SEQ ID NO:132, and HCDR3 as shown in SEQ ID NO:133, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO:134, LCDR2 as shown in SEQ ID NO:135, and LCDR3 as shown in SEQ ID NO:136.

[0089] In one embodiment, the anti-VEGF antibody may include a variable region of hPV-19. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO:137, HCDR2 as shown in SEQ ID NO:138, and HCDR3 as shown in SEQ ID NO:139, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO:140, LCDR2 as shown in SEQ ID NO:141, and LCDR3 as shown in SEQ ID NO:142.

[0090] In one embodiment, the anti-VEGF antibody may include a variable region of AT-001. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO:143, HCDR2 as shown in SEQ ID NO:144, and HCDR3 as shown in SEQ ID NO:145, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO:146, LCDR2 as shown in SEQ ID NO:147, and LCDR3 as shown in SEQ ID NO:148.

[0091] In one embodiment, the anti-VEGF antibody may include: a heavy chain as shown in SEQ ID NO:36 and a light chain as shown in SEQ ID NO:37; a heavy chain as shown in SEQ ID NO:38 and a light chain as shown in SEQ ID NO:39; a heavy chain as shown in SEQ ID NO:40 and a light chain as shown in SEQ ID NO:41; a heavy chain as shown in SEQ ID NO:43 and a light chain as shown in SEQ ID NO:44; a heavy chain as shown in SEQ ID NO:45 and a light chain as shown in SEQ ID NO:46; a heavy chain as shown in SEQ ID NO:47 and a light chain as shown in SEQ ID NO:48; a heavy chain as shown in SEQ ID NO:64 and a light chain as shown in SEQ ID NO:65; a heavy chain as shown in SEQ ID NO:66 and a light chain as shown in SEQ ID NO:67; a heavy chain as shown in SEQ ID NO:68 and a light chain as shown in SEQ ID NO:69; a variable region of the heavy chain as shown in SEQ ID NO:70 and a variable region of the light chain as shown in SEQ ID NO:71; or as shown in SEQ ID NO:36. The heavy chain variable region shown in NO:72 and the light chain variable region shown in SEQ ID NO:73.

[0092] The fragment of the anti-VEGF antibody can be a single-chain variable fragment (scFv). In this case, scFv refers to a form in which the heavy chain variable region and the light chain variable region are linked by a peptide linker. Specifically, scFv can include variable regions comprising CDR1 as shown in SEQ ID NO:95, CDR2 as shown in SEQ ID NO:96, CDR3 as shown in SEQ ID NO:97, CDR4 as shown in SEQ ID NO:98, CDR5 as shown in SEQ ID NO:99, and LCDR6 as shown in SEQ ID NO:100. Furthermore, scFv can contain the amino acid sequence shown in SEQ ID NO:42. In this case, one embodiment of scFv can be iboxetine monoclonal antibody.

[0093] Anti-VEGF antibodies may include variable regions of HuMab G6-31 or B20-4.1. Specifically, the antibody may include heavy chain variable regions comprising HCDR1 as shown in SEQ ID NO:52, HCDR2 as shown in SEQ ID NO:53, and HCDR3 as shown in SEQ ID NO:54, and light chain variable regions comprising LCDR1 as shown in SEQ ID NO:55, LCDR2 as shown in SEQ ID NO:56, and LCDR3 as shown in SEQ ID NO:57. Furthermore, the antibody may include heavy chain variable regions comprising HCDR1 as shown in SEQ ID NO:58, HCDR2 as shown in SEQ ID NO:59, and HCDR3 as shown in SEQ ID NO:60, and light chain variable regions comprising LCDR1 as shown in SEQ ID NO:61, LCDR2 as shown in SEQ ID NO:62, and LCDR3 as shown in SEQ ID NO:63.

[0094] Antibodies that specifically bind to VEGF can refer to antibodies known to those skilled in the art, but are not limited thereto. In another embodiment, anti-VEGF antibodies or fragments thereof disclosed in U.S. Patent 9,527,925B2, U.S. Patent 8,268,314B2, or U.S. Publication 2019-0167790A1 may be used as antibodies.

[0095] The extracellular domains of CRIg or its fragments, as well as proteins that specifically bind to VEGF, can be linked by adapters.

[0096] Furthermore, the extracellular domain of the CRIg or a fragment thereof can be linked to an immunoglobulin fragment via a linker. The linker connects two proteins. In one embodiment, the linker may comprise 1-50 amino acids, albumin or a fragment thereof, or an immunoglobulin with an Fc domain. In this case, the Fc domain of the immunoglobulin refers to a protein including the heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) of the immunoglobulin, but excluding the variable regions of the heavy and light chains and the light chain constant region 1 (CH1). The immunoglobulin may be IgG, IgA, IgE, IgD, or IgM, preferably IgG1. The Fc domain in this specification may refer to the region including the CH2 and CH3 domains, excluding the hinge region.

[0097] Furthermore, fusion proteins can be composed of structural formulas (I) or (II).

[0098] N'-X-[joint(1)]n-Fc structural domain-[joint(2)]mYC' (I)

[0099] N'-Y-[joint(1)]n-Fc structural domain-[joint(2)]mXC' (II)

[0100] In structural formulas (I) and (II),

[0101] N' is the N-terminus of the fusion protein.

[0102] C' is the C-terminus of the fusion protein.

[0103] X is the extracellular domain of CRIg or a fragment thereof.

[0104] Y is a protein that specifically binds to VEGF.

[0105] Linkers (1) and (2) are peptide linkers, and

[0106] n and m are each independently 0 or 1.

[0107] The extracellular domains of proteins that specifically bind VEGF, CRIg, or fragments thereof, and the Fc domains are as described above. The Fc domain may include the CH2 and CH3 regions of the Fc heavy chain of an immunoglobulin. Furthermore, the Fc domain of an immunoglobulin can be an Fc domain variant or a wild-type Fc domain. Additionally, as used herein, the term "Fc domain variant" may refer to an Fc domain having a different glycosylation pattern than the wild-type Fc domain, or may have increased glycosylation, decreased glycosylation, or deglycosylation compared to the wild-type Fc domain. Non-glycosylated Fc domains are also included. Fc domains or variants thereof can be adapted to have adjusted amounts of sialic acid, fucosylation, and glycosylation through culture conditions or host gene manipulation.

[0108] Furthermore, the glycosylation of the Fc domain of immunoglobulins can be modified by conventional methods, such as chemical methods, enzymatic methods, and genetic engineering methods using microorganisms. Additionally, Fc domain variants can be mixtures of the corresponding Fc regions of immunoglobulins IgG, IgA, IgE, IgD, or IgM. Furthermore, Fc domain variants can be forms in which certain amino acids in the Fc domain are replaced by other amino acids.

[0109] As used herein, the term "Fc domain variant" refers to a variant formed by altering the glycosylation of the wild-type Fc domain, wherein the Fc domain sequence is mixed, or a variant formed by deleting, substituting, replacing, and / or adding certain amino acids of the wild-type Fc domain. Variants formed by deleting, substituting, replacing, and / or adding certain amino acids of the wild-type Fc domain can be prepared by methods known to those skilled in the art. In one embodiment, the Fc domain variant can be formed by substituting and / or adding certain amino acid sequences of the wild-type Fc domain.

[0110] The "amino acid" introduced by substitution and / or addition can be any one selected from the group consisting of lysine (K), alanine (A), arginine (R), asparagine (N), aspartic acid (D), cysteine ​​(C), glutamine (Q), glutamic acid (E), glycine (G), histidine (H), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), proline (P), serine (S), threonine (T), tryptophan (W), tyrosine (Y), and valine (V).

[0111] Fc domain variants can modulate antibody activity or function. In one embodiment, Fc domain variants can modulate antibody effector function or cytotoxic activity.

[0112] In one embodiment, the Fc domain variant may include a DANG mutation or an NG mutation. Furthermore, the Fc domain variant may be a variant in which the 265th sequence in the IgG1 Fc domain is substituted from D to A, or a variant in which the 297th sequence is substituted from N to G, or a combination thereof.

[0113] In one embodiment, the Fc domain may have any amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:11, and SEQ ID NO:76. The Fc domain may be encoded by a polynucleotide sequence as shown in SEQ ID NO:28 or SEQ ID NO:33.

[0114] The peptide linker (1) may consist of 5-80 consecutive amino acids, 20-60 consecutive amino acids, 25-50 consecutive amino acids, or 30-40 amino acids. In one embodiment, the peptide linker (1) may consist of 30 amino acids. Furthermore, the peptide linker (1) may contain at least one cysteine ​​residue. Specifically, it may contain one, two, or three cysteine ​​residues. Additionally, the peptide linker (1) may be derived from the hinge of an immunoglobulin. In one embodiment, the peptide linker (1) may be a peptide linker consisting of an amino acid sequence as shown in SEQ ID NO:15 or SEQ ID NO:17.

[0115] The peptide linker (2) may consist of 1-50 consecutive amino acids, 3-30 consecutive amino acids, or 5-15 amino acids. In one embodiment, the peptide linker (2) may be (G4S). n (Here, n is an integer from 1 to 10). In this case, (G4S) n n can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, the peptide linker (2) can be a peptide linker composed of an amino acid sequence as shown in SEQ ID NO:16 or SEQ ID NO:18.

[0116] Preferably, the fusion protein may be composed of structural formula (I).

[0117] In one embodiment, the fusion protein may contain any amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:8 and SEQ ID NO:10.

[0118] In another embodiment, the polypeptide of the fusion protein may contain 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:8, and SEQ ID NO:10.

[0119] In this case, identity can be determined by, for example, a percentage of homology, or by homology comparison software such as BlastN software provided by the National Center for Biotechnology Information (NCBI).

[0120] Fusion protein dimer

[0121] Another aspect of the present invention provides a fusion protein dimer, wherein an extracellular domain or a fragment thereof containing CRIg is linked to two fusion proteins that specifically bind to VEGF proteins.

[0122] In this case, the links between the fusion proteins constituting the dimer can form disulfide bonds through cysteine ​​residues present in the linker, but are not limited thereto. The fusion proteins constituting the dimer can be the same or different from each other. Preferably, the dimer can be a homodimer.

[0123] Polynucleotides encoding fusion proteins

[0124] In another aspect, the present invention provides a polynucleotide encoding a fusion protein containing an extracellular domain of CRIg or a fragment thereof and a protein that specifically binds to VEGF.

[0125] In one embodiment, the nucleic acid sequence contained in the polynucleotide may have at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identity with SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:8, or SEQ ID NO:10.

[0126] In one embodiment, the base sequence of the polynucleotide may have at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identity with any one of the groups selected from SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:30, and SEQ ID NO:32.

[0127] The polynucleotide may also contain nucleic acids encoding a signal sequence or leader sequence. As used herein, the term "signal sequence" refers to a signal peptide that directs the secretion of a target protein. In the host cell, the signal peptide is translated and then cleaved. Specifically, the signal sequence is the amino acid sequence that initiates the transport of a protein across the endoplasmic reticulum (ER) membrane.

[0128] These characteristics of signal sequences are well known in the art. Such signal sequences typically contain 16 to 30 amino acid residues, but may contain more or fewer than the aforementioned amino acid residues. A typical signal peptide consists of three regions: a basic N-terminal region, a central hydrophobic region, and a more polar C-terminal region. The central hydrophobic region contains 4 to 12 hydrophobic residues, which immobilize the signal sequence through the membrane lipid bilayer during the transport of immature peptides.

[0129] Upon initiation, the signal sequence is cleaved within the lumen of the ER by a cellular enzyme (commonly referred to as a signal peptidase). In this case, the signal sequence can be tissue plasminogen activation (tPa), a signal sequence of herpes simplex virus glycoprotein D (HSV gDs), or a growth hormone secretion signal sequence. Preferably, a secretion signal sequence suitable for higher eukaryotic cells, including mammals, can be used. Furthermore, a wild-type signal sequence can be used, or a codon-substituted signal sequence with a high expression frequency in host cells can be used.

[0130] Vectors containing polynucleotides encoding fusion proteins

[0131] In another aspect, the present invention provides a vector comprising the above-mentioned polynucleotides.

[0132] Vectors can be introduced into host cells, recombine with the host cell genome, and insert themselves into it. Alternatively, a vector is understood as a nucleic acid means comprising a polynucleotide sequence that can autonomously replicate as an episome. Vectors include linear nucleic acids, plasmids, bacteriophages, cosmids, RNA vectors, viral vectors, and analogues. Examples of viral vectors include, but are not limited to, retroviruses, adenoviruses, and adeno-associated viruses.

[0133] Specifically, the vector can be plasmid DNA, phage DNA, etc., as well as commercially developed plasmids (pUC18, pBAD, pIDTSAMRT-AMP, etc.), E. coli-derived plasmids (pYG601BR322, pBR325, pUC118, pUC119, etc.), Bacillus subtilis-derived plasmids (pUB110, pTP5, etc.), yeast-derived plasmids (YEp13, YEp24, YCp50, etc.), phage DNA (Charon4A, Charon21A, EMBL3, EMBL4, λgt10, λgt11, λZAP, etc.), animal viral vectors (retroviruses, adenoviruses, vaccinia viruses, etc.), or insect viral vectors (baculoviruses, etc.). Since the vector exhibits different expression levels and protein modifications depending on the host cell, it is preferable to select and use the host cell most suitable for the target.

[0134] As used herein, the term “gene expression” or “expression” of a target protein is understood to refer to the transcription of a DNA sequence, the translation of an mRNA transcript, and the secretion of a fusion protein product or fragment thereof. Useful expression vectors may be RcCMV (Invitrogen, Carlsbad) or variants thereof. Expression vectors may include human cytomegalovirus (CMV) promoters for promoting sequential transcription of target genes in mammalian cells, and bovine growth hormone polyadenylation signaling sequences for enhancing post-transcriptional RNA stability.

[0135] Transformed cells expressing fusion proteins

[0136] In another aspect, the present invention provides a transformed cell introduced with the above-described vector.

[0137] Examples of host cells for transformed cells may include, but are not limited to, prokaryotic cells, eukaryotic cells, and cells derived from mammals, plants, insects, fungi, or bacteria. As an example of a prokaryotic cell, *Escherichia coli* can be used. Furthermore, as an example of a eukaryotic cell, yeast can be used. Additionally, for mammalian cells, CHO cells, F2N cells, CSO cells, BHK cells, Bowes melanoma cells, HeLa cells, 911 cells, AT1080 cells, A549 cells, HEK293 cells, HEK293T cells, etc., can be used, but are not limited to these. Any cell known to those skilled in the art as a mammalian host cell may be used.

[0138] In addition, to introduce expression vectors into host cells, methods such as CaCl2 precipitation, the Hanahan method (which improves efficiency by using a reducing agent (dimethyl sulfoxide (DMSO)) in CaCl2 precipitation), electroporation, calcium phosphate precipitation, protoplast fusion, stirring with silicon carbide fibers, Agrobacterium-mediated transformation, transformation using PEG, dextran sulfate, liposomes, or drying / inhibition-mediated transformation, or similar transformation methods are used.

[0139] As described above, in order to optimize the properties of the fusion protein as a therapeutic agent or for any other purpose, the glycosylation pattern of the fusion protein (e.g., sialic acid, fucosylation, and glycosylation) can be regulated by manipulating glycosylation-related genes in the host cell using methods known to those skilled in the art.

[0140] Methods for producing fusion proteins

[0141] In another aspect, the present invention provides a method for producing a fusion protein or a dimer thereof, the method comprising: culturing transformed cells, wherein the fusion protein contains an extracellular domain of CRIg or a fragment thereof and a protein that specifically binds to VEGF.

[0142] Production methods may include: i) culturing transformed cells to obtain a culture medium; ii) collecting the fusion protein or its dimer from the culture medium.

[0143] The culture of transformed cells can be performed using methods known in the art. Specifically, the culture can be carried out during batch feeding, or continuously during batch feeding or repeated batch feeding.

[0144] Applications of fusion proteins or their dimers

[0145] In another aspect, the present invention provides a pharmaceutical composition for treating or preventing eye diseases, comprising a fusion protein as an active ingredient, or a fusion protein dimer of two fusion proteins.

[0146] Both the fusion protein and the fusion protein dimer are as described above.

[0147] As described herein, the term "eye disease" can be a general term used to describe diseases in which the eye is the site of onset. An eye disease may refer to an eye condition caused or exacerbated by complement activity or angiogenesis, or an eye condition in which excessive angiogenesis is a primary symptom. An eye disease may be selected from any of the following groups: age-related macular degeneration (AMD), geographic atrophy (GA), choroidal neovascularization (CNV), uveitis, diabetic and other ischemic retinopathy, diabetic macular edema, pathological myopia, von Hippel-Lindau disease, ocular histoplasmosis, central retinal vein occlusion (CRVO), corneal angiogenesis, and retinal angiogenesis.

[0148] The extracellular domain or fragments of the CRIg, and the protein that specifically binds to VEGF, are as described above.

[0149] The preferred dosage of the pharmaceutical composition varies depending on the patient's condition and weight, the severity of the disease, the form of the drug, and the route and duration of administration, and can be appropriately selected by those skilled in the art. In the pharmaceutical compositions of the present invention for treating or preventing eye diseases, the active ingredient may be contained in any amount (effective amount) depending on the intended use, dosage form, mixing purpose, etc., as long as the active ingredient can exhibit activity in treating eye diseases or, in particular, in treating macular degeneration. Its conventional effective amount will be determined based on the total weight of the composition in the range of 0.001 wt% to 20.0 wt%. As described herein, the term "effective amount" refers to the amount of active ingredient that can induce an effect of improving or treating the condition of an eye disease, particularly an effect of improving or treating the condition of macular degeneration. Such an effective amount can be determined experimentally within the scope known to those skilled in the art.

[0150] As described herein, the term "treatment" can be used to refer to both therapeutic and preventative treatment. In the context of this application, "prevention" can be used to mean the relief or reduction of a subject's pathological condition or disease. In one embodiment, the term "treatment" includes any form of administration or application for the treatment of diseases in mammals, including humans. Furthermore, the term includes inhibiting or reducing the progression of a disease and includes the meaning of restoring or repairing damaged or lost functions to partially or completely alleviate the disease, stimulating inefficient processes, or alleviating severe disease.

[0151] Pharmacokinetic parameters (e.g., bioavailability) and baseline parameters (e.g., clearance) can also affect efficacy. Therefore, “enhanced efficacy” (e.g., improved efficacy) can be attributed to improvements in pharmacokinetic parameters and efficacy, and can be compared in experimental animals or human subjects by measuring parameters such as clearance and treatment or improvement.

[0152] As described herein, the terms "therapeutic effective amount" or "pharmaceutical effective amount" refer to an amount of compound or composition that is effective in preventing or treating a target disease, and also to an amount sufficient to treat a disease having a reasonable benefit / risk ratio suitable for medical treatment, without causing side effects. The level of an effective amount can be determined based on factors including the patient's health status, disease type, severity, drug activity, drug sensitivity, method of administration, time of administration, route of administration, excretion rate, duration of treatment, combination or concurrent use of drugs, and other factors known in the medical field. In one embodiment, a therapeutic effective amount refers to an amount of drug that is effective in treating an ocular disease.

[0153] In this case, the pharmaceutical composition may also contain a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier can be any carrier, as long as it is a non-toxic substance suitable for delivery to a patient. Distilled water, alcohol, fats, waxes, and inert solids may be included as carriers. Pharmaceutically acceptable adjuvants (buffers or dispersants) may also be included in the pharmaceutical composition.

[0154] Specifically, the pharmaceutical composition contains a pharmaceutically acceptable carrier in addition to the active ingredient and can be prepared as a parenteral dosage form according to conventional methods known in the art. Here, the term "pharmaceutically acceptable" means that it does not inhibit the activity of the active ingredient and does not have toxicity beyond the suitability of the subject of application (prescription).

[0155] When the pharmaceutical composition is prepared as a parenteral dosage form, it can be formulated into an injection, transdermal delivery system, nasal inhaler, or suppository form using methods known in the art, together with a suitable carrier. When formulated as an injection, sterile water, ethanol, polyols such as glycerol or propylene glycol, or mixtures thereof can be used as suitable carriers, and Ringer's solution, phosphate-buffered saline (PBS) containing triethanolamine, and isotonic solutions, such as sterile water for injection or 5% glucose, are preferred. The formulation of the pharmaceutical composition is known in the art and can be specifically referenced in Remington's *Pharmaceutical Science* (19th edition, 1995), etc. This document is incorporated in part into this specification.

[0156] Depending on the patient's condition, weight, sex, age, severity of illness, or route of administration, the preferred dosage of the pharmaceutical composition may be in the range of 0.01 μg / kg to 10 g / kg per day or 0.01 mg / kg to 1 g / kg per day. Administration may be once daily or divided into several doses. Such dosages should not be construed as limiting the scope of the invention in any way.

[0157] The subjects to whom the (prescription) pharmaceutical composition may be applied are mammals and humans, with humans being particularly preferred. In addition to the active ingredient, the pharmaceutical composition of this application may also contain any compound or natural extract known to have therapeutic effects on eye diseases, particularly macular degeneration.

[0158] In another aspect, the present invention provides the use of a fusion protein or a dimer thereof for the treatment of eye diseases, wherein the fusion protein contains an extracellular domain of CRIg or a fragment thereof and a protein that specifically binds to VEGF.

[0159] In another aspect, the present invention provides the use of a fusion protein or a dimer thereof in the preparation of a medicament for treating or preventing eye diseases, wherein the fusion protein contains an extracellular domain of CRIg or a fragment thereof and a protein that specifically binds to VEGF.

[0160] In another aspect of the present invention, a method for treating and / or preventing eye diseases is provided, the method comprising: administering to a subject a fusion protein or a dimer thereof, wherein the fusion protein contains an extracellular domain of CRIg or a fragment thereof and a protein that specifically binds to VEGF.

[0161] The fusion protein, dimer, and ocular disease are all as described above. In this case, the subject can be a subject suffering from an ocular disease. Furthermore, the subject can be a mammal, preferably a human.

[0162] Regarding the route of administration, dosage, and frequency of administration of fusion proteins or fusion protein dimers, they can be administered to subjects in various ways and amounts, depending on the patient's condition and the presence of side effects. Those skilled in the art can select the optimal method of administration, dosage, and frequency within appropriate limits. Furthermore, fusion proteins or fusion protein dimers can be administered in combination with other drugs or physiologically active substances known to have therapeutic effects on the treated disease, or can be formulated into combination preparations with other drugs.

[0163] In one implementation, the fusion protein inhibits the complement pathway, phagocytosis, and / or angiogenesis. Therefore, the fusion protein can be effectively used for ocular diseases such as wet or dry macular degeneration. In particular, it has been demonstrated that binding the extracellular domain of CRIg or a fragment thereof to a protein that specifically binds to VEGF is more effective and synergistic than including only one of them. As a result, the fusion protein can effectively treat both wet and dry macular degeneration by efficiently inhibiting the complement pathway and angiogenesis.

[0164] The present invention will be described in more detail below with reference to the following embodiments. These embodiments are for illustrative purposes only and do not limit the scope of protection of the invention.

[0165] Preparation Example 1. Preparation of fusion protein containing CRIg

[0166] [Table 1]

[0167] coding Format describe Corresponding sequence C1.01 Fc-Fusion hu CRIg-hu IgG1 Fc DANG SEQ ID NO:1 C1.02 Fc-Fusion hu CRIg-hu IgG1 Fc DANG-VEGF binder SEQ ID NO:2 C1.03 Fc-Fusion hu IgG1 Fc DANG-hu CRIg SEQ ID NO:3 C1.04 Fc-Fusion VEGF binder-hu IgG1 Fc DANG-hu CRIg SEQ ID NO:4 C1.05 Fc-Fusion VEGF binder-hu IgG1 Fc DANG SEQ ID NO:5 C1.06 Fc-Fusion hu IgG1 Fc DANG SEQ ID NO:6 C1.01m Fc-Fusion mu CRIg-mu IgG2a Fc DANG SEQ ID NO:7 C1.02m Fc-Fusion mu CRIg-mu IgG2a Fc DANG-VEGF binder SEQ ID NO:8 C1.03m Fc-Fusion mu IgG2a Fc DANG-mu CRIg SEQ ID NO:9 C1.04m Fc-Fusion VEGF conjugate-mu IgG2a Fc DANG-mu CRIg SEQ ID NO:10 C1.06m Fc-Fusion mu IgG2a Fc DANG SEQ ID NO:11 C1.07m Fc-Fusion mu IgG2a Fc DANG-VEGF binder SEQ ID NO:12 Abersipu Fc-Fusion Abersipu SEQ ID NO:13

[0168] C1.01 (SEQ ID NO:1) consists of the extracellular domains (20 to 283) of human CRIg protein, the linker, and human IgG1Fc, wherein effector function is removed by DANG mutation (D265A, N297G).

[0169] C1.02 (SEQ ID NO:2) consists of the extracellular domains (20 to 283) of human CRIg protein, a linker, human IgG1FcDANG, a linker, and a VEGF binder of aflibercept.

[0170] C1.03 (SEQ ID NO:3) consists of human IgG1 Fc DANG, a linker, and extracellular domains (20 to 283) of human CRIg protein.

[0171] C1.04 (SEQ ID NO:4) consists of the VEGF conjugate, adaptor, human IgG1 Fc DANG, adaptor, and extracellular domains (20 to 283) of human CRIg protein.

[0172] C1.05 (SEQ ID NO:5) consists of the VEGF conjugate of aflibercept, the linker, and human IgG1 Fc DANG.

[0173] C1.06 (SEQ ID NO:6) is composed of human IgG1 Fc DANG.

[0174] C1.01m (SEQ ID NO:7) consists of the extracellular domains (20 to 187) of the mouse CRIg protein, the linker, and the mouse IgG2a Fc, in which effector function is removed by DANG mutations (D265A, N297G).

[0175] C1.02m (SEQ ID NO:8) consists of the extracellular domains (20 to 187) of mouse CRIg protein, a linker, mouse IgG2a Fc DANG, a linker, and a VEGF binder of aflibercept.

[0176] C1.03m (SEQ ID NO:9) consists of mouse IgG2a Fc DANG, a linker, and extracellular domains (20 to 187) of mouse CRIg protein.

[0177] C1.04m (SEQ ID NO:10) consists of the VEGF conjugate of aflibercept, the linker, mouse IgG2a Fc DANG, the linker, and the extracellular domains (20 to 187) of mouse CRIg protein.

[0178] C1.06m (SEQ ID NO:11) is composed of mouse IgG2a Fc DANG.

[0179] C1.07m (SEQ ID NO:12) consists of mouse IgG2a Fc DANG, a linker, and an aflibercept VEGF conjugate.

[0180] [SEQ ID NO:1]hu CRIg-hu IgG1 Fc DANG

[0181] RPILEVPESVTGPWKGDVNLPCTYDPLQGYTQVLVKWLVQRGSDPVTIFLRDSSGDHIQQAKYQGRLHVSHKVPGDVSLQLSTLEMDRSHYTCEVTWQTPDGNQVVRDKITELRVQKLSVSKPTVTTGSGYGFTVPQGMRISLQCQARGSPPISYIWYKQQTNNQEPIKVATLSTLLFKPAVIADSGSYFCTAKGQVGSEQHSDIVKFVVKDSSKLLKTTEAPTTMTYPLKATSTVKQSWDWTTDMDGYLGETSAGPGKSLPGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0182] [SEQ ID NO:2]hu CRIg-hu IgG1 Fc DANG-VEGF conjugation

[0183] RPILEVPESVTGPWKGDVNLPCTYDPLQGYTQVLVKWLVQRGSDPVTIFLRDSSGDHIQQAKYQGRLHVSHKVPGDVSLQLSTLEMDRSHYTCEVTWQTPDGNQVVRDKITELRVQKLSVSKPTVTTGSGYGFTVPQGMRISLQCQARGSPPISYIWYKQQTNNQEPIKVATLSTLLFKPAVIADSGSYFCTAKGQVGSEQHSDIVKFVVKDSSKLLKTTEAPTTMTYPLKATSTVKQSWDWTTDMDGYLGETSAGPGKSLPGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAGGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGGGGGSGGGGSSDTGRPFVEMYSEIPEIIHMTEGRELV IPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEK

[0184] [SEQ ID NO:3]hu IgG1 Fc DANG-hu CRIg

[0185] DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSRPILEVPESVTGPWKGDVNLPCTYDPLQGYTQVLVKWLVQRGSDPVTIFLRDSSGDHIQQAKYQGRLHVSHKVPGDVSLQLSTLEMDDRSHYTCEVTWQTPDGNQVVRDKITELRVQKLSVSKPTVTTGSGYGFTVPQGMRISLQCQARGSPPISYIWYKQQTNNQEPIKVATLSTLLFKPAVIADSGSYFCTAKGQVGSEQHSDIVKFVVKDSSKLLKTKTEAPTTMTYPLKATSTVKQSWDWTTDMDGYLGETSAGPGKSLPG

[0186] [SEQ ID NO:4]VEGF binder-hu IgG1 Fc DANG-hu CRIg

[0187] SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSRPILEVPESVTGPWKGDVNLPCTYDPLQGYTQVLVKWLVQRGSDPVTIFLRDSSGDHIQQAKYQGRLHVSHKVPGDVSLQLSTLEMDDRSHYTCEVTWQTPDGNQVVRDKITELRVQKLSVSKPTVTTGSGYGFTVPQGMRISLQCQARGSPPISYIWYKQQTNNQEPIKVATLSTLLFKPAVIADSGSYFCTAKGQVGSEQHSDIVKFVVKDSSKLLKTKTEAPTTMTYPLKATSTVKQSWDWTTDMDGYLGETSAGPGKSLPG

[0188] [SEQ ID NO:5]VEGF binder - hu IgG1 Fc DANG

[0189] SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

[0190] [SEQ ID NO:6]hu IgG1 Fc DANG

[0191] SVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

[0192] [SEQ ID NO:7]mu CRIg-mu IgG2a Fc DANG

[0193] HPTLKTPESVTGTWKGDVKIQCIYDPLRGYRQVLVKWLVRHGSDSVTIFLRDSTGDHIQQAKYRGRLKVSHKVPGDVSLQINTLQMDDRNHYTCEVTWQTPDGNQVIRDKIIELRVRKYNPPRINTEAPTTLHSSLEATTIMSSTSDLTTNGTGKLEETIAGSGRNLPGGGGSEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0194] [SEQ ID NO:8]mu CRIg-mu IgG2a Fc DANG-VEGF Binder

[0195] HPTLKTPESVTGTWKGDVKIQCIYDPLRGYRQVLVKWLVRHGSDSVTIFLRDSTGDHIQQAKYRGRLKVSHKVPGDVSLQINTLQMDDRNHYTCEVTWQTPDGNQVIRDKIIELRVRKYNPPRINTEAPTTLHSSLEATTIMSSTSDLTTNGTGKLEETIAGSGRNLPGGGGSEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGGGGGSGGGGSSDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEK

[0196] [SEQ ID NO:9]mu IgG2a Fc DANG-mu CRIg

[0197] EPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGGGGGSGGGGSHPTLKTPESVTGTWKGDVKIQCIYDPLRGYRQVLVKWLVRHGSDSVTIFLRDSTGDHIQQAKYRGRLKVSHKVPGDVSLQINTLQMDDRNHYTCEVTWQTPDGNQVIRDKIIELRVRKYNPPRINTEAPTTLHSSLEATTIMSSTSDLTTNGTGKLEETIAGSGRNLPG

[0198] [SEQ ID NO:10]VEGF binder - mu IgG2a Fc DANG - mu CRIg

[0199] SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKGGGGSEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGGGGGSGGGGSHPTLKTPESVTGTWKGDVKIQCIYDPLRGYRQVLVKWLVRHGSDSVTIFLRDSTGDHIQQAKYRGRLKVSHKVPGDVSLQINTLQMDDRNHYTCEVTWQTPDGNQVIRDKIIELRVRKYNPPRINTEAPTTLHSSLEATTIMSSTSDLTTNGTGKLEETIAGSGRNLPG

[0200] [SEQ ID NO:11] mu IgG2a Fc DANG

[0201] APNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0202] [SEQ ID NO:12] mu IgG2a Fc DANG-VEGF binder

[0203] EPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGGGGGSGGGGSSDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEK

[0204] [SEQ ID NO:13] Aflibercept

[0205] SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

[0206] Preparation Example 2. Preparation of human protein (C1.01 to C1.06 and aflibercept) and mouse protein (C1.03m and C1.04m)

[0207] Preparation Example 2.1. Vector Construction and Plasmid Maximization

[0208] Tables 2 and 3 list the reagents and equipment used, as shown below.

[0209] [Table 2]

[0210]

[0211] [Table 3]

[0212] Equipment and Instruments Manufacturer Model Name Biosafety cabinet NUAIRE LabGard Class II centrifuge Eppendorf 5424 Gel imaging system Tanon 2500R

[0213] The synthesized DNA fragments were amplified by PCR, and the PCR products were purified by gel electrophoresis. The pTT5 vector was digested with restriction endonucleases EcoRI and BamHI, followed by gel electrophoresis. Each PCR product and linear vector were ligated using an In-Fusion kit. The resulting vectors were transformed into ECOS101 DH5α competent cells and cultured on 2×YT agar plates containing 100 μg / ml ampicillin. All procedures were performed according to standard conversion protocols. Positive recombinants were confirmed by colony PCR, and the recombinant plasmids were sequenced for verification. Single colonies were selected and inoculated into 5 ml of 2×YT medium containing 100 μg / ml ampicillin. The cultures were incubated at 37°C with shaking for 8 hours.

[0214] Subsequently, the bacterial strain was diluted 1:1,000 in 200 ml of 2×YT selective medium. The culture was incubated at 37°C with shaking for 16 hours. Bacterial cells were collected by centrifugation at 4°C and 4,700 rpm for 10 minutes. The bacterial pellet was resuspended in 12 ml of RES-EF buffer. Then, 12 ml of LYS-EF buffer was added, and the sealed tube was vigorously inverted to mix thoroughly, followed by incubation at room temperature for 5 minutes. 12 ml of NEU-EF buffer was added to the lysate, and the tube was vigorously inverted to mix rapidly and thoroughly.

[0215] Injecting lysate Before Xtra column filtration, a homogeneous suspension of the precipitate was prepared three times by inverting the lysis buffer tube to prevent filter clogging. Subsequently, the filter was washed with 10 ml of filter wash buffer FIL-EF. Xtra column filter and Xtra column. Remove Xtra column filter, or remove it via an inverted column. Wash with 90 ml of wash buffer END. Xtra column.

[0216] Wash with 45 ml of Wash-EF buffer. Xtra column. Elute plasmid DNA with 15 ml of elution buffer ELU. Collect the eluent in a 50 ml centrifuge tube. Add 10.5 ml of room temperature isopropanol to precipitate the eluted plasmid DNA. Vortex and let the mixture stand for 2 minutes.

[0217] Next, add 5 ml of 70% ethanol to the precipitate. Carefully remove all the ethanol from the tube using a pipette tip. Dry the precipitate at room temperature (20°C to 25°C). Then, dissolve the DNA precipitate in 1,000 μl of H2O.

[0218] Preparation Example 2.2. Cell Transfection and Protein Expression

[0219] Table 4 lists the materials and reagents used, as shown below.

[0220] [Table 4]

[0221]

[0222] The 293F strain containing complete culture medium was kept in an incubator shaker at 130 rpm, 37°C, and 8% CO2. Cells were incubated at a rate of 0.3 × 10⁻⁶. 6 Cells / ml to 0.4 × 10⁻⁶ 6 Culture at a density of 100 cells / ml, changing the medium every 2 to 3 days. 24 hours before transfection, use a culture medium of 2.6 × 10⁶ cells / ml. 6 Freshly passaged 293F cells were prepared at a density of 1 cell / ml. The prepared cells were cultured in a shaking incubator at 130 rpm, 37°C, and 8% CO2. On the day of transfection, the cell density was adjusted to 5.0 × 10⁶ cells / ml using fresh culture medium. 6 Cells / ml. Adjust to a total volume of 1L in a 3-L shake flask. Dilute 0.4 mg HC and 0.6 mg LC plasmid with 50 ml OPTI MEM I and filter through a 0.22 μm filter. Then, dilute 2 mg PEI with 50 ml OPTI MEM I to prepare the transfection reagent.

[0223] Add the diluted PEI to the DNA mixture and mix immediately. Then incubate at room temperature for 15 minutes. Add the DNA-PEI mixture to a solution containing 2.6 × 10⁻⁶ ppm. 6Cells were prepared at 100 cells / ml in 293F cells. Cells were then continuously cultured in a shaking incubator at 130 rpm, 37°C, and 8% CO2 for 24 hours. 24 hours after transfection, 10% peptone was added to 1 / 20 of the culture medium to a final concentration of 0.5%. Cells were then continuously cultured in a shaking incubator at 130 rpm, 37°C, and 8% CO2. Cell density / viability was measured and recorded daily for 2 to 5 days post-transfection. Cells were collected for purification on day 7 post-transfection or when cell viability fell below 70%.

[0224] Preparation Example 2.3. Protein Purification

[0225] Tables 5 through 7 show the reagents, the composition of each buffer, and the equipment used for protein purification, as shown below.

[0226] [Table 5]

[0227] reagents Manufacturer Item number Mabselect SuRe GE Healthcare 11003493 Tris SIGMA 77-86-1 NaCl ACROS ORGANIVS 7647-14-5 Sodium citrate Adamas-beta 76198B Citric acid GENERAL-Reagent G83162B Arginine VETEC V900343-500G Succinic acid Sigma-Aldrich S9512-500G Triton X-100 ABCONE X10010-1L TRITON X-114 SIGMA-ALDRICH X114 Millex-GP filter unit, 0.22μm, sterile. MILLIPORE SLGP033RS NaOH Merck B146369740

[0228] [Table 6]

[0229]

[0230] [Table 7]

[0231] instrument Manufacturer Model Name AKTA Pure GE Healthcare 29-0182-24 centrifuge Beckman J-26xp Gel imaging system Tanon 2500R Sartopore 2 filter Sartorius 5445307H9-OO-A

[0232] Proteins were purified using a MabSelect Sure column. Specifically, the supernatant was collected by centrifugation at 4°C and 2,000 × g for 20 min. The supernatant was then filtered through a Sartopore 2 filter. The clarified supernatant was loaded onto a 5 mL MabSelect Sure column equilibrated with buffer A. The column was then washed with buffer A until the A280 absorbance reached baseline. The column was washed with 10 CV of buffer B. The column was then washed with 10 CV of buffer A. The bound proteins were eluted with 6 CV of buffer C, and the eluent was neutralized with 1 / 6 volume of buffer D before SDS-PAGE and SEC-HPLC analysis.

[0233] The protein was then purified using a HIC column. The protein was then dialyzed overnight at 4°C against buffer E. The supernatant was loaded onto a HIC column equilibrated with buffer E. The column was then washed with buffer E until the A280 absorbance reached baseline. The bound protein was eluted by a gradient elution (10 CV of buffer F, 0% to 40%). The bound protein was eluted with 2 CV of 100% buffer F and analyzed by SDS-PAGE.

[0234] After protein purification, the protein was collected in one place and then dialyzed against the final buffer overnight at 4°C. Subsequently, SDS-PAGE and SEC-HPLC analyses were performed.

[0235] As a result, Figure 1 and Figure 2 As shown, the purified C1.01, C1.02, C1.03, C1.04, C1.05, C1.06, C1.03m, C1.04m and aflibercept were confirmed by SDS-PAGE.

[0236] Preparation Example 3. Preparation of mouse fusion proteins (C1.01m, C1.02m, C1.06m and C1.07m)

[0237] Preparation Example 3.1. Protein Preparation

[0238] Table 8 shows the materials and reagents used, as shown below.

[0239] [Table 8]

[0240] Materials and reagents supplier Item number <![CDATA[EXPI293F TM Cells Gibco A14527 <![CDATA[EXPI293 TM Expression System Kit Gibco A14635 MabSelect SuRe GE Lifesciences 17543803 Superdex 200 increase 10 / 300 GE Lifesciences 28990944 <![CDATA[MPC TM Ceramic Hydroxyfluoroapatite Bio-rad 1570200

[0241] A DNA fragment corresponding to the protein sequence was synthesized in Genewiz (No. 80-383034849). The corresponding DNA fragment was amplified by PCR and introduced into the linearized pcDNA3.3 expression vector. The construction was verified by sequencing, and then sufficient DNA was obtained for cell transfection using a large-scale plasmid preparation process.

[0242] First, with 2.94 × 10 6 Prepare Expi293F cells per ml (with 95% or more viable in 2-L cell culture medium). Incorporate plasmid DNA and EXPIFECTAMINE. TM Reagent 293 was first diluted in Opti-MEM, then mixed and added to the cell culture medium. Cells were cultured in a platform shaker at 150 rpm. The temperature was maintained at 37°C and the CO2 concentration at 8%. 18 to 20 hours after transfection, enhancer 1 and enhancer 2 were added to the cell culture medium.

[0243] After 6 days of cell culture, the cells were centrifuged at 4,000 rpm for 10 minutes at 25°C. The supernatant was collected for purification and gel electrophoresis. According to NUPAGE... TM The instructions for 4% to 12% Bis-Tris Protein Gels (Thermo Fisher Scientific) state that the supernatant should be loaded onto an SDS-PAGE gel. PAGERULER TMThe Unstained Protein Ladder (Thermo Fisher Scientific) is used with protein samples to measure the molecular weight of proteins. The remaining supernatant for each protein is used in subsequent purification processes.

[0244] Protein purification was performed as follows. Specifically, Protein A column was pre-packaged with MabSelect Sure resin. The column was equilibrated with 0.1 M Tris (pH 7.0) before loading cell culture medium. After loading cell culture medium, the column was washed with 0.1 M Tris (pH 7.0) and then eluted with 0.1 M glycine (pH 3.5). The elution buffer was neutralized by adding 0.1 M Tris (pH 9.0). Subsequently, the sample was dialyzed in PBS buffer (Sangon Biotech, B548117-0500).

[0245] Before loading the sample, equilibrate the SEC column (GE Life Sciences, Superdex 200 increase 10 / 300) with PBS. After loading, elute the sample with PBS and collect it by chromatography. Perform SDS-PAGE to analyze each peak. Dialyze each sample in formulation buffer (10 mM sodium phosphate, 0.3 to 0.4 M NaCl, pH 6.8).

[0246] The CHT column was coupled with CHT resin (Bio-rad, MPC). TM The hydroxyfluoroapatite ceramics were pre-packaged and equilibrated with buffer A (10 mM sodium phosphate, 30 mM NaCl, pH 6.8) before sample loading. After loading, the column was eluted with 30% buffer B (10 mM sodium phosphate, 1 M NaCl, pH 6.8), followed by elution with a 30% to 90% linear gradient buffer B and a final 100% buffer B. The eluent was identified by SDS-PAGE, and the sample was dialyzed in formulated buffer (10 mM sodium phosphate, 0.3 to 0.4 M NaCl, pH 6.8). The final protein was filtered through a 0.2 μm filter and aseptically dispensed into 1.5 mL tubes in 0.5 mL increments.

[0247] As a result, Figure 3 As shown, the purified C1.01m, C1.02m, C1.06m, and C1.07m were confirmed by SDS-PAGE.

[0248] Preparation Example 3.2. Identification of Proteins

[0249] Protein concentration was measured at 280 nm using nanodroplets. Protein purity was confirmed by SDS-PAGE and HPLC-SEC.

[0250] SDS-PAGE samples were prepared by mixing 15 μl of purified protein with 5 μl of 4× loading buffer and boiling the mixture for 5 minutes. 15 μl of the mixed sample was loaded into 4% to 12% NuPAGE Bis-Tris Mini Gels. For SEC-HPLC analysis, 80 μl of purified protein was loaded onto a TSKgel G3000SWxl column of an HPLC system 1260 Infinity II, using 50 mM sodium phosphate (pH 7.0) and 150 mM sodium chloride as electrophoresis buffer.

[0251] Preparation Example 4. Purification of C3 and C3b in rabbits and rats

[0252] Preparation Example 4.1. Purification of C3 from Rabbits and Rats

[0253] Tables 9 to 11 show the reagents, the composition of each buffer solution, and the instruments used for purifying C3 from rabbits and rats, as shown below.

[0254] [Table 9]

[0255] Materials and reagents Manufacturer Item number NaCl ACROS ORGANIVS 7647-14-5 NaOH Merck B146369740 <![CDATA[KH2PO4]]> GENERAL-Reagent 7778-77-0 <![CDATA[NaH2PO4]]> GENERAL-Reagent 7558-80-7 EDTA GENERAL-Reagent 60-00-4 Benzalamidin Adamas 618-39-3 PBS Gibco C10010500BT <![CDATA[MgCl2]]> GENERAL-Reagent 7786-30-3 Factor B Complement Technology A135 Factor D Complement Technology A136

[0256] [Table 10]

[0257]

[0258]

[0259] [Table 11]

[0260] instrument Manufacturer Model Name AKTAPure GE Healthcare 29-0182-24 centrifuge Beckman J-26xp Gel imaging system Tanon 2500R Millex-GP filter unit, 0.22μm, sterile. MILLIPORE SLGP033RS DEAE 16 / 10FF GE Healthcare 10294207 Mono S 5 / 50GL GE Healthcare 10298955 Sephadex S200 GE Healthcare 17104-302 HPLC Waters E2695

[0261] Prior to protein purification, a step was performed to remove high molecular weight substances from the plasma. The plasma volume was measured, and then 10% (w / v) of anhydrous Na₂SO₄ powdered salt crystals were slowly added to the protein solution while stirring. The mixture was then stirred at 4°C for 2 hours. The supernatant was obtained and its volume was measured after centrifugation at 26,892 × g for 30 minutes at 4°C using a Sorvall ultracentrifuge. The obtained supernatant was dialyzed against 5 L of DEAE buffer A, and after 2 hours, it was replaced with 5 L of fresh solution. For optimal results, dialyzing was performed overnight at 4°C. To confirm the completion of dialysis, the volume, A280, and conductivity of the dialysate were measured. When the solution became turbid or precipitated, it was centrifuged at 4,000 × g for 15 minutes at 4°C to remove the precipitate. The dialysate was filtered through a 0.2 μm filter and stored on ice until purification.

[0262] The protein purification process involved anion exchange chromatography, cation exchange chromatography, and size exclusion chromatography, performed sequentially. Before loading the dialysis buffer, the DEAE column (GE Healthcare, HIPREP) was equilibrated with buffer A (10 mM KH₂PO₄, 5 mM EDTA, 1 mM benzidine, pH 7.8). TM DEAE Fast Flow 16 / 10). After sample loading, the column was washed with buffer A and eluted with 0% to 50% linear gradient buffer B (10 mM KH2PO4, 5 mM EDTA, 1 mM benzidine, 1 M NaCl, pH 7.8). The eluent fraction was analyzed by SDS-PAGE, and the fraction containing C3 was collected and its A280 was measured. The obtained eluent was dialyzed in 2 L Dono S buffer A (50 mM sodium phosphate) at 4 °C for 2 h.

[0263] Before loading the dialysis buffer, the Mono S column (GE Healthcare) was equilibrated with buffer A (50 mM sodium phosphate). (5 / 50GL). After loading DEAE eluent, the column was washed with buffer A and eluted with 0% to 35% linear gradient buffer B (50 mM sodium phosphate, 1 M NaCl, pH 5.5). The eluent fractions were analyzed by SDS-PAGE, the central peaks were combined, and their A280 was measured.

[0264] Before loading the sample, the SEC column (GE Lifesciences, Superdex 200 increase 10 / 300) was equilibrated with PBS. After loading, the sample was eluted with PBS and collected by chromatography. SDS-PAGE was performed to analyze each peak. The C3 fraction, located at the center, was concentrated and its A280 was measured.

[0265] Preparation Example 4.2. Purification of C3b in rabbits and rats

[0266] C3 was prepared by dilution with 0.5 mg / ml PBS. C3 was converted to C3b by adding 0.4 μM factor B, 0.05 μM factor D, and 5 mM MgCl2 and incubating at 25 °C for 30 min. C3b was further purified by Superdex 200 (60 ml) gel filtration column. Rabbit C3, rabbit C3b, rat C3, and rat C3b were subsequently analyzed by SDS-PAGE and SEC-HPLC.

[0267] As a result, Figure 4 As shown, the purification of rabbit C3, rabbit C3b, rat C3, and rat C3b was confirmed.

[0268] Experimental Example 1. Measurement of Fusion Protein Binding Force

[0269] Experimental Example 1.1. Biacore Surface Plasmon Resonance (SPR) Analysis Technique

[0270] To measure the binding force of the fusion protein, the physical properties of the prepared fusion protein were analyzed using a Biacore 8K instrument (GE Healthcare, 29129951).

[0271] Table 12 shows the materials and reagents used, as shown below.

[0272] [Table 12]

[0273] reagents Manufacturer Item number CM5 sensor chip GE Healthcare 29-1496-03 HBS-EP+ buffer (10γ) GE Healthcare BR-1006-69 Amine coupling kit GE Healthcare BR-1006-33 Human Antibody Capture Kit GE Healthcare 29234600 10mM glycine 1.5 GE Healthcare BR-1003-54 C3b, C2, and C4 Complement Technology A114, A112, and A105

[0274] Experimental Example 1.2. Immobilization of anti-human immunoglobulin G (Fc) antibody on a CM5 sensor chip

[0275] 1 L of 1×HBS-EP+ buffer was prepared by mixing 100 mL of 10×HBS-EP+ buffer and 900 mL of Milli-Q water. The CM5 chip was activated by mixing 50 mM NHS and 200 mM EDC at a 1:1 ratio for 420 seconds, followed by a flow rate of 10 μl / min. To achieve a fixed level of approximately 10,000 RU, 25 μg / mL of anti-human immunoglobulin G (Fc) antibody (acetate at pH 5.0) was injected at a rate of 10 μl / mL for 400 seconds. The remaining activated ester groups were blocked by injecting 1 M ethanolamine (pH 8.5) at a rate of 10 μl / min for 420 seconds. To stabilize the baseline, the sensor chip was washed with 1×HBS-EP+ at a rate of 10 μl / min for 16 hours.

[0276] Experimental Example 1.3. Measurement Combining Dynamics

[0277] To stabilize the baseline, three start-up cycles consisting of a sample step and a regeneration step were performed. Sample step: 1×HBS-EP+ buffer was injected into the flow cell at a flow rate of 30 μl / min for 120 seconds, followed by a 120-second lysis phase and a 30-second stabilization phase. Regeneration step: 10 mM glycine (pH 1.5) was injected into the flow cell at a rate of 30 μl / min for 30 seconds, followed by a 30-second stabilization phase.

[0278] Subsequently, the kinetics of the combination were measured in the following manner.

[0279] The C3b stock solution was diluted to 50 nM using 1×HBS-EP+ buffer. Human VEGF165 was diluted to 5 nM using 1×HBS-EP+ buffer. The 50 nM and 5 nM solutions were then diluted to 0.78125 nM and 0.078125 nM, respectively. In the sample step, the diluted antigen was injected into the flow cell at a rate of 30 μl / min. Two 0 nM antigens (1×HBS-EP+ buffer) were used and removed from the reference signal. Binding was performed for 180 seconds and separation for 400 seconds. After separation, a 60-second stabilization step was performed. In the regeneration step, 10 mM glycine (pH 1.5) was injected into the flow cell at a rate of 30 μl / min for 30 seconds, followed by a 60-second stabilization step.

[0280] Experimental Example 1.4. Analysis and Results

[0281] After subtracting the reference value and the 0nM value from the sample values, the binding dynamics were calculated using Biacore Insight evaluation software (version 2.0.15.12933) and a 1:1 binding model for curve fitting.

[0282] Table 13 shows the binding affinity of the tested substances, as shown below.

[0283] [Table 13]

[0284] Capture 1 solution Analyte 1 solution ka(1 / Ms) kd(1 / s) KD(M) 0.5 μg / ml C1.01 C3b 3.47E+06 1.21E-02 3.47E-09 2μg / ml C1.02 C3b 3.66E+06 1.59E-02 4.34E-09 2μg / ml C1.02 Human VEGF165 3.94E+06 2.47E-04 6.28E-11

[0285] The binding affinity of C1.01 and C1.02 to human C3b and human VEGF165, as well as the binding affinity of C1.01m and C1.02m to mouse C3b and human VEGF165, were determined by Biacore analysis.

[0286] As shown in Table 13 and Figures 6 and 7, it was confirmed that both human and mouse C1.01 and C1.02 have high binding affinity for C3b, and human and mouse C1.02 has high binding affinity for human VEGF165.

[0287] Experimental Example 2. The binding affinity of the fusion protein to complement protein and VEGF was measured by enzyme-linked immunosorbent assay (ELISA).

[0288] To confirm whether the complement pathway was inhibited by the fusion protein dimer of one implementation scheme, enzyme-linked immunosorbent assay (ELISA) was used to analyze whether C1.01, C1.02, C1.03, C1.04, and C1.01m to C1.03m bound to the C3b protein.

[0289] Specifically, human C3b protein was immobilized on a plate, and C1.01, C1.02, C1.03, C1.04, and hIgG1 were bound to it as controls. Next, anti-human immunoglobulin G antibody and anti-horseradish peroxidase (HRP) antibody were sequentially bound to it. In addition, mouse C3b protein was immobilized on a plate, and C1.01m to C1.03m containing mouse CRIg were bound to mouse C3b.

[0290] As a result, Figure 8a As shown, C1.01, C1.02, C1.03, and C1.04, which contain CRIg, are confirmed to bind to human C3b in a concentration-dependent manner. Furthermore, as... Figure 8c As shown, it was confirmed that mouse CRIg containing C1.01m to C1.03m also binds to mouse C3b in a concentration-dependent manner.

[0291] To confirm whether the fusion protein according to one embodiment has anti-VEGF activity, enzyme-linked immunosorbent assay (ELISA) was used to analyze whether the fusion protein binds to human VEGF165 protein, and the binding affinity of aflibercept, C1.02, C1.04 and C1.05 to human VEGF165 was determined by ELISA.

[0292] Specifically, human VEGF165 protein was immobilized on a plate, and C1.02, C1.04, and C1.05, along with aflibercept and hIgG1 as controls, were bound to it. Next, anti-human immunoglobulin G antibody and anti-horseradish peroxidase (HRP) antibody were sequentially bound to them.

[0293] As a result, Figure 8b As shown, the results measured by enzyme-linked immunosorbent assay (ELISA) confirmed that aflibercept, C1.02, C1.04 and C1.05, which have anti-VEGF properties, bind to human VEGF165 in a concentration-dependent manner.

[0294] To confirm that the fusion protein according to one embodiment binds to the C3b of the bypass pathway to inhibit the bypass pathway, but does not bind to the human C2 or C4 protein of the classical pathway and therefore does not inhibit the classical pathway, the fusion protein C1.01 according to one embodiment was analyzed by ELISA to determine whether it binds to the human Cb3, C2 and C4 proteins.

[0295] Specifically, human Cb3, C2, or C4 proteins are immobilized on a plate, and C1.02 is bound to them. Next, anti-human immunoglobulin G antibody and anti-horseradish peroxidase (HRP) antibody are bound to them sequentially.

[0296] As a result, Figure 8d As shown, it is confirmed that C1.02 binds to C3b, but not to C2 and C4.

[0297] Experimental Example 3. Dynamic Light Scattering (DLS) Analysis

[0298] The hydrodynamic radius of the fusion protein was measured based on whether it contained a VEGF binder. The hydrodynamic radii of C1.01 and C1.02 were analyzed by dynamic light scattering.

[0299] Specifically, C1.01 and C1.02 were centrifuged at 12,000×g for 10 minutes, and the supernatant was added to a 96-well plate. The samples were then measured at 25°C using a Zetasizer APS (Marlvern) as the DLS analyzer.

[0300] Table 14 shows the hydrodynamic radii of C1.01 and C1.02, as shown below.

[0301] [Table 14]

[0302]

[0303] The results are shown in Table 14 and Figure 9a and 9b As shown, measurements confirmed that the hydrodynamic radius of C1.02 containing VEGF conjugates is longer than that of C1.01 without VEGF conjugates.

[0304] Experimental Example 4. Measurement of C1.02 Viscosity

[0305] The viscosity of C1.02 was measured at concentrations of 33, 65, and 130 mg / ml using a microviscometer (m-VROC, RheoSence) and a vROC-mB05 (RheoSence) chip. Additionally, as a control, the viscosity of human serum albumin at 134 mg / ml was measured.

[0306] Table 15 shows the measured viscosity, as shown below.

[0307] [Table 15]

[0308]

[0309] The results are shown in Table 15 and Figure 10 As shown, the viscosity of C1.02 increases with increasing concentration.

[0310] Experimental Example 5. Analysis of complement bypass pathway inhibition using hemolysis analysis

[0311] Table 16 shows the reagents used, as follows.

[0312] [Table 16]

[0313] reagents Manufacturer C1q-deficient serum Comptech Rabbit RBC Yuduo biolody Gelatin Veronal Buffer (5mM Barbiturate) Boston Bioproducts Measurement plate Corning

[0314] To determine the fusion protein's inhibition of the complement bypass pathway in the above implementation scheme, hemolysis analysis (AH50) was performed on C1.01, C1.02, C1.04, C1.01m, C1.02m, and C1.04m.

[0315] Specifically, 3 ml of rabbit red blood cells were washed with TBS for 10 minutes at a 400×g centrifuge. This process was repeated twice. Then, the rabbit red blood cells were washed with GVB EGTA buffer for 10 minutes at a 400×g centrifuge. The concentration of the rabbit red blood cells was then adjusted to 1×10⁻⁶ cells using GVB EGTA buffer. 9 Cells / ml

[0316] AH50 was determined by sensitizing red blood cells. 9% human C1q-deficient serum was added to 96-well plates (50 μl / well). Different concentrations of C1.01, C1.02, C1.01m, and C1.02m were also used for treatment. After incubation at 4°C for 30 minutes, rabbit red blood cells (2 × 10⁻⁶) were added. 6 Cells / well, 50 μl / well. Incubate at 37°C for 1.5 h, then centrifuge at 600 × g for 10 min. Collect 110 μl of supernatant and measure its OD. 415 value.

[0317] AH50 hemolysis analysis confirmed the inhibitory effect of C1.01, C1.02, C1.04, C1.01m, C1.02m, and C1.04m on the alternative complement pathway.

[0318] The results are shown in Table 16 and Figures 11a to 11c As shown, C1.01, C1.02, C1.04, C1.01m, C1.02m, and C1.04m inhibited hemolysis via the alternative complement pathway in a concentration-dependent manner.

[0319] Experimental Example 6. Analysis of the inhibitory effect of the classical complement pathway by hemolysis analysis

[0320] Table 17 is a table of the reagents used, as shown below.

[0321] reagents Manufacturer Factor B-Dpl serum factor Comptech Sheep RBC Yuduo biolody Hemolysin Yuduo biolody Gelatin Veronal Buffer (GVB; 5mM barbiturate) Boston Bioproducts Measurement plate Corning

[0322] To determine whether the fusion protein dimer according to one implementation scheme does not inhibit the classical complement pathway, hemolysis analysis (CH50) was performed on C1.01, C1.02, C1.04, C1.05, C1.06, C1.01m, C1.02m, C1.04m, C1.06m, and C1.07m.

[0323] Specifically, sheep red blood cells were centrifuged in TBS at 400×g for 10 minutes, and this process was repeated twice. Then, 1 ml of 20% sheep red blood cells was added, and the mixture was incubated with hemolysin at 4°C for 30 minutes. Subsequently, the sheep red blood cells were washed with TBS at 400×g for 10 minutes, and this process was repeated twice. Next, the sheep red blood cells were washed with GVB++ buffer at 400×g for 10 minutes. Finally, the concentration of sensitized sheep red blood cells was adjusted to 1×10⁻⁶ using GVB++ buffer. 9 Cells / ml

[0324] To analyze CH50 using sensitized red blood cells, 3% or 4.5% human factor B-deficiency serum was added to 96-well plates (50 μl / well), and then C1.01, C1.02, C1.06, C1.01m, C1.02m, C1.06m, and C1.07m were treated at various concentrations. After incubation at 4°C for 30 minutes, sensitized sheep red blood cells (2.5 × 10⁻⁶) were added. 6 Cells / well, 50 μl / well). Incubate at 37°C for 30 min. Centrifuge at 600×g for 10 min, collect 110 μl of supernatant, and then measure its OD. 415 value.

[0325] The results are shown in Table 16 and Figures 12a to 12c As shown, it was confirmed that C1.01, C1.02, C1.04, C1.05, C1.06, C1.01m, C1.02m, C1.04m, C1.06m, and C1.07m do not inhibit hemolysis via the classical complement pathway.

[0326] Experimental Example 7. Efficacy analysis of fusion protein using VEGF reporter cells.

[0327] To verify whether the fusion protein of one implementation scheme effectively inhibits VEGF protein, the binding of VEGF and VEGF receptor was analyzed to determine whether it was inhibited.

[0328] The inhibitory effects of aflibercept, C1.01, C1.02, C1.05, and C1.06 on VEGF signaling were confirmed using reporter cells. Specifically, VEGF reporter cells (GA3001, Promega, USA) were used to analyze the luminescence intensity of aflibercept, C1.02, and C1.05 to determine whether they inhibited the binding of VEGF and its receptor, VEGF, to VEGF. These VEGF reporter cells emit light via receptor-mediated signal transduction upon binding to VEGF.

[0329] As a result, Figure 13 As shown, aflibercept, C1.02, and C1.05 inhibited VEGF-mediated receptor signaling in a concentration-dependent manner.

[0330] Experimental Example 8. Fusion Protein Assessment and Wound Healing Assay

[0331] The inhibitory effect of the fusion protein dimer on wound healing ability was demonstrated by confirming whether the fusion protein dimer according to one embodiment effectively inhibits VEGF protein.

[0332] Specifically, a cell-based wound healing assay confirmed the inhibitory effects of the VEGF signaling pathway on C1.01, C1.02, and C1.05. Analysis was performed using the adult retinal pigment epithelial cell line-19 (ARPE-19). ARPE-19 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) / F12 using 10% fetal bovine serum (FBS). ARPE-19 cells (80,000 cells / well) were cultured overnight in 24-well plates. The next day, each well was uniformly damaged, and VEGF (6 ng / ml) and C1.01, C1.02, and C1.05 (35 nM) were added to the medium. After 24 hours, the wound healing inhibitory capacity of each fusion protein was analyzed.

[0333] As a result, Figure 14 As shown, compared with the control group, C1.02 significantly inhibited wound healing (p = 0.0031), and this effect was more significant than that of C1.01 (p = 0.0146) and C1.05 (p = 0.0482).

[0334] Experimental Example 9. Species Cross-Reactivity Test

[0335] To confirm the species cross-reactivity of the fusion protein dimer according to one implementation scheme, ELISA was used to analyze whether C1.02 binds to C3b and VEGF derived from other species.

[0336] The binding affinity of human and cynomolgus monkey C3b to C1.02, human and cynomolgus monkey C3b to C1.06, human, cynomolgus monkey, rat, and rabbit VEGF to C1.02, and human, cynomolgus monkey, rat, and rabbit VEGF to C1.01 were confirmed by ELISA. Specifically, human, cynomolgus monkey, rat, or rabbit C3b or VEGF was immobilized on a plate, and C1.01, C1.02, or C1.06 were bound to it. Next, anti-human immunoglobulin G antibody and anti-horseradish peroxidase (HRP) antibody were sequentially bound to them.

[0337] As a result, Figures 15a to 15c As shown, C1.02 exhibits species cross-reactivity by binding to C3b and VEGF in cynomolgus monkeys, rabbits, and rats.

[0338] Experimental Example 10. Efficacy evaluation of treating wet macular degeneration using a mouse animal model.

[0339] To demonstrate the therapeutic effect of a fusion protein according to one embodiment on wet macular degeneration (wet age-related macular degeneration), choroidal neovascularization was induced in a mouse animal model, and then the fusion protein dimer according to one embodiment was directly injected into the eyeball, and the effect was analyzed.

[0340] To induce the choroidal angiogenesis phenotype in mice, the presence of structural abnormalities in mice was confirmed by spectral-domain optical coherence tomography (Envisu R2200 SD-OCT system, Bioptigen, Inc., USA) prior to induction.

[0341] Next, three choroidal neovascularizations were induced (day 0) by penetrating Bruch's membrane in the right eye of mice using a diode laser (OcuLight TX-Green 532nm Laser; Iridex Corporate, USA). After induction of choroidal neovascularization, the success of the model was confirmed using spectral-domain optical coherence tomography and fluorescein angiography (HRA2 FA system; Heidelberg Engineering GmbH, Germany).

[0342] Immediately upon induction, C1.02m (350 μM; 48.3 μg / μl, 2 μl), aflibercept (Eylea; 350 μM; 40.0 μg / μl, 2 μl), or a solvent control (2 μl) were injected intravitreally. In vivo imaging was performed during induction of choroidal neovascularization (day 0) and 7 days post-induction (day 7) using spectral-domain optical coherence tomography and fluorescein angiography. Each choroidal neovascularization in the fluorescein angiography images was scored as follows: 1 point for vascular leakage and 0 points for no leakage. The probability of lesion was then calculated. For example, a 100% symbol indicates that vascular leakage was observed in all three choroidal neovascularizations.

[0343] As a result, Figures 16a to 16c As shown, after 7 days of administration, the C1.02m group had a similar protective effect to the aflibercept group and a significant protective effect compared to the solvent group.

[0344] Experimental Example 11. Evaluation of the therapeutic effect of rabbit animal model on wet macular degeneration

[0345] To confirm the therapeutic effect of a fusion protein according to one embodiment on wet macular degeneration (wet age-related macular degeneration), choroidal neovascularization was induced in a rabbit animal model, and then the fusion protein according to one embodiment was directly injected into the eyeball, and its effect was analyzed.

[0346] A wet macular degeneration model was established in rabbits by inducing choroidal neovascularization using a method similar to that described in Experimental Example 10, except that six choroidal neovascularizations were induced. Immediately after induction of choroidal neovascularization, C1.01 (350 μM; 38.45 μg / μl, 50 μl), aflibercept (350 μM; 40 μg / μl, 50 μl), or a solvent control (50 μl) were injected intravitreally. In vivo imaging was performed using a fluorescein angiography system during choroidal neovascularization induction (day 0), 7 days after induction (day 7), and 14 days after induction (day 14). Vascular leakage was measured by measuring the fluorescein intensity during choroidal neovascularization.

[0347] As a result, Figure 17 As shown, after 7 days of induction, the C1.01 group had a similar protective effect to the aflibercept group and a significant protective effect compared to the solvent group.

[0348] Experimental Example 12. Evaluation of the therapeutic effect on wet macular degeneration using a rat animal model.

[0349] To demonstrate the therapeutic effect of a fusion protein according to one embodiment on wet macular degeneration, choroidal neovascularization was induced in a rat animal model, and then the fusion protein according to one embodiment was directly injected into the eyeball, and the effect was analyzed.

[0350] Wet macular degeneration was induced in rats using a method similar to that described in Experimental Example 10, except that four choroidal neovascularizations were induced. Immediately after induction of choroidal neovascularization, rats were injected intravitreal with C1.02 (350 μM; 54.93 μg / μl, 5 μl), aflibercept (350 μM; 40 μg / μl, 5 μl), or a solvent control (5 μl). In vivo imaging was then performed on days 0 and 10 using a fluorescein angiography system and spectral-domain optical coherence tomography. Imaging quantified and visualized the presence and absence of choroidal neovascularization and areas of vascular leakage at induction and 10 days post-induction.

[0351] As a result, Figure 18a and 18bAs shown, after 10 days of induction, the number of choroidal neovascularizations and the vascular leakage area in the C1.02 group were significantly reduced, giving the C1.02 group a protective effect similar to that of the aflibercept group, and a significant protective effect compared to the solvent group.

[0352] Experimental Example 13. Evaluation of the efficacy of treatment for dry macular degeneration using a mouse animal model.

[0353] To demonstrate the therapeutic effect of a fusion protein according to one embodiment on dry macular degeneration (dry age-related macular degeneration), dry macular degeneration was induced in a mouse animal model, and then the fusion protein according to one embodiment was directly injected into the eyeball, and the effect was analyzed.

[0354] First, a mouse model of dry macular degeneration was induced by injecting 20 mg / kg sodium iodate (NaIO3) into 8-week-old C57BL / 6 mice via tail vein injection.

[0355] Following model induction, C1.02m (260 μM; 36.1 μg / μl, 1.5 μl) or a solvent control (1.5 μl) was administered intravitreally on days 0 and 7. Two weeks after model induction, the experimental animals were euthanized, their eyes were removed, and the samples were fixed in Davidson solution at 4°C for 24 hours. Subsequently, the fixed samples were stored in 30% sucrose solution at 4°C for 3 days. The samples were frozen in an OCT compound (catalog number 4583, Sakura) and then sectioned to a thickness of 20 μm. In the tissue sections, C3 protein (catalog number MA1-40046, Thermo Fisher Scientific) was stained using immunofluorescence, and the outer nuclear layer (ONL) was stained using DAPI (catalog number H-1200, Vector Laboratories). The stained samples were analyzed using a confocal microscope (LSM700; Zeiss, Germany). Specifically, the outer nuclear layer (ONL), cell count in the outer nuclear layer, area of ​​the outer nuclear layer, and C3 expression level in the retina were measured in each experimental group of the dry macular degeneration model.

[0356] As a result, Figure 19 As shown in a to 19f, measurements of cell count and outer nuclear layer area confirmed that retinal degeneration was significantly inhibited in the C1.02m group compared to the solvent group. Furthermore, C3 expression was confirmed to be significantly higher in the solvent group than in the non-AMD group, and C3 expression was significantly reduced in the C1.02m group.

[0357] Experimental Example 14.C1.02 Pharmacokinetic Characteristic Analysis

[0358] To analyze the pharmacokinetic characteristics of the fusion protein dimer according to one embodiment, 15 New Zealand white rabbits were divided into five groups (G01 to G05), with three rabbits in each group. After grouping, 2,500 μg C1.02 (50 μl / eye) was administered via intravitreal injection.

[0359] To obtain samples for pharmacokinetic characterization, 0.5 ml of blood was first collected from a rabbit vein every hour. Plasma was separated from the obtained blood samples and then frozen at -60°C. In addition, vitreous fluid (0.2 ml) and aqueous humor (0.2 ml) were collected every hour and then frozen at -60°C.

[0360] Table 18 shows the rabbit samples obtained according to the rabbit experimental group, subjects, and collection time, as follows.

[0361] [Table 18]

[0362]

[0363] The concentrations of C1.02 in plasma, vitreous fluid, and aqueous humor were determined using enzyme-linked immunosorbent assay (ELISA). Pharmacokinetic parameters were obtained by non-compartmental pharmacokinetic analysis of the measured values. Table 19 shows the pharmacokinetic parameters obtained by non-compartmental pharmacokinetic analysis, as shown below.

[0364] [Table 19]

[0365]

[0366]

[0367] Table 20 below shows the concentration of C1.02 in vitreous fluid after intravitreal injection of 2,500 μg C1.02 into rabbits. RB# represents the animal number, BQL means "below the quantifiable limit", and ND means "not determined".

[0368] [Table 20]

[0369] Time (h) RBn001* RBn002 RBn003 average value SD CV (%) n=1 1 2789070 3594376 3229369 3204272 403239 12.6 n=2 24 1561470 1336610 2160474 1686185 425856 25.3 n=3 72 1638252 2031203 2506814 2058756 434936 21.1 n=4 168 1659880 1767054 1783308 1736747 67064 3.86 n=5 336 1206629 1286796 317153 936859 538176 57.4

[0370] Table 21 below shows the concentration of C1.02 in the aqueous humor of rabbits after intravitreal injection of 2,500 μg C1.02. RB# represents the animal number, BQL means "below the quantifiable limit", and ND means "not determined".

[0371] [Table 21]

[0372] Time (h) RBn001* RBn002 RBn003 average value SD CV (%) n=1 1 1542 4803 304769 103705 174135 168 n=2 24 84982 54751 85448 75061 17590 23.4 n=3 72 38192 78324 90493 69003 27368 39.7 n=4 168 30505 37937 29392 32612 4646 14.2 n=5 336 BQL** BQL BQL ND*** ND ND

[0373] Table 22 below shows the plasma concentration of C1.02 in rabbits after administration of 2,500 μg C1.02 via intravitreal injection. RB# represents the animal number, BQL means "below the quantifiable limit", and ND means "not determined".

[0374] [Table 22]

[0375] Time (h) RBn001* RBn002 RBn003 average value SD CV (%) n=1 1 BQL** BQL BQL ND*** ND ND n=2 24 BQL BQL BQL ND ND ND n=3 72 BQL BQL BQL ND ND ND n=4 168 BQL BQL BQL ND ND ND n=5 336 BQL BQL BQL ND ND ND

[0376] Rabbits were given 2,500 μg of C1.02 via intravitreal injection, and the concentrations of C1.02 in the vitreous fluid and aqueous humor were measured.

[0377] The results are shown in Tables 20 to 22 and Figure 20a and 20b As shown, when 2,500 μg C1.02 was administered via intravitreal injection, the half-life in vitreous fluid was 226 hours, and the half-life in aqueous humor was 114 hours. Since no significant concentration was observed in plasma, pharmacokinetic characterization in plasma was not possible. SEQUENCE LISTING <110> Zhinafu Pharmaceutical Technology Co., Ltd. <120> A fusion protein comprising a complement pathway inhibitor and angiogenesis inhibitor and its uses <130> P22119976WP <150> KR 10-2020-0083536 <151> 2020-07-07 <160> 151 <170> PatentIn version 3.5 <210> 1 <211> 496 <212> PRT <213> Artificial sequence <220> <223> hu CRIg-hu IgG1 Fc DANG <400> 1 Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro Trp Lys Gly 1 5 10 15 Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly Tyr Thr Gln 20 25 30 Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro Val Thr Ile 35 40 45 Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala Lys Tyr Gln 50 55 60 Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val Ser Leu Gln 65 70 75 80 Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr Cys Glu Val 85 90 95 Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp Lys Ile Thr 100 105 110 Glu Leu Arg Val Gln Lys Leu Ser Val Ser Lys Pro Thr Val Thr Thr 115 120 125 Gly Ser Gly Tyr Gly Phe Thr Val Pro Gln Gly Met Arg Ile Ser Leu 130 135 140 Gln Cys Gln Ala Arg Gly Ser Pro Pro Ile Ser Tyr Ile Trp Tyr Lys 145 150 155 160 Gln Gln Thr Asn Asn Gln Glu Pro Ile Lys Val Ala Thr Leu Ser Thr 165 170 175 Leu Leu Phe Lys Pro Ala Val Ile Ala Asp Ser Gly Ser Tyr Phe Cys 180 185 190 Thr Ala Lys Gly Gln Val Gly Ser Glu Gln His Ser Asp Ile Val Lys 195 200 205 Phe Val Val Lys Asp Ser Ser Lys Leu Leu Lys Thr Lys Thr Glu Ala 210 215 220 Pro Thr Thr Met Thr Tyr Pro Leu Lys Ala Thr Ser Thr Val Lys Gln 225 230 235 240 Ser Trp Asp Trp Thr Thr Asp Met Asp Gly Tyr Leu Gly Glu Thr Ser 245 250 255 Ala Gly Pro Gly Lys Ser Leu Pro Gly Gly Gly Gly Ser Asp Lys Thr 260 265 270 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 275 280 285 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 290 295 300 Thr Pro Glu Val Thr Cys Val Val Val Ala Val Ser His Glu Asp Pro 305 310 315 320 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 325 330 335 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Val Val 340 345 350 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 355 360 365 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 370 375 380 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 385 390 395 400 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 405 410 415 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 420 425 430 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 435 440 445 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 450 455 460 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 465 470 475 480 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 485 490 495 <210> 2 <211> 710 <212> PRT <213> Artificial sequence <220> <223> hu CRIg-hu IgG1 Fc DANG-VEGF binder <400> 2 Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro Trp Lys Gly 1 5 10 15 Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly Tyr Thr Gln 20 25 30 Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro Val Thr Ile 35 40 45 Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala Lys Tyr Gln 50 55 60 Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val Ser Leu Gln 65 70 75 80 Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr Cys Glu Val 85 90 95 Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp Lys Ile Thr 100 105 110 Glu Leu Arg Val Gln Lys Leu Ser Val Ser Lys Pro Thr Val Thr Thr 115 120 125 Gly Ser Gly Tyr Gly Phe Thr Val Pro Gln Gly Met Arg Ile Ser Leu 130 135 140 Gln Cys Gln Ala Arg Gly Ser Pro Pro Ile Ser Tyr Ile Trp Tyr Lys 145 150 155 160 Gln Gln Thr Asn Asn Gln Glu Pro Ile Lys Val Ala Thr Leu Ser Thr 165 170 175 Leu Leu Phe Lys Pro Ala Val Ile Ala Asp Ser Gly Ser Tyr Phe Cys 180 185 190 Thr Ala Lys Gly Gln Val Gly Ser Glu Gln His Ser Asp Ile Val Lys 195 200 205 Phe Val Val Lys Asp Ser Ser Lys Leu Leu Lys Thr Lys Thr Glu Ala 210 215 220 Pro Thr Thr Met Thr Tyr Pro Leu Lys Ala Thr Ser Thr Val Lys Gln 225 230 235 240 Ser Trp Asp Trp Thr Thr Asp Met Asp Gly Tyr Leu Gly Glu Thr Ser 245 250 255 Ala Gly Pro Gly Lys Ser Leu Pro Gly Gly Gly Gly Ser Asp Lys Thr 260 265 270 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 275 280 285 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 290 295 300 Thr Pro Glu Val Thr Cys Val Val Val Ala Val Ser His Glu Asp Pro 305 310 315 320 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 325 330 335 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Val Val 340 345 350 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 355 360 365 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 370 375 380 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 385 390 395 400 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 405 410 415 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 420 425 430 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 435 440 445 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 450 455 460 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 465 470 475 480 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly 485 490 495 Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Asp Thr Gly Arg Pro Phe 500 505 510 Val Glu Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly 515 520 525 Arg Glu Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val 530 535 540 Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg 545 550 555 560 Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr 565 570 575 Lys Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu 580 585 590 Tyr Lys Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile Asp 595 600 605 Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu Lys 610 615 620 Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Ile Asp 625 630 635 640 Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu Val 645 650 655 Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe Leu 660 665 670 Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu Tyr 675 680 685 Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr Phe 690 695 700 Val Arg Val His Glu Lys 705 710 <210> 3 <211> 501 <212> PRT <213> Artificial sequence <220> <223> hu IgG1 Fc DANG-hu CRIg <400> 3 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Ala Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Arg Pro Ile Leu 225 230 235 240 Glu Val Pro Glu Ser Val Thr Gly Pro Trp Lys Gly Asp Val Asn Leu 245 250 255 Pro Cys Thr Tyr Asp Pro Leu Gln Gly Tyr Thr Gln Val Leu Val Lys 260 265 270 Trp Leu Val Gln Arg Gly Ser Asp Pro Val Thr Ile Phe Leu Arg Asp 275 280 285 Ser Ser Gly Asp His Ile Gln Gln Ala Lys Tyr Gln Gly Arg Leu His 290 295 300 Val Ser His Lys Val Pro Gly Asp Val Ser Leu Gln Leu Ser Thr Leu 305 310 315 320 Glu Met Asp Asp Arg Ser His Tyr Thr Cys Glu Val Thr Trp Gln Thr 325 330 335 Pro Asp Gly Asn Gln Val Val Arg Asp Lys Ile Thr Glu Leu Arg Val 340 345 350 Gln Lys Leu Ser Val Ser Lys Pro Thr Val Thr Thr Gly Ser Gly Tyr 355 360 365 Gly Phe Thr Val Pro Gln Gly Met Arg Ile Ser Leu Gln Cys Gln Ala 370 375 380 Arg Gly Ser Pro Pro Ile Ser Tyr Ile Trp Tyr Lys Gln Gln Thr Asn 385 390 395 400 Asn Gln Glu Pro Ile Lys Val Ala Thr Leu Ser Thr Leu Leu Phe Lys 405 410 415 Pro Ala Val Ile Ala Asp Ser Gly Ser Tyr Phe Cys Thr Ala Lys Gly 420 425 430 Gln Val Gly Ser Glu Gln His Ser Asp Ile Val Lys Phe Val Val Lys 435 440 445 Asp Ser Ser Lys Leu Leu Lys Thr Lys Thr Glu Ala Pro Thr Thr Met 450 455 460 Thr Tyr Pro Leu Lys Ala Thr Ser Thr Val Lys Gln Ser Trp Asp Trp 465 470 475 480 Thr Thr Asp Met Asp Gly Tyr Leu Gly Glu Thr Ser Ala Gly Pro Gly 485 490 495 Lys Ser Leu Pro Gly 500 <210> 4 <211> 711 <212> PRT <213> Artificial sequence <220> <223> VEGF binder-hu IgG1 Fc DANG-hu CRIg <400> 4 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu 1 5 10 15 Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val 20 25 30 Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 35 40 45 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe 50 55 60 Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu 65 70 75 80 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 85 90 95 Gln Thr Asn Thr Ile Ile Asp Val Val Leu Ser Pro Ser His Gly Ile 100 105 110 Glu Leu Ser Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr 115 120 125 Glu Leu Asn Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys 130 135 140 His Gln His Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln Ser Gly 145 150 155 160 Ser Glu Met Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr 165 170 175 Arg Ser Asp Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met 180 185 190 Thr Lys Lys Asn Ser Thr Phe Val Arg Val His Glu Lys Gly Gly Gly 195 200 205 Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 210 215 220 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 225 230 235 240 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Ala Val 245 250 255 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 260 265 270 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser 275 280 285 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 290 295 300 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 305 310 315 320 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 325 330 335 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 340 345 350 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 355 360 365 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 370 375 380 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 385 390 395 400 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 405 410 415 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 420 425 430 Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Arg Pro 435 440 445 Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro Trp Lys Gly Asp Val 450 455 460 Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly Tyr Thr Gln Val Leu 465 470 475 480 Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro Val Thr Ile Phe Leu 485 490 495 Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala Lys Tyr Gln Gly Arg 500 505 510 Leu His Val Ser His Lys Val Pro Gly Asp Val Ser Leu Gln Leu Ser 515 520 525 Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr Cys Glu Val Thr Trp 530 535 540 Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp Lys Ile Thr Glu Leu 545 550 555 560 Arg Val Gln Lys Leu Ser Val Ser Lys Pro Thr Val Thr Thr Gly Ser 565 570 575 Gly Tyr Gly Phe Thr Val Pro Gln Gly Met Arg Ile Ser Leu Gln Cys 580 585 590 Gln Ala Arg Gly Ser Pro Pro Ile Ser Tyr Ile Trp Tyr Lys Gln Gln 595 600 605 Thr Asn Asn Gln Glu Pro Ile Lys Val Ala Thr Leu Ser Thr Leu Leu 610 615 620 Phe Lys Pro Ala Val Ile Ala Asp Ser Gly Ser Tyr Phe Cys Thr Ala 625 630 635 640 Lys Gly Gln Val Gly Ser Glu Gln His Ser Asp Ile Val Lys Phe Val 645 650 655 Val Lys Asp Ser Ser Lys Leu Leu Lys Thr Lys Thr Glu Ala Pro Thr 660 665 670 Thr Met Thr Tyr Pro Leu Lys Ala Thr Ser Thr Val Lys Gln Ser Trp 675 680 685 Asp Trp Thr Thr Asp Met Asp Gly Tyr Leu Gly Glu Thr Ser Ala Gly 690 695 700 Pro Gly Lys Ser Leu Pro Gly 705 710 <210> 5 <211> 436 <212> PRT <213> Artificial sequence <220> <223> VEGF binder-hu IgG1 Fc DANG <400> 5 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu 1 5 10 15 Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val 20 25 30 Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 35 40 45 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe 50 55 60 Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu 65 70 75 80 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 85 90 95 Gln Thr Asn Thr Ile Ile Asp Val Val Leu Ser Pro Ser His Gly Ile 100 105 110 Glu Leu Ser Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr 115 120 125 Glu Leu Asn Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys 130 135 140 His Gln His Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln Ser Gly 145 150 155 160 Ser Glu Met Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr 165 170 175 Arg Ser Asp Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met 180 185 190 Thr Lys Lys Asn Ser Thr Phe Val Arg Val His Glu Lys Gly Gly Gly 195 200 205 Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 210 215 220 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 225 230 235 240 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Ala Val 245 250 255 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 260 265 270 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser 275 280 285 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 290 295 300 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 305 310 315 320 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 325 330 335 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 340 345 350 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 355 360 365 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 370 375 380 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 385 390 395 400 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 405 410 415 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 420 425 430 Leu Ser Pro Gly 435 <210> 6 <211> 208 <212> PRT <213> Artificial sequence <220> <223> hu IgG1 Fc DANG <400> 6 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 1 5 10 15 Arg Thr Pro Glu Val Thr Cys Val Val Val Ala Val Ser His Glu Asp 20 25 30 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 35 40 45 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Val 50 55 60 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 65 70 75 80 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 85 90 95 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 100 105 110 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 115 120 125 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 130 135 140 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 145 150 155 160 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 165 170 175 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 180 185 190 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 195 200 205 <210> 7 <211> 406 <212> PRT <213> Artificial sequence <220> <223> mu CRIg-mu IgG2a Fc DANG <400> 7 His Pro Thr Leu Lys Thr Pro Glu Ser Val Thr Gly Thr Trp Lys Gly 1 5 10 15 Asp Val Lys Ile Gln Cys Ile Tyr Asp Pro Leu Arg Gly Tyr Arg Gln 20 25 30 Val Leu Val Lys Trp Leu Val Arg His Gly Ser Asp Ser Val Thr Ile 35 40 45 Phe Leu Arg Asp Ser Thr Gly Asp His Ile Gln Gln Ala Lys Tyr Arg 50 55 60 Gly Arg Leu Lys Val Ser His Lys Val Pro Gly Asp Val Ser Leu Gln 65 70 75 80 Ile Asn Thr Leu Gln Met Asp Asp Arg Asn His Tyr Thr Cys Glu Val 85 90 95 Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Ile Arg Asp Lys Ile Ile 100 105 110 Glu Leu Arg Val Arg Lys Tyr Asn Pro Pro Arg Ile Asn Thr Glu Ala 115 120 125 Pro Thr Thr Leu His Ser Ser Leu Glu Ala Thr Thr Ile Met Ser Ser 130 135 140 Thr Ser Asp Leu Thr Thr Asn Gly Thr Gly Lys Leu Glu Glu Thr Ile 145 150 155 160 Ala Gly Ser Gly Arg Asn Leu Pro Gly Gly Gly Gly Ser Glu Pro Arg 165 170 175 Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn 180 185 190 Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp 195 200 205 Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Ala 210 215 220 Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn 225 230 235 240 Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Gly 245 250 255 Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp 260 265 270 Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro 275 280 285 Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala 290 295 300 Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys 305 310 315 320 Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile 325 330 335 Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn 340 345 350 Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys 355 360 365 Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys 370 375 380 Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe 385 390 395 400 Ser Arg Thr Pro Gly Lys 405 <210> 8 <211> 620 <212> PRT <213> Artificial sequence <220> <223> mu CRIg-mu IgG2a Fc DANG-VEGF binder <400> 8 His Pro Thr Leu Lys Thr Pro Glu Ser Val Thr Gly Thr Trp Lys Gly 1 5 10 15 Asp Val Lys Ile Gln Cys Ile Tyr Asp Pro Leu Arg Gly Tyr Arg Gln 20 25 30 Val Leu Val Lys Trp Leu Val Arg His Gly Ser Asp Ser Val Thr Ile 35 40 45 Phe Leu Arg Asp Ser Thr Gly Asp His Ile Gln Gln Ala Lys Tyr Arg 50 55 60 Gly Arg Leu Lys Val Ser His Lys Val Pro Gly Asp Val Ser Leu Gln 65 70 75 80 Ile Asn Thr Leu Gln Met Asp Asp Arg Asn His Tyr Thr Cys Glu Val 85 90 95 Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Ile Arg Asp Lys Ile Ile 100 105 110 Glu Leu Arg Val Arg Lys Tyr Asn Pro Pro Arg Ile Asn Thr Glu Ala 115 120 125 Pro Thr Thr Leu His Ser Ser Leu Glu Ala Thr Thr Ile Met Ser Ser 130 135 140 Thr Ser Asp Leu Thr Thr Asn Gly Thr Gly Lys Leu Glu Glu Thr Ile 145 150 155 160 Ala Gly Ser Gly Arg Asn Leu Pro Gly Gly Gly Gly Ser Glu Pro Arg 165 170 175 Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn 180 185 190 Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp 195 200 205 Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Ala 210 215 220 Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn 225 230 235 240 Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Gly 245 250 255 Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp 260 265 270 Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro 275 280 285 Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala 290 295 300 Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys 305 310 315 320 Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile 325 330 335 Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn 340 345 350 Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys 355 360 365 Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys 370 375 380 Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe 385 390 395 400 Ser Arg Thr Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 405 410 415 Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu Ile 420 425 430 Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val Thr 435 440 445 Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu 450 455 460 Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile 465 470 475 480 Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu Ala 485 490 495 Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg Gln 500 505 510 Thr Asn Thr Ile Ile Asp Val Val Leu Ser Pro Ser His Gly Ile Glu 515 520 525 Leu Ser Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu 530 535 540 Leu Asn Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His 545 550 555 560 Gln His Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser 565 570 575 Glu Met Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg 580 585 590 Ser Asp Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr 595 600 605 Lys Lys Asn Ser Thr Phe Val Arg Val His Glu Lys 610 615 620 <210> 9 <211> 411 <212> PRT <213> Artificial sequence <220> <223> mu IgG2a Fc DANG-mu CRIg <400> 9 Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro 1 5 10 15 Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys 20 25 30 Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val 35 40 45 Val Val Ala Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe 50 55 60 Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu 65 70 75 80 Asp Tyr Gly Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His 85 90 95 Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys 100 105 110 Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser 115 120 125 Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met 130 135 140 Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro 145 150 155 160 Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn 165 170 175 Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met 180 185 190 Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser 195 200 205 Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr 210 215 220 Lys Ser Phe Ser Arg Thr Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly 225 230 235 240 Gly Ser His Pro Thr Leu Lys Thr Pro Glu Ser Val Thr Gly Thr Trp 245 250 255 Lys Gly Asp Val Lys Ile Gln Cys Ile Tyr Asp Pro Leu Arg Gly Tyr 260 265 270 Arg Gln Val Leu Val Lys Trp Leu Val Arg His Gly Ser Asp Ser Val 275 280 285 Thr Ile Phe Leu Arg Asp Ser Thr Gly Asp His Ile Gln Gln Ala Lys 290 295 300 Tyr Arg Gly Arg Leu Lys Val Ser His Lys Val Pro Gly Asp Val Ser 305 310 315 320 Leu Gln Ile Asn Thr Leu Gln Met Asp Asp Arg Asn His Tyr Thr Cys 325 330 335 Glu Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Ile Arg Asp Lys 340 345 350 Ile Ile Glu Leu Arg Val Arg Lys Tyr Asn Pro Pro Arg Ile Asn Thr 355 360 365 Glu Ala Pro Thr Thr Leu His Ser Ser Leu Glu Ala Thr Thr Ile Met 370 375 380 Ser Ser Thr Ser Asp Leu Thr Thr Asn Gly Thr Gly Lys Leu Glu Glu 385 390 395 400 Thr Ile Ala Gly Ser Gly Arg Asn Leu Pro Gly 405 410 <210> 10 <211> 621 <212> PRT <213> Artificial sequence <220> <223> VEGF binder-mu IgG2a Fc DANG-mu CRIg <400> 10 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu 1 5 10 15 Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val 20 25 30 Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 35 40 45 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe 50 55 60 Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu 65 70 75 80 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 85 90 95 Gln Thr Asn Thr Ile Ile Asp Val Val Leu Ser Pro Ser His Gly Ile 100 105 110 Glu Leu Ser Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr 115 120 125 Glu Leu Asn Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys 130 135 140 His Gln His Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln Ser Gly 145 150 155 160 Ser Glu Met Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr 165 170 175 Arg Ser Asp Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met 180 185 190 Thr Lys Lys Asn Ser Thr Phe Val Arg Val His Glu Lys Gly Gly Gly 195 200 205 Gly Ser Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys 210 215 220 Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro 225 230 235 240 Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr 245 250 255 Cys Val Val Val Ala Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser 260 265 270 Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His 275 280 285 Arg Glu Asp Tyr Gly Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile 290 295 300 Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn 305 310 315 320 Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys 325 330 335 Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu 340 345 350 Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe 355 360 365 Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu 370 375 380 Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr 385 390 395 400 Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg 405 410 415 Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His 420 425 430 Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Gly Gly Gly Gly Ser Gly 435 440 445 Gly Gly Gly Ser His Pro Thr Leu Lys Thr Pro Glu Ser Val Thr Gly 450 455 460 Thr Trp Lys Gly Asp Val Lys Ile Gln Cys Ile Tyr Asp Pro Leu Arg 465 470 475 480 Gly Tyr Arg Gln Val Leu Val Lys Trp Leu Val Arg His Gly Ser Asp 485 490 495 Ser Val Thr Ile Phe Leu Arg Asp Ser Thr Gly Asp His Ile Gln Gln 500 505 510 Ala Lys Tyr Arg Gly Arg Leu Lys Val Ser His Lys Val Pro Gly Asp 515 520 525 Val Ser Leu Gln Ile Asn Thr Leu Gln Met Asp Asp Arg Asn His Tyr 530 535 540 Thr Cys Glu Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Ile Arg 545 550 555 560 Asp Lys Ile Ile Glu Leu Arg Val Arg Lys Tyr Asn Pro Pro Arg Ile 565 570 575 Asn Thr Glu Ala Pro Thr Thr Leu His Ser Ser Leu Glu Ala Thr Thr 580 585 590 Ile Met Ser Ser Thr Ser Asp Leu Thr Thr Asn Gly Thr Gly Lys Leu 595 600 605 Glu Glu Thr Ile Ala Gly Ser Gly Arg Asn Leu Pro Gly 610 615 620 <210> 11 <211> 217 <212> PRT <213> Artificial sequence <220> <223> mu IgG2a Fc DANG <400> 11 Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys 1 5 10 15 Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val 20 25 30 Val Val Ala Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe 35 40 45 Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu 50 55 60 Asp Tyr Gly Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His 65 70 75 80 Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys 85 90 95 Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser 100 105 110 Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met 115 120 125 Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro 130 135 140 Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn 145 150 155 160 Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met 165 170 175 Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser 180 185 190 Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr 195 200 205 Lys Ser Phe Ser Arg Thr Pro Gly Lys 210 215 <210> 12 <211> 447 <212> PRT <213> Artificial sequence <220> <223> mu IgG2a Fc DANG-VEGF binder <400> 12 Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro 1 5 10 15 Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys 20 25 30 Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val 35 40 45 Val Val Ala Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe 50 55 60 Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu 65 70 75 80 Asp Tyr Gly Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His 85 90 95 Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys 100 105 110 Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser 115 120 125 Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met 130 135 140 Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro 145 150 155 160 Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn 165 170 175 Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met 180 185 190 Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser 195 200 205 Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr 210 215 220 Lys Ser Phe Ser Arg Thr Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly 225 230 235 240 Gly Ser Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile 245 250 255 Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys 260 265 270 Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu 275 280 285 Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys 290 295 300 Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr 305 310 315 320 Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr 325 330 335 His Arg Gln Thr Asn Thr Ile Ile Asp Val Val Leu Ser Pro Ser His 340 345 350 Gly Ile Glu Leu Ser Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala 355 360 365 Arg Thr Glu Leu Asn Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser 370 375 380 Ser Lys His Gln His Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln 385 390 395 400 Ser Gly Ser Glu Met Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly 405 410 415 Val Thr Arg Ser Asp Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly 420 425 430 Leu Met Thr Lys Lys Asn Ser Thr Phe Val Arg Val His Glu Lys 435 440 445 <210> 13 <211> 431 <212> PRT <213> Artificial sequence <220> <223> aflibercept <400> 13 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu 1 5 10 15 Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val 20 25 30 Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 35 40 45 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe 50 55 60 Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu 65 70 75 80 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 85 90 95 Gln Thr Asn Thr Ile Ile Asp Val Val Leu Ser Pro Ser His Gly Ile 100 105 110 Glu Leu Ser Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr 115 120 125 Glu Leu Asn Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys 130 135 140 His Gln His Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln Ser Gly 145 150 155 160 Ser Glu Met Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr 165 170 175 Arg Ser Asp Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met 180 185 190 Thr Lys Lys Asn Ser Thr Phe Val Arg Val His Glu Lys Asp Lys Thr 195 200 205 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 210 215 220 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 225 230 235 240 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 245 250 255 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 260 265 270 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 275 280 285 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 290 295 300 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 305 310 315 320 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 325 330 335 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 340 345 350 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 355 360 365 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 370 375 380 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 385 390 395 400 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 405 410 415 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 420 425 430 <210> 14 <211> 205 <212> PRT <213> Artificial sequence <220> <223> VEGF binder (VEGFR1 D2-VEGFR2 D3) <400> 14 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu 1 5 10 15 Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val 20 25 30 Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 35 40 45 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe 50 55 60 Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu 65 70 75 80 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 85 90 95 Gln Thr Asn Thr Ile Ile Asp Val Val Leu Ser Pro Ser His Gly Ile 100 105 110 Glu Leu Ser Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr 115 120 125 Glu Leu Asn Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys 130 135 140 His Gln His Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln Ser Gly 145 150 155 160 Ser Glu Met Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr 165 170 175 Arg Ser Asp Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met 180 185 190 Thr Lys Lys Asn Ser Thr Phe Val Arg Val His Glu Lys 195 200 205 <210> 15 <211> 23 <212> PRT <213> Artificial sequence <220> <223> Human-to-human joint-1 <400> 15 Gly Gly Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro 20 <210> 16 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Connector-2 <400> 16 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10 <210> 17 <211> twenty one <212> PRT <213> Artificial sequence <220> <223> Mouse Connector-1 <400> 17 Gly Gly Gly Gly Ser Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro 1 5 10 15 Pro Cys Lys Cys Pro 20 <210> 18 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Connector-2 <400> 18 Gly Gly Gly Gly Ser 1 5 <210> 19 <211> 399 <212> PRT <213> Artificial sequence <220> <223> Intact human CRIg <400> 19 Met Gly Ile Leu Leu Gly Leu Leu Leu Leu Gly His Leu Thr Val Asp 1 5 10 15 Thr Tyr Gly Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro 20 25 30 Trp Lys Gly Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly 35 40 45 Tyr Thr Gln Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro 50 55 60 Val Thr Ile Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala 65 70 75 80 Lys Tyr Gln Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val 85 90 95 Ser Leu Gln Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr 100 105 110 Cys Glu Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp 115 120 125 Lys Ile Thr Glu Leu Arg Val Gln Lys Leu Ser Val Ser Lys Pro Thr 130 135 140 Val Thr Thr Gly Ser Gly Tyr Gly Phe Thr Val Pro Gln Gly Met Arg 145 150 155 160 Ile Ser Leu Gln Cys Gln Ala Arg Gly Ser Pro Pro Ile Ser Tyr Ile 165 170 175 Trp Tyr Lys Gln Gln Thr Asn Asn Gln Glu Pro Ile Lys Val Ala Thr 180 185 190 Leu Ser Thr Leu Leu Phe Lys Pro Ala Val Ile Ala Asp Ser Gly Ser 195 200 205 Tyr Phe Cys Thr Ala Lys Gly Gln Val Gly Ser Glu Gln His Ser Asp 210 215 220 Ile Val Lys Phe Val Val Lys Asp Ser Ser Lys Leu Leu Lys Thr Lys 225 230 235 240 Thr Glu Ala Pro Thr Thr Met Thr Tyr Pro Leu Lys Ala Thr Ser Thr 245 250 255 Val Lys Gln Ser Trp Asp Trp Thr Thr Asp Met Asp Gly Tyr Leu Gly 260 265 270 Glu Thr Ser Ala Gly Pro Gly Lys Ser Leu Pro Val Phe Ala Ile Ile 275 280 285 Leu Ile Ile Ser Leu Cys Cys Met Val Val Phe Thr Met Ala Tyr Ile 290 295 300 Met Leu Cys Arg Lys Thr Ser Gln Gln Glu His Val Tyr Glu Ala Ala 305 310 315 320 Arg Ala His Ala Arg Glu Ala Asn Asp Ser Gly Glu Thr Met Arg Val 325 330 335 Ala Ile Phe Ala Ser Gly Cys Ser Ser Asp Glu Pro Thr Ser Gln Asn 340 345 350 Leu Gly Asn Asn Tyr Ser Asp Glu Pro Cys Ile Gly Gln Glu Tyr Gln 355 360 365 Ile Ile Ala Gln Ile Asn Gly Asn Tyr Ala Arg Leu Leu Asp Thr Val 370 375 380 Pro Leu Asp Tyr Glu Phe Leu Ala Thr Glu Gly Lys Ser Val Cys 385 390 395 <210> 20 <211> 305 <212> PRT <213> Artificial sequence <220> <223> Human CRIg (VSIG4) isoform 3 <400> 20 Met Gly Ile Leu Leu Gly Leu Leu Leu Leu Gly His Leu Thr Val Asp 1 5 10 15 Thr Tyr Gly Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro 20 25 30 Trp Lys Gly Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly 35 40 45 Tyr Thr Gln Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro 50 55 60 Val Thr Ile Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala 65 70 75 80 Lys Tyr Gln Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val 85 90 95 Ser Leu Gln Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr 100 105 110 Cys Glu Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp 115 120 125 Lys Ile Thr Glu Leu Arg Val Gln Lys His Ser Ser Lys Leu Leu Lys 130 135 140 Thr Lys Thr Glu Ala Pro Thr Thr Met Thr Tyr Pro Leu Lys Ala Thr 145 150 155 160 Ser Thr Val Lys Gln Ser Trp Asp Trp Thr Thr Asp Met Asp Gly Tyr 165 170 175 Leu Gly Glu Thr Ser Ala Gly Pro Gly Lys Ser Leu Pro Val Phe Ala 180 185 190 Ile Ile Leu Ile Ile Ser Leu Cys Cys Met Val Val Phe Thr Met Ala 195 200 205 Tyr Ile Met Leu Cys Arg Lys Thr Ser Gln Gln Glu His Val Tyr Glu 210 215 220 Ala Ala Arg Ala His Ala Arg Glu Ala Asn Asp Ser Gly Glu Thr Met 225 230 235 240 Arg Val Ala Ile Phe Ala Ser Gly Cys Ser Ser Asp Glu Pro Thr Ser 245 250 255 Gln Asn Leu Gly Asn Asn Tyr Ser Asp Glu Pro Cys Ile Gly Gln Glu 260 265 270 Tyr Gln Ile Ile Ala Gln Ile Asn Gly Asn Tyr Ala Arg Leu Leu Asp 275 280 285 Thr Val Pro Leu Asp Tyr Glu Phe Leu Ala Thr Glu Gly Lys Ser Val 290 295 300 Cys 305 <210> 21 <211> 280 <212> PRT <213> artificial sequence <220> <223> complete mouseCRIg <400> 21 Met Glu Ile Ser Ser Gly Leu Leu Phe Leu Gly His Leu Ile Val Leu 1 5 10 15 Thr Tyr Gly His Pro Thr Leu Lys Thr Pro Glu Ser Val Thr Gly Thr 20 25 30 Trp Lys Gly Asp Val Lys Ile Gln Cys Ile Tyr Asp Pro Leu Arg Gly 35 40 45 Tyr Arg Gln Val Leu Val Lys Trp Leu Val Arg His Gly Ser Asp Ser 50 55 60 Val Thr Ile Phe Leu Arg Asp Ser Thr Gly Asp His Ile Gln Gln Ala 65 70 75 80 Lys Tyr Arg Gly Arg Leu Lys Val Ser His Lys Val Pro Gly Asp Val 85 90 95 Ser Leu Gln Ile Asn Thr Leu Gln Met Asp Asp Arg Asn His Tyr Thr 100 105 110 Cys Glu Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Ile Arg Asp 115 120 125 Lys Ile Ile Glu Leu Arg Val Arg Lys Tyr Asn Pro Pro Arg Ile Asn 130 135 140 Thr Glu Ala Pro Thr Thr Leu His Ser Ser Leu Glu Ala Thr Thr Ile 145 150 155 160 Met Ser Ser Thr Ser Asp Leu Thr Thr Asn Gly Thr Gly Lys Leu Glu 165 170 175 Glu Thr Ile Ala Gly Ser Gly Arg Asn Leu Pro Ile Phe Ala Ile Ile 180 185 190 Phe Ile Ile Ser Leu Cys Cys Ile Val Ala Val Thr Ile Pro Tyr Ile 195 200 205 Leu Phe Arg Cys Arg Thr Phe Gln Gln Glu Tyr Val Tyr Gly Val Ser 210 215 220 Arg Val Phe Ala Arg Lys Thr Ser Asn Ser Glu Glu Thr Thr Arg Val 225 230 235 240 Thr Thr Ile Ala Thr Asp Glu Pro Asp Ser Gln Ala Leu Ile Ser Asp 245 250 255 Tyr Ser Asp Asp Pro Cys Leu Ser Gln Glu Tyr Gln Ile Thr Ile Arg 260 265 270 Ser Thr Met Ser Ile Pro Ala Cys 275 280 <210> twenty two <211> 264 <212> PRT <213> Artificial sequence <220> <223> Extracellular domains of human CRIg <400> twenty two Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro Trp Lys Gly 1 5 10 15 Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly Tyr Thr Gln 20 25 30 Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro Val Thr Ile 35 40 45 Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala Lys Tyr Gln 50 55 60 Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val Ser Leu Gln 65 70 75 80 Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr Cys Glu Val 85 90 95 Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp Lys Ile Thr 100 105 110 Glu Leu Arg Val Gln Lys Leu Ser Val Ser Lys Pro Thr Val Thr Thr 115 120 125 Gly Ser Gly Tyr Gly Phe Thr Val Pro Gln Gly Met Arg Ile Ser Leu 130 135 140 Gln Cys Gln Ala Arg Gly Ser Pro Pro Ile Ser Tyr Ile Trp Tyr Lys 145 150 155 160 Gln Gln Thr Asn Asn Gln Glu Pro Ile Lys Val Ala Thr Leu Ser Thr 165 170 175 Leu Leu Phe Lys Pro Ala Val Ile Ala Asp Ser Gly Ser Tyr Phe Cys 180 185 190 Thr Ala Lys Gly Gln Val Gly Ser Glu Gln His Ser Asp Ile Val Lys 195 200 205 Phe Val Val Lys Asp Ser Ser Lys Leu Leu Lys Thr Lys Thr Glu Ala 210 215 220 Pro Thr Thr Met Thr Tyr Pro Leu Lys Ala Thr Ser Thr Val Lys Gln 225 230 235 240 Ser Trp Asp Trp Thr Thr Asp Met Asp Gly Tyr Leu Gly Glu Thr Ser 245 250 255 Ala Gly Pro Gly Lys Ser Leu Pro 260 <210> 23 <211> 1488 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence of hu CRIg-hu IgG1 Fc DANG <400> 23 cggcctatcc tggaggtgcc agagtccgtg accggaccat ggaagggcga cgtgaacctg 60 ccctgcacct acgatcctct gcagggctat acacaggtgc tggtgaagtg gctggtgcag 120 aggggcagcg accctgtgac catcttcctg cgcgacagct ccggcgatca catccagcag 180 gccaagtacc agggcaggct gcacgtgtct cacaaggtgc ctggcgatgt gagcctgcag 240 ctgtccaccc tggagatgga cgatcgcagc cactatacat gtgaggtgac ctggcagaca 300 ccagacggca atcaggtggt gcgggataag atcaccgagc tgagagtgca gaagctgtcc 360 gtgtctaagc caaccgtgac cacaggcagc ggctacggct tcacagtgcc ccagggcatg 420 aggatctccc tgcagtgcca ggcaaggggc tctccaccta tcagctacat ctggtataag 480 cagcagacca acaatcagga gcctatcaag gtggccaccc tgtccacact gctgttcaag 540 ccagccgtga tcgccgacag cggctcctat ttttgtacag caaagggaca agtgggctcc 600 gagcagcact ctgacatcgt gaagtttgtg gtgaaggatt ctagcaagct gctgaagacc 660 aagacagagg cccctaccac aatgacctac ccactgaagg ccaccagcac agtgaagcag 720 tcctgggact ggaccacaga catggatggc tatctgggcg agacatctgc cggaccaggc 780 aagagcctgc caggaggagg cggcagcgat aagacccaca catgcccacc ctgtcctgca 840 ccagagctgc tgggaggacc atccgtgttc ctgtttcctc caaagcctaa ggacaccctg 900 atgatctctc ggaccccaga ggtgacatgc gtggtggtgg ccgtgagcca cgaggacccc 960 gaggtgaagt ttaactggta cgtggatggc gtggaggtgc acaatgccaa gaccaagccc 1020 cgggaggagc agtacggctc cacctataga gtggtgtctg tgctgacagt gctgcaccag 1080 gattggctga acggcaagga gtataagtgc aaggtgtcca ataaggccct gcccgcccct 1140 atcgagaaga ccatctctaa ggcaaaggga cagccaaggg agccacaggt gtacacactg 1200 cccccttcca gagacgagct gaccaagaac caggtgtctc tgacatgtct ggtgaagggc 1260 ttctatccct ctgatatcgc cgtggagtgg gagagcaatg gccagcctga gaacaattac 1320 aagaccacac cacccgtgct ggactccgat ggctctttct ttctgtatag caagctgacc 1380 gtggataagt ccagatggca gcagggcaac gtgttttctt gtagcgtgat gcacgaggcc 1440 ctgcacaatc actacacaca gaagtccctg tctctgagcc ccggcaag 1488 <210> 24 <211> 2130 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence of hu CRIg-hu IgG1 Fc DANG-VEGF binder <400> 24 cgccctatcc tggaggtgcc agagtccgtg accggaccat ggaagggcga cgtgaacctg 60 ccctgcacct acgatcctct gcagggctat acacaggtgc tggtgaagtg gctggtgcag 120 aggggcagcg accctgtgac catcttcctg cgcgacagct ccggcgatca catccagcag 180 gccaagtacc agggcaggct gcacgtgtcc cacaaggtgc ctggcgacgt gagcctgcag 240 ctgtctaccc tggagatgga cgatcgcagc cactatacat gtgaggtgac ctggcagaca 300 ccagacggca atcaggtggt gagggataag atcaccgagc tgcgcgtgca gaagctgtcc 360 gtgtctaagc caaccgtgac cacaggctct ggctacggct tcacagtgcc ccagggcatg 420 aggatcagcc tgcagtgcca ggcaaggggc agcccaccta tctcctacat ctggtataag 480 cagcagacca acaatcagga gcctatcaag gtggccaccc tgtccacact gctgttcaag 540 ccagccgtga tcgccgacag cggctcctac ttttgtacag ccaagggcca agtgggctct 600 gagcagcaca gcgacatcgt gaagtttgtg gtgaaggatt ctagcaagct gctgaagacc 660 aagacagagg cccctaccac aatgacctac ccactgaagg ccacctccac agtgaagcag 720 tcttgggact ggaccacaga catggatggc tatctgggag agacaagcgc cggacctggc 780 aagtccctgc caggaggcgg cggctccgat aagacccaca catgcccacc atgtcctgca 840 ccagagctgc tgggaggacc tagcgtgttc ctgtttcctc caaagccaaa ggacaccctg atgatctccc ggaccccaga ggtgacatgc gtggtggtgg ccgtgtctca cgaggacccc 960 gaggtgaagt tcaactggta cgtggatggc gtggaggtgc acaatgccaa gaccaagccc cgggaggagc agtacggctc tacctataga gtggtgagcg tgctgacagt gctgcaccag 1080 gattggctga acggcaagga gtataagtgc aaggtgagca ataaggccct gcccgcccct atcgagaga ccatctccaa ggcaaaggga cagccaaggg agccacaggt gtacacactg cccccttcca gagacgagct gaccaagaac caggtgtctc tgacatgtct ggtgaagggc ttttatccct ctgatatcgc cgtggagtgg gagagcaatg gccagcctga gacaattac aagaccacac cacccgtgct ggactctgat ggcagcttct ttctgtattc caagctgacc 1380. gtggacaagt ctagatggca gcagggcaac gtgttctctt gcagcgtgat gcacgaggcc 1440 ctgcacaatc actacaccca gaagtccctg tctctgagcc caggagg aggaggctct ggaggaggag gctcctctga tacaggcagg ccctttgtgg agatgtatag cgagatccct 1560 gagatcatcc acatgaccga gggaagggag ctggtcatcc catgtagagt gacatcccct 1620 aacatcaccg tgacactgaa gaagttccca ctggacaccc tgatccccga tggcaagcgg 1680 atcatctggg acagcagaaa gggctttatc atctccaatg ccacatacaa ggagatcggc 1740 ctgctgacct gcgaggccac agtgaacggc cacctgtaca agaccaatta tctgacacac 1800 cgccagacca acacaatcat cgatgtggtg ctgtccccat ctcacggcat cgagctgagc 1860 gtgggcgaga agctggtgct gaattgtacc gcccggacag agctgaacgt gggcatcgac 1920 ttcaattggg agtaccctag ctccaagcac cagcacaaga agctggtcaa ccgggatctg 1980 aagacccaga gcggctccga gatgaagaag tttctgagca ccctgacaat cgacggcgtg 2040 accagatccg atcagggcct gtatacatgt gccgcctcta gcggcctgat gaccaagaag 2100 aatagcacat ttgtgagggt gcacgagaag 2130 <210> 25 <211> 1503 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence of hu IgG1 Fc DANG-hu CRIg <400> 25 gataagaccc acacatgccc accctgtcct gcaccagagc tgctgggagg accatccgtg 60 ttcctgtttc ctccaaagcc taaggacacc ctgatgatct ctcggacccc agaggtgaca 120 tgcgtggtgg tggccgtgag ccacgaggac cccgaggtga agtttaactg gtacgtggat 180 ggcgtggagg tgcacaatgc caagaccaag ccccgggagg agcagtacgg ctccacctat 240 agagtggtgt ctgtgctgac agtgctgcac caggattggc tgaacggcaa ggagtataag 300 tgcaaggtgt ccaataaggc cctgcccgcc cctatcgaga agaccatctc taaggcaaag 360 ggacagccaa gggagccaca ggtgtacaca ctgccccctt ccagagacga gctgaccaag 420 aaccaggtgt ctctgacatg tctggtgaag ggcttctatc cctctgatat cgccgtggag 480 tgggagagca atggccagcc tgagaacaat tacaagacca caccacccgt gctggactcc 540 gatggctctt tctttctgta tagcaagctg accgtggata agtccagatg gcagcagggc 600 aacgtgtttt cttgtagcgt gatgcacgag gccctgcaca atcactacac acagaagtcc 660 ctgtctctga gccccggcgg cggaggcggg tctggaggtg gagggagtcg gcctatcctg 720 gaggtgccag agtccgtgac cggaccatgg aagggcgacg tgaacctgcc ctgcacctac 780 gatcctctgc agggctatac acaggtgctg gtgaagtggc tggtgcagag gggcagcgac 840 cctgtgacca tcttcctgcg cgacagctcc ggcgatcaca tccagcaggc caagtaccag 900 ggcaggctgc acgtgtctca caaggtgcct ggcgatgtga gcctgcagct gtccaccctg 960 gagatggacg atcgcagcca ctatacatgt gaggtgacct ggcagacacc agacggcaat 1020 caggtggtgc gggataagat caccgagctg agagtgcaga agctgtccgt gtctaagcca 1080 accgtgacca caggcagcgg ctacggcttc acagtgcccc agggcatgag gatctccctg 1140 cagtgccagg caaggggctc tccacctatc agctacatct ggtataagca gcagaccaac 1200 aatcaggagc ctatcaaggt ggccaccctg tccacactgc tgttcaagcc agccgtgatc 1260 gccgacagcg gctcctattt ttgtacagca aagggacaag tgggctccga gcagcactct 1320 gacatcgtga agtttgtggt gaaggattct agcaagctgc tgaagaccaa gacagaggcc 1380 cctaccacaa tgacctaccc actgaaggcc accagcacag tgaagcagtc ctgggactgg 1440 accacagaca tggatggcta tctgggcgag acatctgccg gaccaggcaa gagcctgcca 1500 gga 1503 <210> 26 <211> 2133 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence of VEGF binder-hu IgG1 Fc DANG-hu CRIg <400> 26 tccgatactg gcagaccctt cgtcgagatg tacagcgaga ttcctgagat catccacatg 60 acagagggac gggaactggt gattccttgc agagtgacat ctccaaacat cacagtgacc 120 ctgaagaagt ttcctctgga caccctgatc cctgacggca agcgcatcat ctgggacagc 180 agaaagggat tcatcatcag caacgccacc tacaaggaaa tcggcctcct gacctgcgag 240 gccaccgtga acggacacct gtataaaacc aattacctga cacaccggca aacaaacacc 300 atcatcgacg tggtgctgag ccctagccac ggcatcgagc tgagcgtggg cgagaagctg 360 gtgctgaact gcaccgccag aaccgaactg aacgtgggca tcgatttcaa ctgggaatac 420 ccctccta agcaccagca taagaaactg gttaatagag atctgaaaac ccagagcggc 480 agcgaaatga aaaagttcct gtctacactg accatcgacg gcgtgaccag aagcgaccag 540 ggcctgtaca cctgtgccgc ttctagcggc ctgatgacca agaagaacag cacattcgtg 600 cgggtgcacg agaagggagg aggcggcagc gataagaccc acacatgccc accctgtcct 660 gcaccagagc tgctgggagg accatccgtg ttcctgtttc ctccaaagcc taaggacacc 720 ctgatgatct ctcggacccc agaggtgaca tgcgtggtgg tggccgtgag ccacgaggac 780 cccgaggtga agtttaactg gtacgtggat ggcgtggagg tgcacaatgc caagaccaag 840 ccccgggagg agcagtacgg ctccacctat agagtggtgt ctgtgctgac agtgctgcac 900 caggattggc tgaacggcaa ggagtataag tgcaaggtgt ccaataaggc cctgcccgcc 960 cctatcgaga agaccatctc taaggcaaag ggacagccaa gggagccaca ggtgtacaca 1020 ctgccccct ccagagacga gctgaccaag aaccaggtgt ctctgacatg tctggtgaag 1080 ggcttctatc cctctgatat cgccgtggag tgggagagca atggccagcc tgagaacaat 1140 tacaagacca caccacccgt gctggactcc gatggctctt tctttctgta tagcaagctg 1200 accgtggata agtccagatg gcagcagggc aacgtgtttt cttgtagcgt gatgcacgag 1260 gccctgcaca atcactacac acagaagtcc ctgtctctga gccccggcgg aggtggcggt 1320 tctgggggag gcggaagccg gcctatcctg gaggtgccag agtccgtgac cggaccatgg 1380 aagggcgacg tgaacctgcc ctgcacctac gatcctctgc agggctatac acaggtgctg 1440 gtgaagtggc tggtgcagag gggcagcgac cctgtgacca tcttcctgcg cgacagctcc 1500 ggcgatcaca tccagcaggc caagtaccag ggcaggctgc acgtgtctca caaggtgcct 1560 ggcgatgtga gcctgcagct gtccaccctg gagatggacg atcgcagcca ctatacatgt 1620 gaggtgacct ggcagacacc agacggcaat caggtggtgc gggataagat caccgagctg 1680 agagtgcaga agctgtccgt gtctaagcca accgtgacca caggcagcgg ctacggcttc 1740 acagtgcccc agggcatgag gatctccctg cagtgccagg caaggggctc tccacctatc 1800 agctacatct ggtataagca gcagaccaac aatcaggagc ctatcaaggt ggccaccctg 1860 tccacactgc tgttcaagcc agccgtgatc gccgacagcg gctcctattt ttgtacagca 1920 aagggacaag tgggctccga gcagcactct gacatcgtga agtttgtggt gaaggattct 1980 agcaagctgc tgaagaccaa gacagaggcc cctaccacaa tgacctaccc actgaaggcc 2040 accagcacag tgaagcagtc ctgggactgg accacagaca tggatggcta tctgggcgag 2100 acatctgccg gaccaggcaa gagcctgcca gga 2133 <210> 27 <211> 1308 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence of VEGF binder-hu IgG1 Fc DANG <400> 27 tccgatactg gcagaccctt cgtcgagatg tacagcgaga ttcctgagat catccacatg 60 acagagggac gggaactggt gattccttgc agagtgacat ctccaaacat cacagtgacc 120 ctgaagaagt ttcctctgga caccctgatc cctgacggca agcgcatcat ctgggacagc 180 agaaagggat tcatcatcag caacgccacc tacaaggaaa tcggcctcct gacctgcgag 240 gccaccgtga acggacacct gtataaaacc aattacctga cacaccggca aacaaacacc 300 atcatcgacg tggtgctgag ccctagccac ggcatcgagc tgagcgtggg cgagaagctg 360 gtgctgaact gcaccgccag aaccgaactg aacgtgggca tcgatttcaa ctgggaatac 420 ccctcctcta agcaccagca taagaaactg gttaatagag atctgaaaac ccagagcggc 480 agcgaatga aaaagttcct gtctacactg accatcgacg gcgtgaccag aagcgaccag 540 ggcctgtaca cctgtgccgc ttctagcggc ctgatgacca agaagaacag cacattcgtg 600 cgggtgcacg agagggagg aggcggcagc gataagaccc acacatgccc accctgtcct 660 gcaccagagc tgctgggagg accatccgtg ttcctgtttc ctccaaagcc taggcacc 720 ctgatgatct ctcggacccc agaggtgaca tgcgtggtgg tggccgtgag ccacgaggac 780 cccgaggtga agtttaactg gtacgtggat ggcgtggagg tgcacaatgc caagaccaag 840 ccccgggagg agcagtacgg ctccacctat agagtggtgt ctgtgctgac agtgctgcac 900 caggattggc tgaacggcaa ggagtataag tgcaaggtgt ccaataaggc cctgcccgcc 960 cctatcgaga agaccatctc taaggcaaag ggacagccaa gggagccaca ggtgtacaca 1020 ctgccccctt ccagagacga gctgaccaag aaccaggtgt ctctgacatg tctggtgaag 1080 ggcttctatc cctctgatat cgccgtggag tgggagagca atggccagcc tgagaacaat 1140 tacaagacca caccacccgt gctggactcc gatggctctt tctttctgta tagcaagctg 1200 accgtggata agtccagatg gcagcagggc aacgtgtttt cttgtagcgt gatgcacgag 1260 gccctgcaca atcactacac acagaagtcc ctgtctctga gccccggc 1308 <210> 28 <211> 624 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence of hu IgG1 Fc DANG <400> 28 tccgtgttcc tgtttccacc caagcccaag gataccctga tgatcagcag gaccccagag 60 gtgacatgcg tggtggtggc cgtgtcccac gaggaccctg aggtgaagtt caactggtac 120 gtggatggcg tggaggtgca caatgccaag accaagccac gggaggagca gtacggctcc 180 acctatagag tggtgtctgt gctgacagtg ctgcaccagg actggctgaa cggcaaggag 240 tataagtgca aggtgtctaa taaggccctg cctgccccaa tcgagaagac catcagcaag 300 gcaaagggac agccaaggga gcctcaggtg tacacactgc ctccatcccg cgacgagctg 360 accaagaacc aggtgtctct gacatgtctg gtgaagggct tctatccttc tgatatcgcc 420 gtggagtggg agagcaatgg ccagccagag aacaattaca agaccacacc ccctgtgctg 480 gactctgatg gcagcttctt tctgtatagc aagctgaccg tggataagtc caggtggcag 540 cagggcaacg tgtttagctg ttccgtgatg cacgaggccc tgcacaatca ctacacacag 600 aagtctctga gcctgtcccc tggc 624 <210> 29 <211> 1221 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence of mu CRIg-mu IgG2a Fc DANG <400> 29 caccctacac tgaagacacc cgagtccgtc accggcacat ggaagggaga cgtcaagatc 60 cagtgcatct acgaccccct cagaggctat agacaagtgc tcgtcaaatg gctcgtgaga 120 cacggctccg atagcgtgac catctttctg agagacagca ccggcgacca tatccagcaa 180 gccaagtata gaggcagact gaaggtgagc cacaaggtgc ccggcgatgt gtctctgcag 240 atcacacac tgcagatgga tgatagaac cactatacat gcgaggtcac atggcagacc 300 cccgatggaa accaagtgat tagagacaag atcatcgagc tgaggtgag gaagtacaac 360 ccccctagga tcacaccga gctcctacc acacctgcaca gctctgga ggccacaca 420 atcatgtcca gcaccagcga tctgacaacc aacggaaccg gcaagctgga agagaccac 480 gccggcagcg gaaggaatct gcccggcgga ggaggcagcg agcctagagg accacatt 540 aagccttgcc ccccttgca atgtcccgcc cctaatctgc tcggcggccc cagcgtgttc 600 atcttccccc ccaagattaa ggacgtgctg atgatctctc tgtccccat tgtgacatgc 660 gtggtcgtgg ctgtctccga ggacgacccc gacgtccaga tcagctggtt cgtcacaat 720 gtggaggtcc attackcgccaccacagacc catagagagg attackacggcag cacactgaga 780 gtggtcagcg ctctgcccat ccaaccaa gactggatga gcggcaagga gttcaagtgt 840 aaagtgaaca acaggatct gcccgccccc attgagagga ccatctccaa acctaagggc 900 agcgtgagggg ctcctcaagt gtatgtgctc cccccccccg aggaggaat gaccagaag 960 caagtgacac tgacatgcat ggtcaccgac ttcatgcccg aggacatcta cgtggagtgg 1020 accaacaacg gcaagaccga gctgaattac aagaacaccg aacccgtgct ggatagcgat 1080 ggctcctact tcatgtacag caagctgaga gtggagaaaa agaactgggt cgagaggaac 1140 agctacagct gctccgtcgt gcatgagggc ctccacaacc accatacaac caagagcttc 1200 tctaggacac ccggcaaatg a 1221 <210> 30 <211> 1863 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence of mu CRIg-mu IgG2a Fc DANG-VEGF binder <400> 30 caccctacac tgaagacacc cgagtccgtc accggcacat ggaagggaga cgtcaagatc 60 cagtgcatct acgaccccct cagaggctat agacaagtgc tcgtcaaatg gctcgtgaga 120 cacggctccg atagcgtgac catctttctg agagacagca ccggcgacca tatccagcaa 180 gccaagtata gaggcagact gaaggtgagc cacaaggtgc ccggcgatgt gtctctgcag 240 atcaacacac tgcagatgga tgatagaaac cactatacat gcgaggtcac atggcagacc 300 cccgatggaa accaagtgat tagagacaag atcatcgagc tgaggtgag gaagtacaac 360 ccccctagga tcacaccga gctcctacc acacctgcaca gctctgga ggccacaca 420 atcatgtcca gcaccagcga tctgacaacc aacggaaccg gcaagctgga agagaccac 480 gccggcagcg gaaggaatct gcccggcgga ggaggcagcg agcctagagg accacatt 540 aagccttgcc ccccttgca atgtcccgcc cctaatctgc tcggcggccc cagcgtgttc 600 atcttccccc ccaagattaa ggacgtgctg atgatctctc tgtccccat tgtgacatgc 660 gtggtcgtgg ctgtctccga ggacgacccc gacgtccaga tcagctggtt cgtcacaat 720 gtggaggtcc attackcgccaccacagacc catagagagg attackacggcag cacactgaga 780 gtggtcagcg ctctgcccat ccaaccaa gactggatga gcggcaagga gttcaagtgt 840 aaagtgaaca acaggatct gcccgccccc attgagagga ccatctccaa acctaagggc 900 agcgtgagggg ctcctcaagt gtatgtgctc cccccccccg aggaggaat gaccagaag 960 caagtgacac tgacatgcat gtcaccgac ttcatcccg aggacatcta cgtggagtgg 1020 accaacaacg gcaagaccga gctgaattac aagaacaccg aacccgtgct ggatagcgat 1080 ggctcctact tcatgtacag caagctgaga gtggagaaaa agaactgggt cgagaggaac 1140 agctacagct gctccgtcgt gcatgaggggc ctccacaacc accatacac caagagcttc 1200 tctaggacac ccggcggcgg aggcggatcc gcagctccg taccggaga 1260 cctttcgtgg agatgtattc cgagattccc gagatcatcc acatgaccga gggaagagag 1320 ctggtcatcc cttgtagagt cacaagcccc aacattaccg tgaccctca gaagttccct 1380 ctggacacac tgatcccga cggcagagg attatctggg actctaggaa gggcttcatc 1440 atcagcaacg ccacctataa agagatcgga ctgctgacat gcgaggccac agtgaatggc 1500 cacctctaca agaccacta tctgacccat agaccaacca accattat cgacgtggtg 1560 ctgagcccta gccacggcat cgaactcagc gtgggagaga aactggtgct gattgcacc 1620 gctaggaccg aactcaacgt gggaatcgac ttcaactggg agtaccccctc cagcaagcac 1680 1740 1740 ttcctctcca cactgaccat cgatggcgtg acaaggagcg accaaggact gtacacatgc 1800 gctgcttcca gcggactgat gacaaagaag aacagcacct tcgtgagggt ccacgaaaaa 1860 tga 1863 <210> 31 <211> 1233 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence of mu IgG2a Fc DANG-mu CRIg <400> 31 gagcctagag gcccaacaat caagccttgt cctccttgca aatgccctgc tcctaacctg 60 ctgggcggcc ctagcgtctt tatcttccct cctaagatca aagacgtgct gatgatcagc 120 ctgagcccta tcgtgacctg cgtggtggtg gccgtgtctg aggacgatcc tgacgtgcag 180 atcagctggt tcgtgaacaa tgtggaagtg cacacagccc agacacaaac acacagagag 240 gattacggca gcacactgcg cgtggtttcc gccctgccaa tccagcacca ggactggatg 300 agcggcaagg aattcaagtg caaagtgaac aacaaggacc tgcctgcccc tatcgagaga 360 accattagca agcccaaggg atcagttaga gcccctcagg tgtacgtgct gccccccccc 420 gaggaggaaa tgaccaaaaa gcaggtgacc ctgacatgca tggtgactga cttcatgcct 480 gaggacatct acgtggaatg gaccaacaac ggaaagaccg agctcaacta caagaacacc 540 gagcccgtgc ttgattctga cggcagctac ttcatgtaca gcaagctgcg ggtggaaaag 600 aagaactggg tggaaagaaa tagctatagc tgttctgtgg tgcacgaggg cctgcataat 660 caccacacca ccaagtcctt cagccggacc cctggcggcg gcggaggatc cggcggaggc 720 gggagccacc ccaccctgaa aacccccgag agcgtgacag gaacatggaa gggcgatgtc 780 aagatccaat gtatctacga ccccctgaga ggctacagac aggtgctggt gaagtggctg 840 gtcaggcacg gcagcgacag cgtgaccatc tttctgcggg actctacagg agatcacatc 900 cagcaggcca agtaccgggg cagactgaag gtctcccaca aggtgcctgg cgacgtgtcc 960 ctgcagatca acacactgca gatggatgac agaaaccact acacctgcga ggtgacctgg 1020 cagacccctg atggcaacca ggtgatcaga gataagatca tcgagctgcg ggtgcggaag 1080 tacaaccccc cgcggatcaa caccgaggcc ccaaccaccc tccattctag cctggaagct 1140 1200. acaaccatca tgagcagcac cagcgacctg accaccatg gcacaggcaa gctggaagag acaatcgccg gctctggcag aaacctgcct ggc <210> 32 <211> 1863 <212> DNA <213> The snowstorm <220> <223> VEGF enzyme-induced IgG2a Fc DANG-induced CRIg activation <400> 32 tccgatactg gcagaccctt cgtcgagatg tacagcgaga ttcctgagat catccacatg 120. acagagggac gggaactggt gattccttgc ctccaaacat cacagtgacc ctgaagaagt ttcctctgga caccctgatc cctgacggca agcgcatcat ctgggacagc agaaagggat tcatcatcag caacgccacc tacaaggaa tcggcctcct gacctgcgag gccaccgtga acggacacct gtataaaacc aattacctga cacaccggca aacaaacacc atcatcgacg tggtgctgag ccctagccac ggcatcgagc tgagcgtggg cgagaagctg 360 gtgctgaact gcaccgccag aaccgaactg aacgtgggca tcgatttcaa ctgggaatac ccctcctcta agcaccagca gttaatagg atctgaaac ccagagcggc agcgaaatga aaaagttcct gtctacactg accatcgacg gcgtgaccag aagcgaccag 540 ggcctgtaca cctgtgccgc ttctagcggc ctgatgacca agaagaacag cacattcgtg 600 cgggtgcacg agaagggcgg cggaggtagc gagcctagag gcccaacaat caagccttgt 660 cctccttgca aatgccctgc tcctaacctg ctgggcggcc ctagcgtctt tatcttccct 720 cctaagatca aagacgtgct gatgatcagc ctgagcccta tcgtgacctg cgtggtggtg 780 gccgtgtctg aggacgatcc tgacgtgcag atcagctggt tcgtgaacaa tgtggaagtg 840 cacacagccc agacacaaac acacagagag gattacggca gcacactgcg cgtggtttcc 900 gccctgccaa tccagcacca ggactggatg agcggcaagg aattcaagtg caaagtgaac 960 aacaaggacc tgcctgcccc tatcgagaga accattagca agcccaaggg atcagttaga 1020 gcccctcagg tgtacgtgct gcccccccc gaggaggaaa tgaccaaaaa gcaggtgacc 1080 ctgacatgca tggtgactga cttcatgcct gaggacatct acgtggaatg gaccaacaac 1140 ggaaagaccg agctcaacta caagaacacc gagcccgtgc ttgattctga cggcagctac 1200 ttcatgtaca gcaagctgcg gttggaaaag aagaactggg tggaaagaaa tagctatagc 1260 tgttctgtgg tgcacgaggg cctgcataat caccacacca ccaagtcctt cagccggacc 1320 cctggcggcg gcggaggatc cggcggaggc gggagccacc ccaccctgaa aacccccgag 1380 agcgtgacag gaacatggaa gggcgatgtc aagatccaat gtatctacga ccccctgaga 1440 ggctacagac aggtgctggt gaagtggctg gtcaggcacg gcagcgacag cgtgaccatc 1500 tttctgcggg actctacagg agatcacatc cagcaggcca agtaccgggg cagactgaag 1560 gtctcccaca aggtgcctgg cgacgtgtcc ctgcagatca acacactgca gatggatgac 1620 agaaaccact acacctgcga ggtgacctgg cagacccctg atggcaacca ggtgatcaga 1680 gataagatca tcgagctgcg ggtgcggaag tacaaccccc cgcggatcaa caccgaggcc 1740 ccaaccaccc tccattctag cctggaagct acaaccatca tgagcagcac cagcgacctg 1800 accaccaatg gcacaggcaa gctggaagag acaatcgccg gctctggcag aaacctgcct 1860 ggc 1863 <210> 33 <211> 654 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence of mu IgG2a Fc DANG <400> 33 gcccccaatc tgctgggagg cccttccgtc ttcatcttcc cccccaagat caaggacgtg 60 ctgatgatct ctctgagccc catcgtgaca tgcgtggtgg tggccgtgag cgaggacgat 120 cccgacgtgc agatcagctg gttcgtcaac aacgtggagg tgcataccgc ccaaacacag 180 acccatagag aggactacgg ctccacactg agagtggtgt ccgctctgcc catccagcat 240 caagactgga tgagcggcaa ggagttcaag tgcaaggtga acaacaagga tctgcccgcc 300 cctatcgaga ggaccatctc caagcccaaa ggctccgtga gagctcccca agtgtatgtg 360 ctgcctcccc ccgaggagga gatgaccaag aagcaagtga cactgacatg catggtgacc 420 gatttcatgc ccgaagacat ctacgtggag tggaccaaca acggcaagac cgagctcaac 480 tacaagaaca ccgagcccgt gctcgacagc gacggcagct acttcatgta cagcaagctg 540 agggtcgaga agaaaaactg ggtggagagg aacagctaca gctgtagcgt ggtgcacgag 600 ggactgcaca accaccatac caccaagagc ttctccagaa cacccggcaa gtga 654 <210> 34 <211> 1344 <212> DNA <213> The snowstorm <220> <223> in the IgG2a Fc DANG-VEGF complex inhibitor <400> 34 gagcctagg gacccacaat tagccttgc cccccttgca aatgtcccgc ccctaatctg ctcggcggcc ccagcgtgtt catcttcccc cccaagatta aggacgtgct gatgatctct 120 ctgtccccca ttgtgacatg cgtggtcgtg gctgtctccg aggaccc cgacgtccag 180 atcagctggt tcgtcaacaa tgtggaggtc cataccgccc agacacagac ccatagagag 240 gattacggca gcacactgag agtggtcagc gctctgccca tccaacacca agactggatg agcggcaagg agttcaagtg taaagtgaac aacaaggatc tgcccgcccc cattgagagg accatctcca aacctaaggg cagcgtgagg gctcctcaag tgtatgtgct cccccccccc 420 gaggaga tgaccagaca gcaagtgaca ctgacatgca tggtcaccga cttcatgccc gaggacatct acgtggagtg gaccaacaac ggcaagaccg agctgaatta caagaacacc gaacccgtgc tggatagcga tggctcctac ttcatgtaca gcaagctgag agtggagaaa aagaactggg tcgagaggaa cagctacagc tgctccgtcg tgcatgaggg cctccacaac 660 caccatacaa ccaagagctt ctctaggaca cccggcggcg gaggcggatc cggaggaggc 720 ggcagctccg ataccggaag acctttcgtg gagatgtatt ccgagattcc cgagatcatc 780 cacatgaccg agggaagaga gctggtcatc ccttgtagag tcacaagccc caacattacc 840 gtgaccctca agaagttccc tctggacaca ctgattcccg acggcaagag gattatctgg 900 gactctagga agggcttcat catcagcaac gccacctata aagagatcgg actgctgaca 960 tgcgaggcca cagtgaatgg ccacctctac aagaccaact atctgaccca tagacaaacc 1020 aacaccatta tcgacgtggt gctgagccct agccacggca tcgaactcag cgtgggagag 1080 aaactggtgc tgaattgcac cgctaggacc gaactcaacg tgggaatcga cttcaactgg 1140 gagtacccct ccagcaagca ccagcacaag aagctcgtga atagagatct gaagacccag 1200 agcggaagcg agatgaagaa attcctctcc acactgacca tcgatggcgt gacaaggagc 1260 gaccaaggac tgtacacatg cgctgcttcc agcggactga tgacaaagaa gaacagcacc 1320 ttcgtgaggg tccacgaaaa atga 1344 <210> 35 <211> 1293 <212> DNA <213> Artificial sequence <220> <223> Nucleotide sequence of aflibercept <400> 35 tccgatactg gcagaccctt cgtcgagatg tacagcgaga ttcctgagat catccacatg 60 acagagggac gggaactggt gattccttgc agagtgacat ctccaaacat cacagtgacc 120 ctgaagaagt ttcctctgga caccctgatc cctgacggca agcgcatcat ctgggacagc 180 agaaagggat tcatcatcag caacgccacc tacaaggaaa tcggcctcct gacctgcgag 240 gccaccgtga acggacacct gtataaaacc aattacctga cacaccggca aacaaacacc 300 atcatcgacg tggtgctgag ccctagccac ggcatcgagc tgagcgtggg cgagaagctg 360 gtgctgaact gcaccgccag aaccgaactg aacgtgggca tcgatttcaa ctgggaatac 420 ccctcctcta agcaccagca taagaaactg gttaatagag atctgaaaac ccagagcggc 480 agcgaaatga aaaagttcct gtctacactg accatcgacg gcgtgaccag aagcgaccag 540 ggcctgtaca cctgtgccgc ttctagcggc ctgatgacca agaagaacag cacattcgtg 600 cgggtgcacg agaaggacaa aactcacaca tgcccaccgt gcccagcacc tgaactcctg 660 gggggaccgt cagtcttcct cttcccccca aaacccaagg acaccctcat gatctcccgg 720 acccctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc 780 aactggtacg tggacggcgt ggaggtgcat aatgccaaga caaagccgcg ggaggagcag 840 tacaacagca cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat 900 ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc cagcccccat cgagaaaacc 960 atctccaaag ccaaagggca gccccgagaa ccacaggtgt acaccctgcc cccatcccgg 1020 gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatcccagc 1080 gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct 1140 cccgtgctgg actccgacgg ctccttcttc ctctacagca agctcaccgt ggacaagagc 1200 aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 1260 tacacgcaga agagcctctc cctgtctccg ggt 1293 <210> 36 <211> 453 <212> PRT <213> Artificial sequence <220> <223> Heavy chain of anti-VEGF antibody bevacizumab <400> 36 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 37 <211> 214 <212> PRT <213> Artificial sequence <220> <223> Light chain of anti-VEGF antibody bevacizumab <400> 37 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile 35 40 45 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 38 <211> 231 <212> PRT <213> Artificial sequence <220> <223> The variable heavy chain of the anti-VEGF antibody ranibizumab <400> 38 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Leu 225 230 <210> 39 <211> 214 <212> PRT <213> Artificial sequence <220> <223> Light chain of anti-VEGF antibody ranibizumab <400> 39 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile 35 40 45 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 40 <211> 446 <212> PRT <213> Artificial sequence <220> <223> Heavy chain of the anti-VEGF antibody ramucirumab <400> 40 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Thr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val 100 105 110 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 115 120 125 Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu 130 135 140 Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 145 150 155 160 Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 165 170 175 Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 180 185 190 Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 195 200 205 Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr 210 215 220 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 225 230 235 240 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 245 250 255 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 260 265 270 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 275 280 285 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 290 295 300 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 305 310 315 320 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 325 330 335 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 340 345 350 Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 355 360 365 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 370 375 380 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 385 390 395 400 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 405 410 415 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 420 425 430 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 41 <211> 214 <212> PRT Artificial sequence <220> <223> Light chain of the anti-VEGF antibody ramucirumab <400> 41 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Ile Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asp Asn Trp 20 25 30 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Leu Asp Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Tyr Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala 65 70 75 80 Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Ala Lys Ala Phe Pro Pro 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Gly Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 42 <211> 252 <212> PRT <213> Artificial sequence <220> <223> anti-VEGF antibody brolucizumab (VL-linker-VL) scFv <400> 42 Met Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val 1 5 10 15 Gly Asp Arg Val Ile Ile Thr Cys Gln Ala Ser Glu Ile Ile His Ser 20 25 30 Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Leu Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln 65 70 75 80 Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Asn Val Tyr Leu Ala Ser 85 90 95 Thr Asn Gly Ala Asn Phe Gly Gln Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 115 120 125 Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 130 135 140 Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser 145 150 155 160 Leu Thr Asp Tyr Tyr Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys 165 170 175 Gly Leu Glu Trp Val Gly Phe Ile Asp Pro Asp Asp Asp Pro Tyr Tyr 180 185 190 Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys 195 200 205 Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala 210 215 220 Val Tyr Tyr Cys Ala Gly Gly Asp His Asn Ser Gly Trp Gly Leu Asp 225 230 235 240 Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 245 250 <210> 43 <211> 453 <212> PRT <213> Artificial sequence <220> <223> Heavy chain of the anti-VEGF antibody faricimab <400> 43 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala 225 230 235 240 Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ala Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu Ala Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln 355 360 365 Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn Ala Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 44 <211> 214 <212> PRT <213> Artificial sequence <220> <223> Light chain of anti-VEGF antibody faricimab <400> 44 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile 35 40 45 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 45 <211> 453 <212> PRT <213> Artificial sequence <220> <223> Heavy chain of anti-VEGF antibody KSI-301 <400> 45 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala 225 230 235 240 Ala Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Cys Ser Pro Gly Lys 450 <210> 46 <211> 214 <212> PRT <213> Artificial sequence <220> <223> Light chain of anti-VEGF antibody KSI-301 <400> 46 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile 35 40 45 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 47 <211> 453 <212> PRT <213> Artificial sequence <220> <223> Heavy chain of the anti-VEGF antibody vanucizumab <400> 47 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55 60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln 355 360 365 Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 48 <211> 214 <212> PRT <213> Artificial sequence <220> <223> The light chain of the anti-VEGF antibody vanucizumab <400> 48 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile 35 40 45 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 49 <211> 5 <212> PRT <213> Artificial sequence <220> <223> CDR1 of anti-VEGF VHH-antibody BI-836880 <400> 49 Ser Tyr Ser Met Gly 1 5 <210> 50 <211> 16 <212> PRT <213> Artificial sequence <220> <223> CDR2 of anti-VEGF VHH-antibody BI-836880 <400> 50 Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu Gly 1 5 10 15 <210> 51 <211> 17 <212> PRT <213> Artificial sequence <220> <223> CDR3 of anti-VEGF VHH-antibody BI-836880 <400> 51 Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr Glu 1 5 10 15 Tyr <210> 52 <211> 11 <212> PRT <213> Artificial sequence <220> <223> HuMab G6-31 HC-CDR1 <400> 52 Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 53 <211> 16 <212> PRT <213> Artificial sequence <220> <223> HuMab G6-31 HC-CDR2 <400> 53 Gly Ile Thr Pro Ala Gly Gly Tyr Thr Tyr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 <210> 54 <211> 5 <212> PRT <213> Artificial sequence <220> <223> HuMab G6-31 HC-CDR3 <400> 54 Asp Tyr Trp Ile His 1 5 <210> 55 <211> 9 <212> PRT <213> Artificial sequence <220> <223> HuMab G6-31 LC-CDR1 <400> 55 Gln Gln Gly Tyr Gly Asn Pro Phe Thr 1 5 <210> 56 <211> 7 <212> PRT <213> Artificial sequence <220> <223> HuMab G6-31 LC-CDR2 <400> 56 Ser Ala Ser Phe Leu Tyr Ser 1 5 <210> 57 <211> 11 <212> PRT <213> Artificial sequence <220> <223> HuMab G6-31 LC-CDR3 <400> 57 Arg Ala Ser Gln Asp Val Ser Thr Ala Val Ala 1 5 10 <210> 58 <211> 12 <212> PRT <213> Artificial sequence <220> <223> HC-CDR1 of B20-4.1 <400> 58 Trp Gly His Ser Thr Ser Pro Trp Ala Met Asp Tyr 1 5 10 <210> 59 <211> 16 <212> PRT <213> Artificial sequence <220> <223> HC-CDR2 of B20-4.1 <400> 59 Ala Ile Trp Pro Phe Gly Gly Tyr Thr His Tyr Ala Asp Ser Val Lys 1 5 10 15 <210> 60 <211> 8 <212> PRT <213> Artificial sequence <220> <223> HC-CDR3 of B20-4.1 <400> 60 Phe Ser Ile Asn Gly Ser Trp Ile 1 5 <210> 61 <211> 9 <212> PRT <213> Artificial sequence <220> <223> LC-CDR1 of B20-4.1 <400> 61 Gln Gln Ser Asn Thr Ser Pro Leu Thr 1 5 <210> 62 <211> 8 <212> PRT <213> Artificial sequence <220> <223> LC-CDR2 of B20-4.1 <400> 62 Tyr Ala Ala Ser Asn Leu Ala Ser 1 5 <210> 63 <211> 11 <212> PRT <213> Artificial sequence <220> <223> LC-CDR3 of B20-4.1 <400> 63 Arg Ala Ser Gln Val Ile Arg Arg Ser Leu Ala 1 5 10 <210> 64 <211> 453 <212> PRT <213> Artificial sequence <220> <223> BAT-5906 heavy chain <400> 64 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe Lys 50 55 60 Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro 115 120 125 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 130 135 140 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 145 150 155 160 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 165 170 175 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 180 185 190 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 195 200 205 Ile Ile Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Lys 450 <210> 65 <211> 214 <212> PRT <213> Artificial sequence <220> <223> Light chain of BAT-5906 <400> 65 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile 35 40 45 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 66 <211> 447 <212> PRT <213> Artificial sequence <220> <223> Heavy chain of navicixizumab <400> 66 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Asp Ile Asn Pro Ser Asn Gly Arg Thr Ser Tyr Lys Glu Lys Phe 50 55 60 Lys Arg Arg Val Thr Leu Ser Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Thr Ile His Tyr Asp Asp Lys Tyr Tyr Pro Leu Met Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys 210 215 220 Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser 290 295 300 Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile 325 330 335 Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Arg Glu Lys Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Lys Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 67 <211> 218 <212> PRT <213> Artificial sequence <220> <223> Navicixizumab light chain <400> 67 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr 20 25 30 Gly Ile Ser Phe Met Lys Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Asn Gln Gly Ser Gly Val Pro Asp 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Ser Lys 85 90 95 Glu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 68 <211> 577 <212> PRT <213> Artificial sequence <220> <223> Heavy chain of dilpacimab <400> 68 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Pro Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Ser Ser Ser Asp Gly Thr Thr Tyr Tyr Arg Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Tyr Tyr Asn Ser Pro Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Glu Val Gln Leu 115 120 125 Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu 130 135 140 Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn Trp 145 150 155 160 Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Trp Ile Asn 165 170 175 Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe Lys Arg Arg Phe 180 185 190 Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr Leu Gln Met Asn 195 200 205 Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Tyr Pro 210 215 220 His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val Trp Gly Gln Gly 225 230 235 240 Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 245 250 255 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 260 265 270 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 275 280 285 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 290 295 300 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 305 310 315 320 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 325 330 335 Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 340 345 350 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro 355 360 365 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 370 375 380 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 385 390 395 400 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 405 410 415 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 420 425 430 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 435 440 445 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 450 455 460 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 465 470 475 480 Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 485 490 495 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 500 505 510 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 515 520 525 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 530 535 540 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 545 550 555 560 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 565 570 575 Lys <210> 69 <211> 334 <212> PRT <213> Artificial sequence <220> <223> The light chain of dilpacimab <400> 69 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asp Ile Tyr Ser Asn 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Thr Asn Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Asn Tyr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Asp Ile Gln Met Thr Gln Ser Pro 115 120 125 Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Ser 130 135 140 Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro 145 150 155 160 Gly Lys Ala Pro Lys Val Leu Ile Tyr Phe Thr Ser Ser Leu His Ser 165 170 175 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 180 185 190 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 195 200 205 Gln Gln Tyr Ser Thr Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val 210 215 220 Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 225 230 235 240 Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu 245 250 255 Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn 260 265 270 Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser 275 280 285 Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala 290 295 300 Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly 305 310 315 320 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 325 330 <210> 70 <211> 116 <212> PRT <213> Artificial sequence <220> <223> Heavy chain variable region of hPV-19 <400> 70 Asp Val Gln Leu Val Gln Ser Gly Val Glu Val Lys Asn Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Arg Ala Ser Gly Tyr Ser Phe Thr Asn Ser 20 25 30 Gly Ile Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Ser Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Phe Gly Asp Gly Tyr Tyr Trp Phe Phe Asp Val Trp Gly Ala 100 105 110 Gly Thr Thr Val 115 <210> 71 <211> 113 <212> PRT <213> Artificial sequence <220> <223> Light chain variable region of hPV-19 <400> 71 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30 Arg Thr Arg Lys Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Lys Gln 85 90 95 Ser Tyr Asn Leu Tyr Thr Phe Gly Gly Gly Thr Asn Leu Glu Ile Lys 100 105 110 Arg <210> 72 <211> 126 <212> PRT <213> Artificial sequence <220> <223> Heavy chain variable region of AT-001 <400> 72 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Gly Arg Ser Met Val Arg Gly Val Ile Ile Pro Phe Asn Gly 100 105 110 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 73 <211> 107 <212> PRT <213> Artificial sequence <220> <223> Light chain variable region of AT-001 <400> 73 Asp Ile Arg Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 74 <211> 118 <212> PRT <213> Artificial sequence <220> <223> Crig's human lgV amino acid sequence <400> 74 Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro Trp Lys Gly 1 5 10 15 Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly Tyr Thr Gln 20 25 30 Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro Val Thr Ile 35 40 45 Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala Lys Tyr Gln 50 55 60 Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val Ser Leu Gln 65 70 75 80 Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr Cys Glu Val 85 90 95 Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp Lys Ile Thr 100 105 110 Glu Leu Arg Val Gln Lys 115 <210> 75 <211> 168 <212> PRT <213> Artificial sequence <220> <223> Extracellular domain of mouse CRIg <400> 75 His Pro Thr Leu Lys Thr Pro Glu Ser Val Thr Gly Thr Trp Lys Gly 1 5 10 15 Asp Val Lys Ile Gln Cys Ile Tyr Asp Pro Leu Arg Gly Tyr Arg Gln 20 25 30 Val Leu Val Lys Trp Leu Val Arg His Gly Ser Asp Ser Val Thr Ile 35 40 45 Phe Leu Arg Asp Ser Thr Gly Asp His Ile Gln Gln Ala Lys Tyr Arg 50 55 60 Gly Arg Leu Lys Val Ser His Lys Val Pro Gly Asp Val Ser Leu Gln 65 70 75 80 Ile Asn Thr Leu Gln Met Asp Asp Arg Asn His Tyr Thr Cys Glu Val 85 90 95 Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Ile Arg Asp Lys Ile Ile 100 105 110 Glu Leu Arg Val Arg Lys Tyr Asn Pro Pro Arg Ile Asn Thr Glu Ala 115 120 125 Pro Thr Thr Leu His Ser Ser Leu Glu Ala Thr Thr Ile Met Ser Ser 130 135 140 Thr Ser Asp Leu Thr Thr Asn Gly Thr Gly Lys Leu Glu Glu Thr Ile 145 150 155 160 Ala Gly Ser Gly Arg Asn Leu Pro 165 <210> 76 <211> 209 <212> PRT <213> Artificial sequence <220> <223> Human IgG1 Fc DANG-K <400> 76 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 1 5 10 15 Arg Thr Pro Glu Val Thr Cys Val Val Val Ala Val Ser His Glu Asp 20 25 30 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 35 40 45 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr Arg Val 50 55 60 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 65 70 75 80 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 85 90 95 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 100 105 110 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 115 120 125 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 130 135 140 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 145 150 155 160 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 165 170 175 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 180 185 190 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 195 200 205 Lys <210> 77 <211> 118 <212> PRT <213> Artificial sequence <220> <223> HCDR1 of bevacizumab <400> 77 Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro Trp Lys Gly 1 5 10 15 Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly Tyr Thr Gln 20 25 30 Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro Val Thr Ile 35 40 45 Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala Lys Tyr Gln 50 55 60 Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val Ser Leu Gln 65 70 75 80 Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr Cys Glu Val 85 90 95 Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp Lys Ile Thr 100 105 110 Glu Leu Arg Val Gln Lys 115 <210> 78 <211> 17 <212> PRT <213> Artificial sequence <220> <223> bevacizumab's HCDR2 <400> 78 Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe Lys 1 5 10 15 Arg <210> 79 <211> 14 <212> PRT <213> Artificial sequence <220> <223> bevacizumab's HCDR3 <400> 79 Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 1 5 10 <210> 80 <211> 11 <212> PRT <213> Artificial sequence <220> <223> bevacizumab's LCDR1 <400> 80 Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 81 <211> 7 <212> PRT <213> Artificial sequence <220> <223> bevacizumab's LCDR2 <400> 81 Phe Thr Ser Ser Leu His Ser 1 5 <210> 82 <211> 9 <212> PRT <213> Artificial sequence <220> <223> bevacizumab's LCDR3 <400> 82 Gln Gln Tyr Ser Thr Val Pro Trp Thr 1 5 <210> 83 <211> 10 <212> PRT <213> Artificial sequence <220> <223> ranibizumab's HCDR1 <400> 83 Gly Tyr Asp Phe Thr His Tyr Gly Met Asn 1 5 10 <210> 84 <211> 17 <212> PRT <213> Artificial sequence <220> <223> ranibizumab's HCDR2 <400> 84 Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe Lys 1 5 10 15 Arg <210> 85 <211> 14 <212> PRT <213> Artificial sequence <220> <223> ranibizumab's HCDR3 <400> 85 Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val 1 5 10 <210> 86 <211> 11 <212> PRT <213> Artificial sequence <220> <223> LCDR1 of ranibizumab <400> 86 Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 87 <211> 7 <212> PRT <213> Artificial sequence <220> <223> LCDR2 of ranibizumab <400> 87 Phe Thr Ser Ser Leu His Ser 1 5 <210> 88 <211> 9 <212> PRT <213> Artificial sequence <220> <223> LCDR3 of ranibizumab <400> 88 Gln Gln Tyr Ser Thr Val Pro Trp Thr 1 5 <210> 89 <211> 10 <212> PRT <213> Artificial sequence <220> <223> HCDR1 of ramucirumab <400> 89 Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn 1 5 10 <210> 90 <211> 17 <212> PRT <213> Artificial sequence <220> <223> HCDR2 of ramucirumab <400> 90 Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 91 <211> 7 <212> PRT <213> Artificial sequence <220> <223> HCDR3 of ramucirumab <400> 91 Val Thr Asp Ala Phe Asp Ile 1 5 <210> 92 <211> 11 <212> PRT <213> Artificial sequence <220> <223> ramucirumab's LCDR1 <400> 92 Arg Ala Ser Gln Gly Ile Asp Asn Trp Leu Gly 1 5 10 <210> 93 <211> 7 <212> PRT <213> Artificial sequence <220> <223> ramucirumab's LCDR2 <400> 93 Asp Ala Ser Asn Leu Asp Thr 1 5 <210> 94 <211> 9 <212> PRT <213> Artificial sequence <220> <223> ramucirumab's LCDR3 <400> 94 Gln Gln Ala Lys Ala Phe Pro Pro Thr 1 5 <210> 95 <211> 11 <212> PRT <213> Artificial sequence <220> <223> CDR1 of brolucizumab <400> 95 Gln Ala Ser Glu Ile Ile His Ser Trp Leu Ala 1 5 10 <210> 96 <211> 7 <212> PRT <213> Artificial sequence <220> <223> CDR2 of brolucizumab <400> 96 Leu Ala Ser Thr Leu Ala Ser 1 5 <210> 97 <211> 12 <212> PRT <213> Artificial sequence <220> <223> CDR3 of brolucizumab <400> 97 Gln Asn Val Tyr Leu Ala Ser Thr Asn Gly Ala Asn 1 5 10 <210> 98 <211> 11 <212> PRT <213> Artificial sequence <220> <223> CDR4 of brolucizumab <400> 98 Gly Phe Ser Leu Thr Asp Tyr Tyr Tyr Met Thr 1 5 10 <210> 99 <211> 16 <212> PRT <213> Artificial sequence <220> <223> CDR5 of brolucizumab <400> 99 Phe Ile Asp Pro Asp Asp Asp Pro Tyr Tyr Ala Thr Trp Ala Lys Gly 1 5 10 15 <210> 100 <211> 11 <212> PRT <213> Artificial sequence <220> <223> CDR6 of brolucizumab <400> 100 Gly Asp His Asn Ser Gly Trp Gly Leu Asp Ile 1 5 10 <210> 101 <211> 10 <212> PRT <213> Artificial sequence <220> <223> HCDR1 of faricimab <400> 101 Gly Tyr Asp Phe Thr His Tyr Gly Met Asn 1 5 10 <210> 102 <211> 17 <212> PRT <213> Artificial sequence <220> <223> HCDR2 of faricimab <400> 102 Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe Lys 1 5 10 15 Arg <210> 103 <211> 14 <212> PRT <213> Artificial sequence <220> <223> HCDR3 of faricimab <400> 103 Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val 1 5 10 <210> 104 <211> 11 <212> PRT <213> Artificial sequence <220> <223> LCDR1 of faricimab <400> 104 Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 105 <211> 7 <212> PRT <213> Artificial sequence <220> <223> LCDR2 of faricimab <400> 105 Phe Thr Ser Ser Leu His Ser 1 5 <210> 106 <211> 9 <212> PRT <213> Artificial sequence <220> <223> LCDR3 of faricimab <400> 106 Gln Gln Tyr Ser Thr Val Pro Trp Thr 1 5 <210> 107 <211> 10 <212> PRT <213> Artificial sequence <220> <223> HCDR1 of KSI-301 <400> 107 Gly Tyr Asp Phe Thr His Tyr Gly Met Asn 1 5 10 <210> 108 <211> 17 <212> PRT <213> Artificial sequence <220> <223> HCDR2 of KSI-301 <400> 108 Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe Lys 1 5 10 15 Arg <210> 109 <211> 14 <212> PRT <213> Artificial sequence <220> <223> HCDR3 of KSI-301 <400> 109 Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val 1 5 10 <210> 110 <211> 11 <212> PRT <213> Artificial sequence <220> <223> LCDR1 of KSI-301 <400> 110 Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 111 <211> 7 <212> PRT <213> Artificial sequence <220> <223> LCDR2 of KSI-301 <400> 111 Phe Thr Ser Ser Leu His Ser 1 5 <210> 112 <211> 9 <212> PRT <213> Artificial sequence <220> <223> LCDR3 of KSI-301 <400> 112 Gln Gln Tyr Ser Thr Val Pro Trp Thr 1 5 <210> 113 <211> 10 <212> PRT <213> Artificial sequence <220> <223> HCDR1 of vanucizumab <400> 113 Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn 1 5 10 <210> 114 <211> 17 <212> PRT <213> Artificial sequence <220> <223> HCDR2 of vanucizumab <400> 114 Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe Lys 1 5 10 15 Arg <210> 115 <211> 14 <212> PRT <213> Artificial sequence <220> <223> HCDR3 of vanucizumab <400> 115 Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 1 5 10 <210> 116 <211> 11 <212> PRT <213> Artificial sequence <220> <223> LCDR1 of vanucizumab <400> 116 Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 117 <211> 7 <212> PRT <213> Artificial sequence <220> <223> LCDR2 of vanucizumab <400> 117 Phe Thr Ser Ser Leu His Ser 1 5 <210> 118 <211> 9 <212> PRT <213> Artificial sequence <220> <223> LCDR3 of vanucizumab <400> 118 Gln Gln Tyr Ser Thr Val Pro Trp Thr 1 5 <210> 119 <211> 10 <212> PRT <213> Artificial sequence <220> <223> HCDR1 of BAT-5906 <400> 119 Gly Tyr Asp Phe Thr His Tyr Gly Met Asn 1 5 10 <210> 120 <211> 17 <212> PRT <213> Artificial sequence <220> <223> HCDR2 of BAT-5906 <400> 120 Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe Lys 1 5 10 15 Arg <210> 121 <211> 14 <212> PRT <213> Artificial sequence <220> <223> HCDR3 of BAT-5906 <400> 121 Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val 1 5 10 <210> 122 <211> 11 <212> PRT <213> Artificial sequence <220> <223> LCDR1 of BAT-5906 <400> 122 Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 123 <211> 7 <212> PRT <213> Artificial sequence <220> <223> LCDR2 of BAT-5906 <400> 123 Phe Thr Ser Ser Leu His Ser 1 5 <210> 124 <211> 10 <212> PRT <213> Artificial sequence <220> <223> LCDR3 of BAT-5906 <400> 124 Cys Gln Gln Tyr Ser Thr Val Pro Trp Thr 1 5 10 <210> 125 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Navicixizumab's HCDR1 <400> 125 Asn Tyr Trp Met His 1 5 <210> 126 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Navicixizumab's HCDR2 <400> 126 Asp Ile Asn Pro Ser Asn Gly Arg Thr Ser Tyr Lys Glu Lys Phe Lys 1 5 10 15 Arg <210> 127 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Navicixizumab's HCDR3 <400> 127 His Tyr Asp Asp Lys Tyr Tyr Pro Leu Met Asp Tyr 1 5 10 <210> 128 <211> 15 <212> PRT <213> Artificial sequence <220> <223> Navicixizumab's LCDR1 <400> 128 Arg Ala Ser Glu Ser Val Asp Asn Tyr Gly Ile Ser Phe Met Lys 1 5 10 15 <210> 129 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Navicixizumab's LCDR2 <400> 129 Ala Ala Ser Asn Gln Gly Ser 1 5 <210> 130 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Navicixizumab's LCDR3 <400> 130 Gln Gln Ser Lys Glu Val Pro Trp Thr Phe Gly Gly 1 5 10 <210> 131 <211> 11 <212> PRT <213> Artificial sequence <220> <223> HCDR1 of dilpacimab <400> 131 Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn 1 5 10 <210> 132 <211> 16 <212> PRT <213> Artificial sequence <220> <223> HCDR2 of dilpacimab <400> 132 Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe Lys Arg 1 5 10 15 <210> 133 <211> 14 <212> PRT <213> Artificial sequence <220> <223> HCDR3 of dilpacimab <400> 133 Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val 1 5 10 <210> 134 <211> 11 <212> PRT <213> Artificial sequence <220> <223> LCDR1 of dilpacimab <400> 134 Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 135 <211> 7 <212> PRT <213> Artificial sequence <220> <223> LCDR2 of dilpacimab <400> 135 Phe Thr Ser Ser Leu His Ser 1 5 <210> 136 <211> 8 <212> PRT <213> Artificial sequence <220> <223> LCDR3 of dilpacimab <400> 136 Gln Gln Tyr Ser Thr Val Pro Trp 1 5 <210> 137 <211> 10 <212> PRT <213> Artificial sequence <220> <223> HCDR1 of HPV-19 <400> 137 Gly Tyr Ser Phe Thr Asn Ser Gly Ile Asn 1 5 10 <210> 138 <211> 14 <212> PRT <213> Artificial sequence <220> <223> HCDR2 of HPV-19 <400> 138 Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 1 5 10 <210> 139 <211> 10 <212> PRT <213> Artificial sequence <220> <223> HCDR3 of HPV-19 <400> 139 Phe Gly Asp Gly Tyr Tyr Trp Phe Phe Asp 1 5 10 <210> 140 <211> 17 <212> PRT <213> Artificial sequence <220> <223> LCDR1 of hPV-19 <400> 140 Lys Ser Ser Gln Ser Leu Leu Asn Ser Arg Thr Arg Lys Asn Phe Leu 1 5 10 15 Ala <210> 141 <211> 7 <212> PRT <213> Artificial sequence <220> <223> LCDR2 of hPV-19 <400> 141 Trp Ala Ser Thr Arg Glu Ser 1 5 <210> 142 <211> 11 <212> PRT <213> Artificial sequence <220> <223> LCDR3 for HPV-19 <400> 142 Lys Gln Ser Tyr Asn Leu Tyr Thr Phe Gly Gly 1 5 10 <210> 143 <211> 5 <212> PRT <213> Artificial sequence <220> <223> AT-001's HCDR1 <400> 143 Ser Tyr Ala Ile Ser 1 5 <210> 144 <211> 17 <212> PRT <213> Artificial sequence <220> <223> AT-001's HCDR2 <400> 144 Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 145 <211> 17 <212> PRT <213> Artificial sequence <220> <223> AT-001's HCDR3 <400> 145 Gly Arg Ser Met Val Arg Gly Val Ile Ile Pro Phe Asn Gly Met Asp 1 5 10 15 Val <210> 146 <211> 11 <212> PRT <213> Artificial sequence <220> <223> LCDR1 of AT-001 <400> 146 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 1 5 10 <210> 147 <211> 7 <212> PRT <213> Artificial sequence <220> <223> AT-001's LCDR2 <400> 147 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 148 <211> 9 <212> PRT <213> Artificial sequence <220> <223> AT-001's LCDR3 <400> 148 Gln Gln Ser Tyr Ser Thr Pro Leu Thr 1 5 <210> 149 <211> 1673 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of rabbit C3 <400> 149 Met Ala Glu Pro Trp Pro Leu Ala Leu Met Leu Leu Leu Cys Gly Ser 1 5 10 15 Pro Leu Tyr Arg Ala Glu Pro Leu Tyr Ile Leu Val Thr Pro Arg Val 20 25 30 Leu Arg Leu Gly Ser Pro Glu Asn Ile His Val Gln Ala His Ser Glu 35 40 45 Ser Arg Glu Arg Leu Gln Gly Ser Phe Lys Val Asn Leu Thr Val Trp 50 55 60 Asp Phe Pro Leu Arg Lys Thr Leu Leu Ala Ser Ser Arg Val Val Leu 65 70 75 80 Ser Ala Thr Asn Asp Phe Met Glu Gln Thr Pro Val Thr Val Pro Glu 85 90 95 Ser Leu Leu Phe Pro Arg His Glu Lys Pro Gly Gln His Tyr Val Ile 100 105 110 Ile Arg Ala Asp Trp Lys Pro Thr Ser Val Ser Ser Phe Met Glu Lys 115 120 125 Ile Val Leu Val Ala Pro His Ala Gly Tyr Ile Phe Ile Gln Thr Asp 130 135 140 Lys Thr Ile Tyr Thr Pro Asp His Met Val Gln Tyr Arg Val Phe Ala 145 150 155 160 Val Asn His Lys Met Asp Pro Val Asn Arg Ala Ile Leu Leu Asp Ile 165 170 175 Lys Asn Pro Asp Gly Val Thr Val Ile Ser His Ser Arg Gln Val Ile 180 185 190 Asn Gly Leu Phe Asp Ser Ser Phe His Leu Pro Glu Leu Val Ser Leu 195 200 205 Gly Thr Trp Thr Ile Glu Ala Ser Tyr Gln Ser Ala Gly Lys Gln Lys 210 215 220 Phe Lys Ala Thr Phe Asp Val Lys Glu Tyr Val Leu Pro Ser Phe Glu 225 230 235 240 Val Gln Leu Thr Pro Asn Lys Thr Phe Phe Thr Leu Asn Asp Glu Ala 245 250 255 Leu Gly Val Asp Ile Gln Ala Arg Tyr Ile Phe Asn Lys Pro Val Asp 260 265 270 Gly His Ala Leu Ala Ile Phe Gly Leu Lys Val Asp Asn Ile Arg Thr 275 280 285 Thr Ile Gln Gly Ser Leu Gln Arg Val Glu Val Ser Glu Gly Gln Gly 290 295 300 His Val Ser Leu Gln Lys Asp Thr Leu Leu Ala Ala Phe Gln Asp Pro 305 310 315 320 Glu Gly Asp Phe Ser Gly Ala Ser Ile Phe Val Asn Val Thr Val Phe 325 330 335 Ser Ser Gly Gly Glu Met Val Gln Ala Glu Thr Ser Gly Val Lys Ile 340 345 350 Thr Arg Lys Ala Phe Asn Ile Lys Phe Thr Lys Thr Pro Gln Tyr Phe 355 360 365 Lys Pro Gly Met Pro Phe His Phe Arg Val Phe Val Ser Asn Pro Asp 370 375 380 Gly Ser Pro Ala Ala Arg Val Leu Val Arg Cys Gln Asn His Lys Val 385 390 395 400 Tyr Thr Ser Asp Asn Gly Ile Ala Ala Leu Ala Ile Asn Thr Asp Ala 405 410 415 Ala Ser Ser Glu Leu Thr Val Leu Val Glu Thr Glu Ser Pro His Pro 420 425 430 Glu Gln Gln Val Ser Ala Arg Met Thr Ala Trp Pro Tyr Ser Thr Gln 435 440 445 Glu Asn Ser Gly Asn Phe Leu His Val Glu Val Asn Thr Met Gly Thr 450 455 460 Asp Val Gly Asn Ser Leu Gln Leu Ser Leu Asn Thr Arg His Ala Asn 465 470 475 480 Pro Ala Thr Lys Asp Glu Ile Thr His Phe Thr Ile Met Val Leu Ser 485 490 495 Lys Gly Arg Val Val Ser Ala Arg Gln Gln Leu Lys Ser Ser Gly Ser 500 505 510 Val Tyr Thr Ser Ala Ile Ile Asp Val Thr Pro Glu Met Leu Pro Ser 515 520 525 Phe Arg Ile Val Ala Phe Tyr Leu Leu Pro Arg Gly Met Ser Gln Asn 530 535 540 Pro Glu Leu Val Ala Asp Ser Ile Trp Ile Asp Val Asn Asp Arg Cys 545 550 555 560 Met Gly Thr Leu Lys Val Gly Leu Lys Arg Asp Gly Val Ile Gln Pro 565 570 575 Leu Glu Pro Gln Ser Gln Val Glu Leu Lys Val Thr Gly Asp Ala Glu 580 585 590 Ala Arg Val Trp Leu Leu Ala Val Asp Lys Ala Val Tyr Ala Leu Asn 595 600 605 Ser Lys His Lys Leu Thr Gln Lys Lys Val Trp Asp Val Val Glu Glu 610 615 620 His Asp Ile Gly Cys Thr Ala Gly Ser Gly Lys Asn Asn Phe Ala Val 625 630 635 640 Phe Lys Asp Ala Gly Leu Asp Leu Lys Ile Ser Thr Gly Met Asp Thr 645 650 655 Leu Ala Ser Ser Asp Trp Arg Cys Pro Gln Ser Pro Pro Pro Ser Arg 660 665 670 Arg Arg Arg Ser Leu Arg Arg Leu Glu Ala Lys Arg Asp Ala Val Asn 675 680 685 Lys Phe Lys Thr Glu Leu Glu Arg Lys Cys Cys Glu Ala Gly Leu Lys 690 695 700 Glu Asn Pro Ala Gly Leu Ala Cys Glu Glu Arg Thr Arg His Val Leu 705 710 715 720 His Gly Pro Ser Cys Met Ala Ala Phe Leu Asp Cys Cys Gln Leu Ser 725 730 735 Glu Thr Leu Thr Arg Glu Ala Arg Glu Glu Arg Leu Leu Leu Gly Thr 740 745 750 Thr Asp Asp Asp Asp Glu Phe Leu Asp Asp Ile Phe Leu Asp Asp Leu 755 760 765 Pro Val Arg Thr Leu Phe Pro Glu Ser Trp Leu Trp Arg Ser Val Thr 770 775 780 Leu Pro Glu Ser Ala Ser Gly Thr Ser His Leu Leu Thr Leu Val Ser 785 790 795 800 Met Pro Asp Ser Ile Thr Thr Trp Glu Phe Val Ala Val Ser Leu Lys 805 810 815 Ala Gly Arg Gly Leu Cys Val Ser Asp Pro Phe Glu Leu Thr Val Met 820 825 830 Lys Ser Phe Phe Val Asp Leu Lys Leu Pro Ser Ser Val Val Arg Asn 835 840 845 Glu Gln Ile Gln Ile Gln Ala Val Leu Tyr Asn Phe Arg Ser Arg Gln 850 855 860 Val Lys Val Arg Val Glu Phe Pro Tyr Lys Glu Pro Leu Cys Ser Ala 865 870 875 880 Ser Lys Pro Gly Ala Pro Ser Arg Gln Val Val Thr Val Pro Pro Thr 885 890 895 Ser Ser Lys Ile Val Pro Phe Val Leu Leu Pro Leu Glu Leu Gly Glu 900 905 910 Val Glu Val Glu Val Lys Ala Val Gly Pro Glu Ala Arg Asp His Val 915 920 925 Lys Lys Thr Leu Leu Val Arg Ala Gly Gly Gln Val Gln Arg Leu Ser 930 935 940 His Ser Phe Leu Leu Asn Pro Gln Gly Arg Thr Gln Thr Glu Leu Val 945 950 955 960 Pro Arg Arg Glu Leu Leu Asn Lys Val Pro Asp Thr Glu Ala Glu Val 965 970 975 Phe Val Ser Val Gln Gly Asp Ile Leu Gly Glu Thr Ile Val Gly Ser 980 985 990 Leu Thr Pro Lys Glu Thr Arg Lys Leu Leu Thr Val Pro Thr Gly Cys 995 1000 1005 Pro Glu Gln Thr Leu Ser Lys Leu Ala Pro Val Ile Ile Leu Thr Lys 1010 1015 1020 Tyr Leu Asp Ser Thr Gly Gln Trp Ser Lys Val Gly Val Glu His Arg 1025 1030 1035 1040 Glu Gln Val Leu Lys Asn Leu Val Ile Gly His Thr Gln Met Leu Arg 1045 1050 1055 Tyr Arg Ser Ala Asp Gly Ile Tyr Arg Leu Thr Gln Asn Ser Pro Gly 1060 1065 1070 Ser Thr Trp Phe Thr Ser Tyr Met Phe Arg Ile Phe Ala Leu Ala Tyr 1075 1080 1085 Pro Ile Met Thr Asp Lys Leu Pro Arg Leu Ser Glu Leu Cys Ala Met 1090 1095 1100 Ala Lys Trp Val Ile Thr Gln Arg Gln Ala Glu Asp Gly His Phe Leu 1105 1110 1115 1120 Glu Asn Gly Pro Val Val Met Lys Ser Met Gln Gly Gly Tyr Lys Gly 1125 1130 1135 Ser Glu Ala Asp Ile Ser Leu Thr Ala Leu Val Leu Ile Ala Leu His 1140 1145 1150 Ser Gly Gln Glu Leu Cys Ser Pro Thr Met Gln Asn Leu Asp Ala Ser 1155 1160 1165 Ile Lys Arg Ala Ser Asn Phe Leu Glu Thr Lys Leu Pro Thr Ile Gln 1170 1175 1180 Thr Thr Phe Ala Ile Ala Ile Val Ser Tyr Ala Leu Ala Leu Ala Asn 1185 1190 1195 1200 Ser Pro Lys Ala Asn Asp Arg Leu Asp Ser Phe Ala Asn Tyr Ser His 1205 1210 1215 Cys Gly Asp Cys Gly Glu Gly Ala Ala Asp Lys Thr Tyr Trp Pro Val 1220 1225 1230 Gly Glu Pro Asp Glu Asp Ser Leu Tyr Thr Ile Glu Ala Thr Ala Tyr 1235 1240 1245 Ala Leu Met Gln Lys Leu Gln Leu Gly Arg Phe Asn Glu Thr His Ala 1250 1255 1260 Ile Ala Asn Trp Leu Leu Glu Lys Arg Glu Leu Gly Gly Gly Phe Lys 1265 1270 1275 1280 Ser Thr Gln Thr Thr Val Val Ala Ile Glu Ala Leu Thr Ser Phe Arg 1285 1290 1295 Lys Asn Val Pro Phe Glu Gly Glu Gln Asn Leu Asp Val Gln Ile Ser 1300 1305 1310 Val Pro Lys Arg Ala Val His Val Asn Trp Leu Ile Asn His Asn Asn 1315 1320 1325 Ala Tyr Gln Gln Arg Ser Ala Lys Phe Phe Ser Gln Asp Asp Leu Val 1330 1335 1340 Ile Thr Ala Ser Gly His Gly Thr Gly Thr Ile Ser Ile Leu Thr Thr 1345 1350 1355 1360 Tyr Tyr Lys Ser Pro Glu Ser Trp Glu Ser Pro Cys Thr Arg Tyr His 1365 1370 1375 Leu Asn Val Thr Leu His Ser Thr Pro Glu Ala Asn Lys Lys Gly Glu 1380 1385 1390 Glu Thr Phe Arg Leu Arg Met Glu Thr Arg Tyr Leu Gly Ala Gln Asp 1395 1400 1405 Ala Thr Met Thr Ile Met Glu Val Ser Leu Leu Thr Gly Phe Tyr Pro 1410 1415 1420 Asn Gln Glu Asp Leu Lys Gln Leu Thr Asn Asn Val Glu Pro Tyr Ala 1425 1430 1435 1440 Phe Gln Tyr Glu Thr Lys Thr Ser Ser Ser Asp Ser Ser Val Val Leu 1445 1450 1455 Tyr Leu Glu Lys Leu Ser His Gln Glu Asn Thr Val Leu Gly Phe Arg 1460 1465 1470 Ile His Gln Met Leu Gln Ala Asp Phe Leu Gln Ala Ala Met Val Thr 1475 1480 1485 Val Tyr Asp Tyr Tyr Glu Pro Ser His Arg Cys Ser Ala Phe Tyr Asn 1490 1495 1500 Leu Pro Thr Glu Arg Ser Ser Leu Arg Lys Ile Cys His Lys Asp Val 1505 1510 1515 1520 Cys Arg Cys Ala Glu Gly Gln Cys Thr Ala Leu Arg Thr Asp Ser Ser 1525 1530 1535 Arg Leu Ser Lys Glu Glu Leu Gln Glu Ala Ala Cys Glu Ala Gly Val 1540 1545 1550 Asp Phe Val Tyr Lys Ile Lys Leu Glu Gly Val Glu Ala Ser Ala Thr 1555 1560 1565 Thr Pro Tyr Val Tyr Tyr Asn Met Arg Leu Gln Ala Val Ile Lys Ser 1570 1575 1580 Gly Thr Asp Pro Val Ile Pro Asn Thr Leu Lys Lys Phe Val Ser His 1585 1590 1595 1600 Ala Thr Cys His Asp Ser Leu Asp Leu Gln Glu Gln Glu Ser Tyr Leu 1605 1610 1615 Val Met Gly Gln Thr Ser Asp Leu Trp Lys Val Lys Ser Asp Tyr Thr 1620 1625 1630 Tyr Val Leu Gly Lys Asp Thr Phe Leu Met Leu Trp Pro Ala Asp Gly 1635 1640 1645 Asp Val Arg Arg Arg Lys Leu Leu Gly Glu Leu Glu Glu Phe Ser Glu 1650 1655 1660 Tyr Leu Thr Thr His Gly Cys Gln Ser 1665 1670 <210> 150 <211> 1639 <212> PRT <213> Artificial sequence <220> <223> Amino acid sequence of rat C3 (25-1663) <400> 150 Ser Pro Met Tyr Ser Ile Ile Thr Pro Asn Val Leu Arg Leu Glu Ser 1 5 10 15 Glu Glu Thr Phe Ile Leu Glu Ala His Asp Ala Gln Gly Asp Val Pro 20 25 30 Val Thr Val Thr Val Gln Asp Phe Leu Lys Lys Gln Val Leu Thr Ser 35 40 45 Glu Lys Thr Val Leu Thr Gly Ala Thr Gly His Leu Asn Arg Val Phe 50 55 60 Ile Lys Ile Pro Ala Ser Lys Glu Phe Asn Ala Asp Lys Gly His Lys 65 70 75 80 Tyr Val Thr Val Val Ala Asn Phe Gly Ala Thr Val Val Glu Lys Ala 85 90 95 Val Leu Val Ser Phe Gln Ser Gly Tyr Leu Phe Ile Gln Thr Asp Lys 100 105 110 Thr Ile Tyr Thr Pro Gly Ser Thr Val Phe Tyr Arg Ile Phe Thr Val 115 120 125 Asp Asn Asn Leu Leu Pro Val Gly Lys Thr Val Val Ile Val Ile Glu 130 135 140 Thr Pro Asp Gly Val Pro Ile Lys Arg Asp Ile Leu Ser Ser His Asn 145 150 155 160 Gln Tyr Gly Ile Leu Pro Leu Ser Trp Asn Ile Pro Glu Leu Val Asn 165 170 175 Met Gly Gln Trp Lys Ile Arg Ala Phe Tyr Glu His Ala Pro Lys Gln 180 185 190 Thr Phe Ser Ala Glu Phe Glu Val Lys Glu Tyr Val Leu Pro Ser Phe 195 200 205 Glu Val Leu Val Glu Pro Thr Glu Lys Phe Tyr Tyr Ile His Gly Pro 210 215 220 Lys Gly Leu Glu Val Ser Ile Thr Ala Arg Phe Leu Tyr Gly Lys Asn 225 230 235 240 Val Asp Gly Thr Ala Phe Val Ile Phe Gly Val Gln Asp Glu Asp Lys 245 250 255 Lys Ile Ser Leu Ala Leu Ser Leu Thr Arg Val Leu Ile Glu Asp Gly 260 265 270 Ser Gly Glu Ala Val Leu Ser Arg Lys Val Leu Met Asp Gly Val Arg 275 280 285 Pro Ser Ser Pro Glu Ala Leu Val Gly Lys Ser Leu Tyr Val Ser Val 290 295 300 Thr Val Ile Leu His Ser Gly Ser Asp Met Val Glu Ala Glu Arg Ser 305 310 315 320 Gly Ile Pro Ile Val Thr Ser Pro Tyr Gln Ile His Phe Thr Lys Thr 325 330 335 Pro Lys Phe Phe Lys Pro Ala Met Pro Phe Asp Leu Met Val Phe Val 340 345 350 Thr Asn Pro Asp Gly Ser Pro Ala Arg Arg Val Pro Val Val Thr Gln 355 360 365 Gly Ser Asp Ala Gln Ala Leu Thr Gln Asp Asp Gly Val Ala Lys Leu 370 375 380 Ser Val Asn Thr Pro Asn Asn Arg Gln Pro Leu Thr Ile Thr Val Ser 385 390 395 400 Thr Lys Lys Glu Gly Ile Pro Asp Ala Arg Gln Ala Thr Arg Thr Met 405 410 415 Gln Ala Gln Pro Tyr Ser Thr Met His Asn Ser Asn Asn Tyr Leu His 420 425 430 Leu Ser Val Ser Arg Val Glu Leu Lys Pro Gly Asp Asn Leu Asn Val 435 440 445 Asn Phe His Leu Arg Thr Asp Ala Gly Gln Glu Ala Lys Ile Arg Tyr 450 455 460 Tyr Thr Tyr Leu Val Met Asn Lys Gly Lys Leu Leu Lys Ala Gly Arg 465 470 475 480 Gln Val Arg Glu Pro Gly Gln Asp Leu Val Val Leu Ser Leu Pro Ile 485 490 495 Thr Pro Glu Phe Ile Pro Ser Phe Arg Leu Val Ala Tyr Tyr Thr Leu 500 505 510 Ile Gly Ala Asn Gly Gln Arg Glu Val Val Ala Asp Ser Val Trp Val 515 520 525 Asp Val Lys Asp Ser Cys Val Gly Thr Leu Val Val Lys Gly Asp Pro 530 535 540 Arg Asp Asn Arg Gln Pro Ala Pro Gly His Gln Thr Thr Leu Arg Ile 545 550 555 560 Glu Gly Asn Gln Gly Ala Arg Val Gly Leu Val Ala Val Asp Lys Gly 565 570 575 Val Phe Val Leu Asn Lys Lys Asn Lys Leu Thr Gln Ser Lys Ile Trp 580 585 590 Asp Val Val Glu Lys Ala Asp Ile Gly Cys Thr Pro Gly Ser Gly Lys 595 600 605 Asn Tyr Ala Gly Val Phe Met Asp Ala Gly Leu Thr Phe Lys Thr Asn 610 615 620 Gln Gly Leu Gln Thr Asp Gln Arg Glu Asp Pro Glu Cys Ala Lys Pro 625 630 635 640 Ala Ala Arg Arg Arg Arg Ser Val Gln Leu Met Glu Arg Arg Met Asp 645 650 655 Lys Ala Gly Gln Tyr Thr Asp Lys Gly Leu Arg Lys Cys Cys Glu Asp 660 665 670 Gly Met Arg Asp Ile Pro Met Pro Tyr Ser Cys Gln Arg Arg Ala Arg 675 680 685 Leu Ile Thr Gln Gly Glu Ser Cys Leu Lys Ala Phe Met Asp Cys Cys 690 695 700 Asn Tyr Ile Thr Lys Leu Arg Glu Gln His Arg Arg Asp His Val Leu 705 710 715 720 Gly Leu Ala Arg Ser Asp Val Asp Glu Asp Ile Ile Pro Glu Glu Asp 725 730 735 Ile Ile Ser Arg Ser His Phe Pro Glu Ser Trp Leu Trp Thr Ile Glu 740 745 750 Glu Leu Lys Glu Pro Glu Lys Asn Gly Ile Ser Thr Lys Val Met Asn 755 760 765 Ile Phe Leu Lys Asp Ser Ile Thr Thr Trp Glu Ile Leu Ala Val Ser 770 775 780 Leu Ser Asp Lys Lys Gly Ile Cys Val Ala Asp Pro Tyr Glu Ile Thr 785 790 795 800 Val Met Gln Asp Phe Phe Ile Asp Leu Arg Leu Pro Tyr Ser Val Val 805 810 815 Arg Asn Glu Gln Val Glu Ile Arg Ala Val Leu Phe Asn Tyr Arg Glu 820 825 830 Gln Glu Lys Leu Lys Val Arg Val Glu Leu Leu His Asn Pro Ala Phe 835 840 845 Cys Ser Met Ala Thr Ala Lys Lys Arg Tyr Tyr Gln Thr Ile Glu Ile 850 855 860 Pro Pro Lys Ser Ser Val Ala Val Pro Tyr Val Ile Val Pro Leu Lys 865 870 875 880 Ile Gly Leu Gln Glu Val Glu Val Lys Ala Ala Val Phe Asn His Phe 885 890 895 Ile Ser Asp Gly Val Lys Lys Ile Leu Lys Val Val Pro Glu Gly Met 900 905 910 Arg Val Asn Lys Thr Val Ala Val Arg Thr Leu Asp Pro Glu His Leu 915 920 925 Asn Gln Gly Gly Val Gln Arg Glu Asp Val Asn Ala Ala Asp Leu Ser 930 935 940 Asp Gln Val Pro Asp Thr Asp Ser Glu Thr Arg Ile Leu Leu Gln Gly 945 950 955 960 Thr Pro Val Ala Gln Met Ala Glu Asp Ala Val Asp Gly Glu Arg Leu 965 970 975 Lys His Leu Ile Val Thr Pro Ser Gly Cys Gly Glu Gln Asn Met Ile 980 985 990 Gly Met Thr Pro Thr Val Ile Ala Val His Tyr Leu Asp Gln Thr Glu 995 1000 1005 Gln Trp Glu Lys Phe Gly Leu Glu Lys Arg Gln Glu Ala Leu Glu Leu 1010 1015 1020 Ile Lys Lys Gly Tyr Thr Gln Gln Leu Ala Phe Lys Gln Pro Ile Ser 1025 1030 1035 1040 Ala Tyr Ala Ala Phe Asn Asn Arg Pro Pro Ser Thr Trp Leu Thr Ala 1045 1050 1055 Met Trp Ser Arg Ser Phe Ser Leu Ala Ala Asn Leu Ile Ala Ile Asp 1060 1065 1070 Ser Gln Val Leu Cys Gly Ala Val Lys Trp Leu Ile Leu Glu Lys Gln 1075 1080 1085 Lys Pro Asp Gly Val Phe Gln Glu Asp Gly Pro Val Ile His Gln Glu 1090 1095 1100 Met Ile Gly Gly Phe Arg Asn Thr Lys Glu Ala Asp Val Ser Leu Thr 1105 1110 1115 1120 Ala Phe Val Leu Ile Ala Leu Gln Glu Ala Arg Asp Ile Cys Glu Gly 1125 1130 1135 Gln Val Asn Ser Leu Pro Gly Ser Ile Asn Lys Ala Gly Glu Tyr Leu 1140 1145 1150 Glu Ala Ser Tyr Leu Asn Leu Gln Arg Pro Tyr Thr Val Ala Ile Ala 1155 1160 1165 Gly Tyr Ala Leu Ala Leu Met Asn Lys Leu Glu Glu Pro Tyr Leu Thr 1170 1175 1180 Lys Phe Leu Asn Thr Ala Lys Asp Arg Asn Arg Trp Glu Glu Pro Gly 1185 1190 1195 1200 Gln Gln Leu Tyr Asn Val Glu Ala Thr Ser Tyr Ala Leu Leu Ala Leu 1205 1210 1215 Leu Leu Leu Lys Asp Phe Asp Ser Val Pro Pro Val Val Arg Trp Leu 1220 1225 1230 Asn Asp Glu Arg Tyr Tyr Gly Gly Gly Tyr Gly Ser Thr Gln Ala Thr 1235 1240 1245 Phe Met Val Phe Gln Ala Leu Ala Gln Tyr Arg Ala Asp Val Pro Asp 1250 1255 1260 His Lys Asp Leu Asn Met Asp Val Ser Leu His Leu Pro Ser Arg Ser 1265 1270 1275 1280 Ser Pro Thr Val Phe Arg Leu Leu Trp Glu Ser Gly Ser Leu Leu Arg 1285 1290 1295 Ser Glu Glu Thr Lys Gln Asn Glu Gly Phe Ser Leu Thr Ala Lys Gly 1300 1305 1310 Lys Gly Gln Gly Thr Leu Ser Val Val Thr Val Tyr His Ala Lys Val 1315 1320 1325 Lys Gly Lys Thr Thr Cys Lys Lys Phe Asp Leu Arg Val Thr Ile Lys 1330 1335 1340 Pro Ala Pro Glu Thr Ala Lys Lys Pro Gln Asp Ala Lys Ser Ser Met 1345 1350 1355 1360 Ile Leu Asp Ile Cys Thr Arg Tyr Leu Gly Asp Val Asp Ala Thr Met 1365 1370 1375 Ser Ile Leu Asp Ile Ser Met Met Thr Gly Phe Ile Pro Asp Thr Asn 1380 1385 1390 Asp Leu Glu Leu Leu Ser Ser Gly Val Asp Arg Tyr Ile Ser Lys Tyr 1395 1400 1405 Glu Met Asp Lys Ala Phe Ser Asn Lys Asn Thr Leu Ile Ile Tyr Leu 1410 1415 1420 Glu Lys Ile Ser His Ser Glu Glu Asp Cys Leu Ser Phe Lys Val His 1425 1430 1435 1440 Gln Phe Phe Asn Val Gly Leu Ile Gln Pro Gly Ser Val Lys Val Tyr 1445 1450 1455 Ser Tyr Tyr Asn Leu Glu Glu Ser Cys Thr Arg Phe Tyr His Pro Glu 1460 1465 1470 Lys Asp Asp Gly Met Leu Ser Lys Leu Cys His Asn Glu Met Cys Arg 1475 1480 1485 Cys Ala Glu Glu Asn Cys Phe Met His Gln Ser Gln Asp Gln Val Ser 1490 1495 1500 Leu Asn Glu Arg Leu Asp Lys Ala Cys Glu Pro Gly Val Asp Tyr Val 1505 1510 1515 1520 Tyr Lys Thr Lys Leu Thr Thr Ile Glu Leu Ser Asp Asp Phe Asp Glu 1525 1530 1535 Tyr Ile Met Thr Ile Glu Gln Val Ile Lys Ser Gly Ser Asp Glu Val 1540 1545 1550 Gln Ala Gly Gln Glu Arg Arg Phe Ile Ser His Val Lys Cys Arg Asn 1555 1560 1565 Ala Leu Lys Leu Gln Lys Gly Lys Gln Tyr Leu Met Trp Gly Leu Ser 1570 1575 1580 Ser Asp Leu Trp Gly Glu Lys Pro Asn Thr Ser Tyr Ile Ile Gly Lys 1585 1590 1595 1600 Asp Thr Trp Val Glu His Trp Pro Glu Ala Glu Glu Arg Gln Asp Gln 1605 1610 1615 Lys Asn Gln Lys Gln Cys Glu Asp Leu Gly Ala Phe Thr Glu Thr Met 1620 1625 1630 Val Val Phe Gly Cys Pro Asn 1635 <210> 151 <211> 321 <212> PRT <213> Artificial sequence <220> <223> CRIg (VSIG4) isoform 2 <400> 151 Met Gly Ile Leu Leu Gly Leu Leu Leu Leu Gly His Leu Thr Val Asp 1 5 10 15 Thr Tyr Gly Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr Gly Pro 20 25 30 Trp Lys Gly Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro Leu Gln Gly 35 40 45 Tyr Thr Gln Val Leu Val Lys Trp Leu Val Gln Arg Gly Ser Asp Pro 50 55 60 Val Thr Ile Phe Leu Arg Asp Ser Ser Gly Asp His Ile Gln Gln Ala 65 70 75 80 Lys Tyr Gln Gly Arg Leu His Val Ser His Lys Val Pro Gly Asp Val 85 90 95 Ser Leu Gln Leu Ser Thr Leu Glu Met Asp Asp Arg Ser His Tyr Thr 100 105 110 Cys Glu Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Val Arg Asp 115 120 125 Lys Ile Thr Glu Leu Arg Val Gln Lys Leu Ser Val Ser Lys Pro Thr 130 135 140 Val Thr Thr Gly Ser Gly Tyr Gly Phe Thr Val Pro Gln Gly Met Arg 145 150 155 160 Ile Ser Leu Gln Cys Gln Ala Arg Gly Ser Pro Pro Ile Ser Tyr Ile 165 170 175 Trp Tyr Lys Gln Gln Thr Asn Asn Gln Glu Pro Ile Lys Val Ala Thr 180 185 190 Leu Ser Thr Leu Leu Phe Lys Pro Ala Val Ile Ala Asp Ser Gly Ser 195 200 205 Tyr Phe Cys Thr Ala Lys Gly Gln Val Gly Ser Glu Gln His Ser Asp 210 215 220 Ile Val Lys Phe Val Val Lys Asp Ser Ser Lys Leu Leu Lys Thr Lys 225 230 235 240 Thr Glu Ala Pro Thr Thr Met Thr Tyr Pro Leu Lys Ala Thr Ser Thr 245 250 255 Val Lys Gln Ser Trp Asp Trp Thr Thr Asp Met Asp Gly Tyr Leu Gly 260 265 270 Glu Thr Ser Ala Gly Pro Gly Lys Ser Leu Pro Val Phe Ala Ile Ile 275 280 285 Leu Ile Ile Ser Leu Cys Cys Met Val Val Phe Thr Met Ala Tyr Ile 290 295 300 Met Leu Cys Arg Lys Thr Ser Gln Gln Glu His Val Tyr Glu Ala Ala 305 310 315 320 Arg

Claims

1. A fusion protein comprising: Extracellular domain of complement receptors of the immunoglobulin superfamily (CRIg); and A protein that specifically binds to vascular endothelial growth factor (VEGF); The fusion protein described herein is composed of structural formula (I) or (II): N'-X-[joint(1)]n-Fc structural domain-[joint(2)]mYC' (I) N'-Y-[joint(1)]n-Fc structural domain-[joint(2)]mXC' (II) In structural formulas (I) and (II), N' is the N-terminus of the fusion protein. C' is the C-terminus of the fusion protein. X is the extracellular domain of CRIg. Y is a protein that specifically binds to VEGF. Linkers (1) and (2) are peptide linkers, and n and m are each independently 1; The extracellular domain of the CRIg is selected from the amino acid sequences shown in SEQ ID NO: 22 and SEQ ID NO: 75; The protein that specifically binds to VEGF consists of the extracellular domain of the VEGF receptor, which consists of the amino acid sequence shown in SEQ ID NO:

14.

2. The fusion protein according to claim 1, characterized in that, The Fc domain is selected from the amino acid sequences shown in SEQ ID NO: 6, SEQ ID NO: 11 or SEQ ID NO:

76.

3. The fusion protein according to claim 1, characterized in that, The connector (1) is selected from the amino acid sequence shown in SEQ ID NO: 15 or SEQ ID NO:

17.

4. The fusion protein according to claim 1, characterized in that, The connector (2) is selected from the amino acid sequence shown in SEQ ID NO: 16 or SEQ ID NO:

18.

5. The fusion protein according to claim 1, characterized in that, The fusion protein is composed of structure (I).

6. The fusion protein according to claim 1, characterized in that, The fusion protein is selected from any one of the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 8 and SEQ ID NO:

10.

7. A fusion protein dimer comprising two fusion proteins according to any one of claims 1 to 6, wherein the fusion proteins are homodimers formed by disulfide bonds.

8. A polynucleotide encoding the fusion protein according to any one of claims 1 to 6.

9. The polynucleotide according to claim 8, characterized in that, The polynucleotide is selected from any one of the group consisting of SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 30 and SEQ ID NO:

32.

10. A vector comprising the polynucleotide according to claim 8.

11. A transformed cell introduced with the vector according to claim 10.

12. A pharmaceutical composition for treating or preventing eye diseases, comprising, as an active ingredient, the fusion protein according to claim 1 or the fusion protein dimer according to claim 7.

13. The pharmaceutical composition for treating or preventing eye diseases according to claim 12, characterized in that, The pharmaceutical composition also includes a pharmaceutically acceptable carrier.

14. The use of a fusion protein according to claim 1 or a fusion protein dimer according to claim 7 in the preparation of a medicament for treating or preventing eye diseases, wherein, The eye disease is selected from any one of the following groups: age-related macular degeneration (AMD), geographic atrophy (GA), choroidal neovascularization (CNV), uveitis, central retinal vein occlusion (CRVO), corneal angiogenesis, and retinal angiogenesis.

Citation Information

Patent Citations

  • Method and apparatus for displaying virtual landscapes

    JP2007536964A

  • ABT-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers

    US20190167790A1

  • Bispecific anti-VEGF / anti-ANG-2 antibodies

    US8268314B2

  • Bispecific binding molecules binding to VEGF and ANG2

    US9527925B2

  • CRIg polypeptide for prevention and treatment of complement-associated disorders

    CN101107005A